Regulation of feeding and body weight by ciliary g protein-coupled receptor 75 (GPR75)

Targeting GPR75 with siRNA and inhibitors addresses the inadequacies of current treatments for metabolic disorders by reducing body weight and improving metabolic health through modulation of energy homeostasis and neuronal cilia signaling.

WO2026241627A1PCT designated stage Publication Date: 2026-11-19BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028346
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current treatment strategies for metabolic disorders such as obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension, and cardiovascular disease are inadequate in addressing energy balance and muscle maintenance, and there is a need for new approaches to regulate body weight and metabolic health.

Method used

The use of small interfering RNA (siRNA) targeting GPR75, which reduces its ciliary localization in neuronal cells, and inhibitors that decrease GPR75 protein levels, thereby modulating energy homeostasis and reducing weight gain by decreasing IP3 and DAG levels in primary cilia of neurons.

Benefits of technology

The siRNA and inhibitors effectively reduce body weight and decrease the risk of metabolic diseases by targeting GPR75, leading to decreased food intake and improved metabolic health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028346_19112026_PF_FP_ABST
    Figure US2026028346_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are compositions and methods for regulating body weight and treating obesity and other metabolic diseases by modulating GPR75 expression, abundance, ciliary localization, and / or ciliary signaling. In some aspects, the compositions comprise small interfering RNA (siRNA) molecules targeting GPR75. In some aspects, GPR75-targeting siRNA molecules reduce GPR75 mRNA levels, protein abundance, and / or ciliary localization of GPR75 in neuronal cells. In some aspects, the compositions comprise siRNA molecules targeting TULP3, which reduce ciliary localization of GPR75 in neuronal cells. Also provided are pharmaceutical compositions, methods of treatment, screening assays, and kits comprising the disclosed compositions.
Need to check novelty before this filing date? Find Prior Art

Description

Atty. Docket No.: UTSDP4583WO-1001393863TITLE REGULATION OF FEEDING AND BODY WEIGHT BY CILIARY G PROTEIN-COUPLED RECEPTOR 75 (GPR75)CROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to U.S. Provisional Patent Application Serial No.63 / 806,489, filed May 15, 2025, and titled “REGULATION OF FEEDING AND BODY WEIGHT BY CILIARY G-PROTEIN COUPLED RECEPTOR 75 (GPR75),” which is incorporated by reference herein in its entirety.STATEMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with government support under grant number DK115766 awarded by The National Institutes of Health (NIH). The government has certain rights in the invention.SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted in ST.26 format and is hereby incorporated by reference in its entirety. Said ST.26 copy, created on May 12, 2026, is named UTSD4583WO_SEQ_LIST.xml and is 49,000 bytes in size.BACKGROUND1. Field

[0004] The present disclosure encompasses compositions for regulating body weight and treating metabolic diseases using the disclosed compositions.2. Discussion of Related Art

[0005] Metabolic dysregulation plays a critical role in a variety of conditions, impacting energy balance, muscle function, and overall physiological homeostasis. The prevalence and severity of metabolic disorders vary depending on the underlying disease. For example, obesity affects a significant portion of the global population and is a major risk factor for cardiovascular disease, diabetes, and fatty liver disease. These metabolic conditions, whether linked to excessive weight gain, insulin resistance, or severe muscle atrophy, significantly impact morbidity and mortality.

[0006] The prevalence of obesity has become a major threat to human health. The development of obesity is a complex process determined by both genetics and the environment. It has become clear that an obesogenic environment increases the risk of obesity, while genetic factors play an important role in determining the susceptibility to obesity304076022 - 1 -Atty. Docket No.: UTSDP4583WO-1001393863

[0007] Given the widespread impact of metabolic dysregulation across various conditions, there is a need to develop new treatment strategies that address energy balance, muscle maintenance, and metabolic health.SUMMARY

[0008] In some aspects the current disclosure encompasses a composition comprising a small interfering RNA (siRNA) comprising a guide strand and a passenger strand, wherein the guide strand is at least 80% complementary to a 15-23 nucleotide sequence within SEQ ID NO: 3 or SEQ ID NO: 4. In some aspects, the guide strand is at least 80% complementary to a 15-23 nucleotide sequence within any one of SEQ ID NOS: 21-25. In some aspects, the guide strand is at least 80% complementary to a 15-23 nucleotide sequence within any one of SEQ ID NOS: 6-10. In some aspects, the guide strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 26-30 and the passenger strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 31-35. In some aspects, the guide strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 11-15, and the passenger strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 16-20. In some aspects, the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 26 and the passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 31. In some aspects, the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 29 and the passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 34. In some aspects, the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 15 and the passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 20. In some aspects, the siRNA reduces ciliary localization of GPR75 protein in neuronal cells.

[0009] In some aspects the current disclosure encompasses a composition comprising an siRNA targeting TULP3, wherein the siRNA comprises a guide strand comprising a sequence at least 90% identical to SEQ I D NO: 38 or SEQ I D NO: 39, and a passenger strand comprising a sequence at least 90% identical to SEQ ID NO: 40 or SEQ ID NO: 41. In some aspects, the composition further comprises one or more nucleic acid modifications. In some aspects, the modifications comprise one or more of backbone modifications, sugar modifications, base modifications, end modifications, conjugates, or any combination thereof.

[0010] In some aspects the current disclosure encompasses a pharmaceutical composition comprising the composition as described herein and a pharmaceutically acceptable excipient.

[0011] In some aspects the current disclosure encompasses a method of treating obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension, or cardiovascular disease in a subject in need thereof, the method comprising administering to304076022 - 2 -Atty. Docket No.: UTSDP4583WO-1001393863the subject a therapeutically effective amount of the pharmaceutical composition as described herein.

[0012] In some aspects the current disclosure encompasses a composition comprising an inhibitor of G protein-coupled receptor 75 (GPR75). In some aspects, the inhibitor directly or indirectly reduces the levels of GPR75 protein on a cell surface. In some aspects, the inhibitor directly or indirectly decreases the levels of GPR75 protein in the primary cilia. In some aspects, the GPR75 protein comprises an amino acid sequence at least 60% identical to any one of SEQ ID NOS: 1 or 2. In some aspects, the inhibitor comprises a small molecule inhibitor, a drug, a peptide, a protein, an aptamer, a nucleic acid, an antibody molecule, or any combination thereof. In some aspects, the peptide specifically binds to 2-50 consecutive amino acid residues on any one of SEQ ID NOS: 1 or 2. In some aspects, the antibody molecule comprises a human antibody, a humanized antibody, a recombinant antibody, a chimeric antibody, an antibody derivative, a veneered antibody, a nanobody, a scFv, a minibody, a diabody, a monoclonal antibody, or a polyclonal antibody. In some aspects, the antibody molecule directly or indirectly reduces ciliary localization of GPR75. In some aspects, the antibody molecule reduces or eliminates interaction of GPR75 with GNAQ, TLILP3, or both GNAQ and TLILP3. In some aspects, the nucleic acid is a small interfering RNA (siRNA), an antisense oligonucleotide (ASO), a short hairpin RNA (shRNA), a microRNA (miRNA), or a CRISPR guide RNA. In some aspects, the nucleic acid specifically binds a 10-50 nucleotide sequence region within SEQ ID NO: 3 or SEQ ID NO: 4. In some aspects, the nucleic acid is a small interfering RNA (siRNA) comprising a guide strand and a passenger strand, wherein the guide strand is at least 60% complementary to a 15-23 nucleotide sequence within SEQ ID NO: 3 or SEQ ID NO: 4. In some aspects, the guide strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 26-30 and the passenger strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 31-35. In some aspects, the guide strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 11-15, and the passenger strand comprises a sequence at least 90% identical to any one of SEQ I D NOS: 16-20. In some aspects, the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 26 and the passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 31. In some aspects, the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 29 and the corresponding passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 34. In some aspects, the siRNA exhibits cross-species activity, reducing GPR75 mRNA and / or GPR75 protein levels in both human and mouse cells. In some aspects, the siRNA reduces ciliary localization of GPR75 protein in neuronal cells. In some aspects, the inhibitor is an siRNA targeting TLILP3, wherein the siRNA comprises a guide strand comprising a sequence at least 90% identical to SEQ ID NO: 38 or SEQ ID NO: 39,304076022 - 3 -Atty. Docket No.: UTSDP4583WO-1001393863and a passenger strand comprising a sequence at least 90% identical to SEQ ID NO: 40 or SEQ ID NO: 41, and wherein the siRNA reduces ciliary localization of GPR75. In some aspects, the composition comprises a CRISPR / Cas system on a delivery vector. In some aspects, the composition further comprises a nucleic acid sequence encoding a Cas protein. In some aspects, the composition directly or indirectly reduces the levels of proteolipid protein (myelin) 1 (Plp1 ). In some aspects, the inhibitor directly or indirectly reduces the association between GPR75 and a ciliary trafficking protein. In some aspects, the ciliary trafficking protein comprises TLILP3. In some aspects, the inhibitor directly or indirectly reduces GPR75 interactions with Gq. In some aspects, the inhibitor reduces the translocation of Gq into primary cilia, thereby decreasing IP3 and DAG levels in cilia of neurons. In some aspects, the inhibitor reduces the activity of other GPCRs in cilia of neurons. In some aspects, the administration of the composition to a subject reduces body weight or reduces the risks of one or more metabolic diseases. In some aspects, the metabolic disease is type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension, cardiovascular disease, or obesity, or any combination thereof.

[0013] In some aspects the current disclosure encompasses a pharmaceutical composition comprising the composition as described herein and a pharmaceutically acceptable excipient.

[0014] In some aspects the current disclosure encompasses a method of treating obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension, or cardiovascular disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition as described herein.

[0015] In some aspects the current disclosure encompasses a method of treating obesity in a subject, comprising administering a therapeutically effective amount of a GPR75 inhibitor to the subject. In some aspects, administering the inhibitor decreases IP3 and DAG levels, and / or reduces the levels of PLP1 , and / or reduces other GPCRs signaling in cilia of neurons. In some aspects, administering of the GPR75 inhibitor reduces the translocation of Gq into primary cilia, thereby decreasing IP3 and DAG levels in cilia of neurons. In some aspects, administering the GPR75 inhibitor reduces the activity of other GPCRs in cilia of neurons.

[0016] In some aspects the current disclosure encompasses a method of reducing food intake or treating hyperphagia in a subject, comprising administering a GPR75 inhibitor to the subject, wherein administering the inhibitor decreases IP3 and DAG levels and / or reduces other GPCRs signaling in cilia of neurons.

[0017] In some aspects the current disclosure encompasses a method of modulating energy homeostasis, reducing weight gain, or decreasing other GPCRs signaling in primary cilia in a304076022 - 4 -Atty. Docket No.: UTSDP4583WO-1001393863subject, comprising administering a GPR75 inhibitor to the subject, wherein administering the inhibitor decreases IP3 and DAG levels and / or reduces other GPCRs signaling in cilia of neurons.

[0018] In some aspects the current disclosure encompasses a kit comprising: (i) a unit dose of the pharmaceutical composition as described herein in a sterile container; and (ii) instructions for use.

[0019] In some aspects the current disclosure encompasses a kit comprising: (i) a unit dose of the pharmaceutical composition as described herein in a sterile container; and (ii) instructions for use.BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. Aspects of the present disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific aspects presented herein.

[0021] FIGS. 1A-1F provide experimental data for the identification and mapping of the Thinner allele. FIG. 1A shows the relative body weight phenotypic data plotted versus genotype at the Gpr75 mutation site; FIG. 1 B shows fat weight phenotypic data plotted versus genotype at the Gpr75 mutation site and FIG. 1C shows lean weight phenotypic data plotted versus genotype at the Gpr75 mutation site. Mean (p) and SD (o) are indicated. REF, homozygous for the reference allele; HET, heterozygous for the reference allele and for the Thinner allele; VAR, homozygous for the Thinner allele. Raw weight data were compared to the predicted weight of mice based on age and sex to calculate the relative values, minimizing the effects of age and sex differences in G3 mice. FIG. 1 D provides a Manhattan plot showing P values calculated using an additive model of inheritance about relative body weight, FIG.1E provides a Manhattan plot showing P values calculated using an additive model of inheritance about relative fat weight, and FIG. 1F provides a Manhattan plot showing P values calculated using an additive model of inheritance about relative lean weight. The -Log10 P values (y axis) are plotted versus the chromosomal positions of 53 mutations (x axis) identified in the G1 founder of the pedigree. Horizontal dark red and pink lines represent thresholds of P = 0.05 with or without Bonferroni correction, respectively.

[0022] FIGS. 2A-2N provide details on the phenotype of Gpr75_ / - mice. FIG. 2A shows body weight, FIG. 2B shows fat weight, and FIG. 2C shows lean weight of male Gpr75-- mice (n = 9) and WT littermates (n = 9) fed with HFD from 6 to 14 weeks of age. FIG. 2D shows photograph of a 14-week-old male Gpr75_ / - mice and WT (+ / +) littermate fed with HFD for 8 weeks. FIG. 2E provides representative photographs of eWAT, iWAT, iBAT, and liver from 14-304076022 - 5 -Atty. Docket No.: UTSDP4583WO-1001393863week-old male mice fed with HFD for 8 weeks. FIG. 2F provides liver weight and FIG. 2G provides liver triglycerides of 14-week-old male mice fed with HFD for 8 weeks. FIG. 2H shows H&E staining of sections from eWAT, iWAT, iBAT, and liver of 14-week-old male mice fed with HFD for 8 weeks. Scale bar, 100 pm. FIG. 2I shows body weight, FIG. 2J shows fat weight, and FIG. 2K shows lean weight of male Gpr75~7- mice (n = 5) and WT littermates (n = 5) fed with unsaturated HFD from 6 to 9 weeks of age. FIG. 2L shows body weight, FIG. 2M shows fat weight, and FIG. 2N shows lean weight of male Gpr75-- mice (n = 7) and WT littermates (n = 7) fed with a chow diet from 10 to 16 weeks of age. Data are presented as means ± SD. P values were determined by mixed-effects model with Holm-Sidak’s multiple comparisons test (A-C, l-N) or two-tailed unpaired Student’s t test (F-G). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant with P > 0.05. Data points represent individual mice (F-G). Data are representative of two independent experiments.

[0023] FIGS. 3A-3G show that Gpr75~7- mice exhibit decreased food intake which causes the lean phenotype. FIG. 3A shows cumulative food intake (g) of male Gpr75~- mice (n = 7) and WT littermates (n = 7) on chow diet monitored from 6 to 8 weeks of age. FIG. 3B shows the average food intake per mouse per day (g / day) during the 2-weeks period. FIG. 3C shows cumulative food intake (g) of male Gpr75~- mice (n = 6) and WT littermates (n = 6) fed with HFD monitored from 6 to 8 weeks of age. Cumulative food intake (g). FIG. 3D shows the average food intake per mouse per day (g / day) during the 2-week period. FIG. 3E shows body weight, FIG. 3F shows fat weight, and FIG. 3G shows lean weight of male Gpr75~- mice (n = 5) and WT littermates (n = 5) before and after pair-feeding since 6 weeks of age. Data are presented as means ± SD. P values were determined by two-tailed unpaired Student’s / test (A-D) or mixed-effects model with Holm-Sidak’s multiple comparisons test (E-G). *P < 0.05; **P < 0.01 ; ***P < 0.001 ; ****p < 0.0001 ; ns, not significant with P > 0.05. Data points represent individual mice (B, D). Data are representative of two independent experiments.

[0024] FIGS. 4A-4K show that GPR75 is highly expressed in the brain and directly binds to Gaqto regulate various downstream signaling pathways. FIG. 4A shows the relative Gpr75 mRNA level in different mouse tissues normalized by Polr2a (n = 3 mice). FIG. 4B shows generation of 3xFlag tagged Gpr75 knock-in mice by CRISPR. FIG. 4C shows an immunoblot analysis of 3xFlag-Gpr75 protein expression in different mouse tissues (8 weeks male) by immunoprecipitation. Gapdh was used as a loading control. FIG. 4D shows an immunoblot analysis of 3xFlag-Gpr75 protein expression in various brain regions (8 weeks male) by immunoprecipitation. Gapdh was used as a loading control. FIG. 4E shows mass spectrometry identification of GPR75 interacting proteins from Flag immunoprecipitates of Gpr75-3xFlag knock-in brain lysates. FIG. 4F is an immunoblot analysis of immunoprecipitates (top and middle) or lysates (bottom) of 293T cells expressing HA-tagged Gnaq and 3xFlag-tagged304076022 - 6 -Atty. Docket No.: UTSDP4583WO-1001393863Gpr75. FIG. 4G provides a summary of significantly changed genes (FDR < 0.05) from RNA-seq of hypothalamus from 8 weeks male WT and Gpr75~~ mice fed with chow diet or 2 weeks HFD (n = 3 mice for each group). FIG. 4H shows a volcano plot of differentially expressed genes in the hypothalamus of Gpr75'- vs WT mice on chow diet. FIG. 4I shows a volcano plot of differentially expressed genes in the hypothalamus of Gpr75~- vs WT mice on 2 weeks HFD. Differentially expressed genes (FDR < 0.05) are colored in red and blue indicating upregulation and down-regulation, respectively. FIG. 4J shows a Manhattan-like plot of pathways significantly associated (P < 0.05) with the loss of GPR75 on HFD feeding identified from a pathway overrepresentation analysis mapping significant gene to the Reactome and Wiki Pathways databases. FIG. 4K shows visualization of significantly associated pathways (P < 0.05) from (J). Data are presented as means ± SD. Data points represent individual mice (A). Data are representative of three independent experiments.

[0025] FIGS. 5A-5J show that GPR75 is located in the primary cilia. FIG. 5A shows mlMCD3 cells expressing 3xFlag-tagged Gpr75 were immunostained with Flag antibody (green), Ac-Tubulin (red), and Hoechst 33342 (blue). FIG. 5B shows Tulp3-- mlMCD3 cells expressing 3xFlag-tagged Gpr75 were immunostained with Flag antibody (green), Ac-Tubulin (red), and Hoechst 33342 (blue). FIG. 5C shows N11 cells expressing 3xFlag-tagged Gpr75 WT or FIG.5D L144P immunostained with Flag antibody (green), Ac-Tubulin (red), and Hoechst 33342 (blue). FIG. 5E shows mouse primary hypothalamic neurons expressing 3xFlag tagged Gpr75 immunostained with Flag antibody (green), ADCY3 (red), and Hoechst 33342 (blue). FIG. 5F shows primary hypothalamic neurons isolated from WT mice or FIG. 5G homozygous 3xFlag-Gpr75 knock-in mice immunostained with Flag antibody (green), ADCY3 (red), and Hoechst 33342 (blue). FIG. 5H shows N11 cells expressing 3xFlag-tagged human-GPR75 WT; p.Ala110fs (FIG. 5I), or p.Gln234* (FIG. 5J) were immunostained with Flag antibody (green), Ac-Tubulin (red), and Hoechst 33342 (blue). Data are representative of three independent experiments. Scale bars, 10 pm.

[0026] FIGS. 6A-6F show that Gpr75-- does not inhibit the development of obesity in Lepoband Adcy3 mutant mice. FIG. 6A shows body weight, FIG. 6B shows fat weight, and FIG. 6C shows lean weight of of 5-week-old male mice. FIG. 6D shows body weight, FIG. 6E shows fat weight, and FIG. 6F shows lean weight of 8-week-old male mice. Data are presented as means ± SD. P values were determined by one-way ANOVA with Holm-Sidak’s multiple comparisons test (FIGS. 6A-6F). *P < 0.05; **P < 0.01; ***P < 0.001;0.0001; ns, not significant with P > 0.05. Data points represent individual mice (FIGS. 6A-6F). Data are representative of three independent experiments.

[0027] FIGS. 7A-7F provide data relevant to exploring ligands of GPR75. FIG. 7A provides MRE / CRE / SRE luciferase assay. 293T cells expressing human GPR75 and pGL3-304076022 - 7 -Atty. Docket No.: UTSDP4583WO-1001393863MRE / CRE / SRE-luciferase plasmids were treated with different concentrations of CCL5 and 20-HETE. FIG. 7B provides PRESTO-tango p-arrestin recruitment assay in HTLA cells overexpressing GPR75-tango constructs treated with different concentrations of CCL5 and 20-HETE. FIG. 7C provides MRE / CRE / SRE luciferase assay. 293T cells expressing human GPR75 and pGL3-MRE / CRE / SRE-luciferase plasmids were treated with different concentrations of 5,14-HEDE. FIG. 7D provides PRESTO-tango p-arrestin recruitment assay in HTL cells overexpressing GPR75-tango constructs treated with different concentrations of 5,14-HEDE. FIG. 7E provides cAMP assay. 293T cells expressing human GPR75 were treated with different concentrations of 5,14-HEDE and forskolin. FIG. 7F provides IP1 assay. HTLA cells expressing human GPR75 were treated with different concentrations of 5,14-HEDE. Data are presented as means ± SD. P values were determined by one-way ANOVA with Holm-Sidak’s multiple comparisons test (FIGS. 7A-7F). *P < 0.05; **P < 0.01; ***P < 0.001 ; ****p < 0.0001 ; ns, not significant with P > 0.05. Data points represent individual wells (FIGS. 7A-7F). Data are representative of three independent experiments.

[0028] FIGS. 8A-8C show data for characterization of the Thinner mutation and Gpr75~7- mice. FIG. 8A provides protein domain diagrams of mouse GPR75 WT form, with the Thinner mutation, and truncated form generated by CRISPR KO. FIG. 8B is an immunoblot analysis of 3xFlag tagged WT and Thinner mutant (L144P) GPR75 proteins expressed in 293T cells. Gapdh was used as a loading control. FIG. 8C provides relative mRNA levels of Gpr75 in the brain lysates of WT and Gpr75~- mice were measured. Gpr75# and Gpr75#2 represent two sets of primers spanning the Gpr75 KO site used for the qPCR assay. Data are presented as means ± SD. P values were determined by two-tailed unpaired Student’s t test (FIG. 8C). *P < 0.05; **P < 0.01 ; ***P < 0.001 ; ****p < 0.0001 ; ns, not significant with P > 0.05. Data points represent individual mice (FIG. 8C). Data are representative of two independent experiments.

[0029] FIGS. 9A-9G provide the blood index of Gpr75~- mice. FIG. 9A provides serum glucose, FIG. 9B provides insulin, FIG. 9C provides cholesterol, FIG. 9D provides triglycerides, and FIG. 9E provides leptin in 14-week-old male mice fed with HFD for 8 weeks after a 6-h fast. FIG. 9F provides a glucose tolerance test. Blood glucose was measured at indicated times after i.p. glucose injection in 14-week-old male mice fed with HFD for 8 weeks (n = 5). FIG. 9G shows an insulin tolerance test. Blood glucose was measured at indicated times after i.p. insulin injection in 14-week-old male mice fed with HFD for 8 weeks (n = 5). Data are presented as means ± SD. P values were determined by two-tailed unpaired Student’s t test (FIGS. 9A-9E) or mixed-effects model with Holm-Sidak’s multiple comparisons test (FIGS. 9F-9G). *P < 0.05; **P < 0.01 ; ***P < 0.001 ; ****P < 0.0001 ; ns, not significant with P> 0.05. Data points represent individual mice (FIGS. 9A-9E). Data are representative of two independent experiments.304076022 - 8 -Atty. Docket No.: UTSDP4583WO-1001393863

[0030] FIGS. 10A-10J provide energy expenditure and physical activity of Gpr75'- mice fed with HFD for 2 weeks. FIG. 10A shows body weight, FIG. 10B shows fat weight, and FIG. 10C shows lean weight of 8-week-old male Gpr75~- mice (n = 6) and WT littermates (n = 6) fed with HFD for 2 weeks. These mice were used for metabolic cage experiments in FIGS. 10D-10I. FIG. 10D shows metabolic cage measurements of energy expenditure, FIG. 10E shows respiratory exchange ratio, FIG. 10F shows central fine movement, FIG. 10G shows central ambulatory movement, FIG. 10H shows peripheral fine movement, and FIG. 101 shows peripheral ambulatory movement of 8-week-old male Gpr75-- mice (n = 6) and WT littermates (n = 6) housed at 23°C. Dark color indicates dark phase when light was off. FIG. 10J shows internal temperature of 10-week-old male mice fed with HFD for 4 weeks housed in the cold in the absence of food (n = 7 WT, 7 Gpr75-7). Data are presented as means ± SD. P values were determined by two-tailed unpaired Student’s t test (FIGS. 10A-10C) or mixed-effects model with Holm-Sidak’s multiple comparisons test (FIG. 10J). A linear correlation with a two-tailed comparison of slope and intercept was calculated and compared between different mouse groups (FIG. 10D). *P<0.05; **P< 0.01 ; ***p< 0.001; ****P< 0.0001; ns, not significant with P> 0.05. Data points represent individual mice (FIGS. 10A-10D). Data are representative of two independent experiments.

[0031] FIGS. 11A-11J provide data related to energy expenditure and physical activity of Gpr75-- mice on pair feeding. FIG. 11A shows body weight, FIG. 11B shows fat weight, and FIG. 11C shows lean weight of 8-week-old male Gpr75~- mice (n = 6) and WT littermates (n = 6) on pair feeding. These mice were used for metabolic cage experiments in FIGS. 11D-11I. FIG. 11D shows metabolic cage measurements of energy expenditure, FIG. 11E shows respiratory exchange ratio, FIG. 11F shows central fine movement, FIG. 11G shows central ambulatory movement, FIG. 11H shows peripheral fine movement, and FIG. 111 shows peripheral ambulatory movement of 8-week-old male Gpr75~- mice (n = 6) and WT littermates (n = 6) housed at 23°C. Dark color indicates dark phase when light was off. FIG. 11 J shows fecal energy density of 10-week-old male Gpr75-- mice and WT littermates fed with HFD. Data are presented as means ± SD. P values were determined by two-tailed unpaired Student’s t test (FIGS. 11A-11C, FIG. 11 J). A linear correlation with a two-tailed comparison of slope and intercept was calculated and compared between different mouse groups (FIG. 11D). *P< 0.05; **P < 0.01 ; ***P < 0.001 ; ****P < 0.0001 ; ns, not significant with P > 0.05. Data points represent individual mice (FIGS. 11A-11D, FIG. 11 J). Data are representative of two independent experiments.

[0032] FIGS. 12A-12G show scRNA-seq data analysis of Gpr75 expression profile in mouse brain. FIG. 12A shows a LIMAP representation of Gpr75 expression in all brain cells from the Allen Brain Cell Atlas. The bottom plot shows the cell counts (y-axis) versus Gpr75 expression304076022 - 9 -Atty. Docket No.: UTSDP4583WO-1001393863levels [Log2(CPM+1), x-axis], FIG. 12B shows LIMAP representation of all cell types colored by class. FIG. 12C shows quantification of the percentage of Gpr75+ cells among the 34 classes. FIG. 12D shows LIMAP representation of all cell types colored by dissection region.FIG. 12E shows quantification of the percentage of Gpr75+ cells among the 29 dissection regions. FIG. 12F is a LIMAP representation of all cell types colored by major neurotransmitter type. FIG. 12G provides quantification of the percentage of Gpr75+ cells among the 10 neurotransmitter types.

[0033] FIG. 13 shows that GPR75 interacts with TLILP3. Immunoblot analysis of immunoprecipitates (top and middle) or lysates (bottom) of 293T cells expressing HA-tagged Tulp3 and 3xFlag-tagged Gpr75. Data are representative of two independent experiments.

[0034] FIGS. 14A-14C show that species-matched human GPR75 siRNAs reduce human GPR75 mRNA and human GPR75-3xFlag protein in N11 cells stably expressing human GPR75-3xFlag. FIG. 14A shows relative human GPR75 mRNA levels in N11 cells stably expressing human GPR75-3xFlag after transfection with control siRNA, matched-species human siRNAs hGpr75_294-316, hGpr75_1104-1126, hGpr75_1267-1289, hGpr75_1439-1461, and hGpr75_1503-1525, or the cross-species mouse siRNA mGpr75_811-833. Values were plotted relative to control, n = 4; data are mean ± SD. p values were determined by Student's t test versus control and are indicated on the graph. FIG. 14B shows a representative anti-Flag immunoblot of human GPR75-3xFlag in the same cell line after transfection with the indicated siRNAs. GAPDH was used as a loading control. FIG. 14C shows densitometric quantification of Flag signal normalized to GAPDH and plotted relative to control siRNA. Species-specific qPCR primers detect human GPR75 CDS and, because endogenous GPR75 expression in N11 cells is very low, the signal predominantly reflects the transgene.

[0035] FIGS. 15A-15C show that species-matched mouse Gpr75 siRNAs reduce mouse Gpr75 mRNA and mouse Gpr75-3xFlag protein in N11 cells stably expressing mouse Gpr75-3xFlag. FIG. 15A shows relative mouse Gpr75 mRNA levels in N11 cells stably expressing mouse Gpr75-3xFlag after transfection with control siRNA, matched-species mouse siRNAs mGpr75_686-708, mGpr75_811-833, mGpr75_854-876, mGpr75_1106-1128, and mGpr75_1440-1462, or the cross-species human siRNA hGpr75_1104-1126. Values were plotted relative to control, n = 4; data are mean ± SD. p values were determined by Student's t test versus control and are indicated on the graph. FIG. 15B shows a representative antiFlag immunoblot of mouse Gpr75-3xFlag in the same cell line after transfection with the indicated siRNAs. GAPDH was used as a loading control. FIG. 15C shows densitometric quantification of Flag signal normalized to GAPDH and plotted relative to control siRNA.304076022 - 10 -Atty. Docket No.: UTSDP4583WO-1001393863Species-specific qPCR primers detect mouse Gpr75 CDS and, because endogenous Gpr75 expression in N11 cells is very low, the signal predominantly reflects the transgene.

[0036] FIG. 16 shows representative images demonstrating that matched-species human GPR75 siRNAs and Tulp3 siRNA reduce ciliary human GPR75-3xFlag signal in N11 cells. Representative immunofluorescence / confocal images of N11 mouse hypothalamic cells stably expressing human GPR75-3xFlag following transfection with control siRNA, the indicated matched-species human GPR75 siRNAs, cross-species mouse siRNA mGpr75_811-833, or Tulp3 siRNA. Cells were stained for Flag, acetylated a-tubulin (Ac-Tub), and Hoechst. Representative images are consistent with the qPCR and Western blot data, with stronger reduction in ciliary Flag signal observed for the best matched-species siRNAs than for the cross-species mouse siRNA. Tulp3 siRNA reduced ciliary localization of human GPR75-3xFlag without an obvious change in cilia length in representative images. Scale bar, 10 pm.

[0037] FIG. 17 shows representative images demonstrating that matched-species mouse Gpr75 siRNAs and Tulp3 siRNA reduce ciliary mouse Gpr75-3xFlag signal in N11 cells. Representative immunofluorescence / confocal images of N11 mouse hypothalamic cells stably expressing mouse Gpr75-3xFlag following transfection with control siRNA, the indicated matched-species mouse Gpr75 siRNAs, cross-species human siRNA hGpr75_1104-1126, or Tulp3 siRNA. Cells were stained for Flag, acetylated a-tubulin (Ac-Tub), and Hoechst. Representative images are consistent with the qPCR and Western blot data, with stronger reduction in ciliary Flag signal observed for the best matched-species siRNAs than for the cross-species human siRNA. Tulp3 siRNA reduced ciliary localization of mouse Gpr75-3xFlag without an obvious change in cilia length in representative images. Scale bar, 10 pm.DETAILED DESCRIPTION

[0038] The following detailed description references the accompanying drawings that illustrate various aspects of the present disclosure. The drawings and description are intended to describe aspects of the present disclosure in sufficient detail to enable those skilled in the art to practice the present disclosure. Other components can be utilized, and changes can be made without departing from the scope of the present disclosure. The following description is, therefore, not to be taken in a limiting sense.

[0039] Variants of the G protein-coupled receptor 75 (GPR75) are associated with lower BMI in large-scale human exome sequencing studies. However, how GPR75 regulates body weight remains poorly understood. In some aspects, the current disclosure describes, using a random germline mutagenesis in mice, the identification of a missense allele (Thinner) of Gpr75 that resulted in a lean phenotype and verified the decreased body weight and fat weight in Gpr75 knockout (Gpr75~~) mice. Gpr75~- mice displayed reduced food intake under a high-304076022 - 11 -Atty. Docket No.: UTSDP4583WO-1001393863fat diet (HFD), and pair-feeding normalized their body weight. The endogenous GPR75 protein was exclusively expressed in the brains of 3xFlag tagged Gpr75 knock-in (3xFlag-Gpr75) mice, with consistent expression across different brain regions. GPR75 interacted with G«q to activate various signaling pathways after HFD feeding. Additionally, GPR75 was localized in the primary cilia of hypothalamic cells, whereas the Thinner mutation (L144P) and human GPR75 variants with lower BMI failed to localize in the cilia. Loss of GPR75 selectively inhibited weight gain in HFD-fed mice but failed to suppress the development of obesity in leptin (Lep) ob mice and adenylate cyclase 3 (Adcy3) mutant mice on a chow diet. The disclosure reveals that GPR75 is a ciliary protein expressed in the brain which plays an important role in regulating food intake, inhibition of which can be used fortreatment of obesity.I. Terminology

[0040] The phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting. For example, the use of a singular term, such as, “a” is not intended as limiting of the number of items. Also, the use of relational terms such as, but not limited to, “top,” “bottom,” “left,” “right,” “upper,” “lower,” “down,” “up,” and “side,” are used in the description for clarity in specific reference to the figures and are not intended to limit the scope of the present disclosure or the appended claims.

[0041] Any term of degree such as, but not limited to, “substantially” as used in the description and the appended claims, should be understood to include an exact, or a similar, but not exact configuration. For example, “a substantially planar surface” means having an exact planar surface or a similar, but not exact planar surface.

[0042] The terms “comprising,” “including,” and “having” are used interchangeably in this disclosure. The terms “comprising,” “including,” and “having” mean to include, but not necessarily be limited to the things so described.

[0043] The terms “or” and “and / or,” as used herein, are to be interpreted as inclusive or meaning any one or any combination. Therefore, “A, B, or C” or “A, B, and / or C” mean any of the following: “A,” “B,” or “C”; “A and B”; “A and C”; “B and C”; “A, B, and C.” An exception to this definition will occur only when a combination of elements, functions, steps, or acts are in some way inherently mutually exclusive.

[0044] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this disclosure belongs. The following references provide one of skill with a general definition of many of the terms used in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (3rd ed. 2006); Chambers Dictionary of Science and Technology(Walker ed., 1999); The Glossary304076022 - 12 -Atty. Docket No.: UTSDP4583WO-1001393863of Genetics, 5th Ed., R. Rieger et al. (2008), The Harper Collins Dictionary of Biology (1991), all of which are incorporated by reference herein. As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.

[0045] The phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting. When introducing elements of the present disclosure or the preferred aspects(s) thereof, the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements. The terms “comprising,” “including,” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements. Wherever the terms “comprising” or “including” are used, it should be understood the disclosure also expressly contemplates and encompasses additional aspects “consisting of” the disclosed elements, in which additional elements other than the listed elements are not included.

[0046] The term “about” or “approximately,” as used herein, can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the given value. Where particular values are described in the application and claims, unless otherwise stated the term “about” can mean an acceptable error range for the particular value, such as 10% of the value modified by the term “about.” As used herein, the term “about,” can mean relative to the recited value, e.g., amount, dose, temperature, time, percentage, etc., ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1%.

[0047] As used herein, “treatment,” “therapy,” and / or “therapy regimen” refer to the clinical intervention made in response to a disease, disorder or physiological condition manifested by a patient or to which a patient may be susceptible. The aim of treatment includes the alleviation or prevention of symptoms, slowing or stopping the progression or worsening of a disease, disorder, or condition and / or the remission of the disease, disorder or condition.

[0048] As used herein, “prevent” or “prevention” refers to eliminating or delaying the onset of a particular disease, disorder or physiological condition, or to the reduction of the degree of severity of a particular disease, disorder or physiological condition, relative to the time and / or degree of onset or severity in the absence of intervention.

[0049] As used herein, “individual,” “subject,” “host,” and “patient” can be used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, prophylaxis or therapy is desired, for example, humans, pets, livestock, horses or other animals. As used herein, the term “subject” and “patient” are used interchangeably herein and304076022 - 13 -Atty. Docket No.: UTSDP4583WO-1001393863refer to both human and nonhuman animals. The term “nonhuman animals” of the disclosure includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dog, cat, horse, cow, chickens, amphibians, reptiles, and the like. In some aspects, the subject can be a human. In other aspects, the subject can be a human in need of treating obesity, or related disease or disorder.

[0050] The term “inhibitor” as used herein refers to any moiety, including a chemical compound, biological molecule or complex that represses, slows, interferes, reduces, suppresses, modulates or blocks the activity of a protein or prevents a protein from engaging in a reaction. In some aspects, the inhibitor can directly or indirectly repress, slow, interfere with, reduce, suppress, modulate or block the activity of GPR75. In some aspects, the inhibitor decreases expression (i.e., surface expression) of GPR75 in a cell. In some aspects, the inhibitor can be a small molecule. In some aspects, the inhibitor can be a macromolecule. In some aspects, the inhibitor can be a drug or a pharmaceutical composition. In some aspects, the inhibitor or pharmaceutical composition comprising the inhibitor are applicable to prevent, alleviate, improve, and / or treat various metabolic diseases like type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension, cardiovascular disease, obesity, or any combination thereof.

[0051] By “specifically binds” it is meant that a binding molecule, e.g., an antibody or antigenbinding fragment thereof binds to an epitope via its antigen binding domain, and that the binding entails some recognition between the antigen binding domain and the epitope. According to this definition, a binding molecule is said to “specifically bind” to an epitope when it binds to that epitope, via its antigen-binding domain binds more readily than it would bind to a random, unrelated epitope. A molecule is said to exhibit “specific binding” if for example it reacts more frequently, with more avidity, more rapidly, with greater duration, and / or with greater affinity with a particular target antigen than it does with alternative targets. Specific binding can be measured, for example, by determining binding of a target molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity.

[0052] The term “antibody,” or “antigen binding agent” as used herein, is used in the broadest sense and encompasses various antibody and antibody-like structures, including but not limited to monoclonal antibodies, polyclonal antibodies, recombinant antibody, IgG, Fv, single chain antibody, single domain antibodies, nanobodies, diabodies, multispecific antibodies (e.g., bispecific antibodies), scFv, Fab, F(ab')2, and Fab and antibody fragments so long as they exhibit the desired antigen-binding activity. The domain(s) of an antibody that is involved in binding an antigen is referred to as a “variable region” or “variable domain,” and is described in further detail below. A single variable domain may be sufficient to confer antigen-binding304076022 - 14 -Atty. Docket No.: UTSDP4583WO-1001393863specificity. Preferably, but not necessarily, antibodies useful in the discovery are produced recombinantly. Antibodies may or may not be glycosylated, though glycosylated antibodies may be preferred. An “isolated” antibody is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by methods known in the art.

[0053] The term “administration” and variants thereof (e.g., “administering” a composition) in reference to a composition of the disclosure means introducing the composition or a prodrug of the composition into the system of the subject in need of treatment. When a composition of the disclosure or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.), “administration” and its variants are each understood to include concurrent and sequential introduction of the composition or prodrug thereof and other agents. The present disclosure includes within its scope prodrugs of the compositions of this disclosure. In general, such prodrugs will be functional derivatives of the compositions of this disclosure which are readily convertible in vivo into the required composition. Thus, in the methods of treatment of the present disclosure, the term “administering” shall encompass the treatment of the various conditions described with the composition specifically disclosed or with a composition which may not be specifically disclosed, but which converts to the specified composition in vivo after administration to the patient.

[0054] The term “therapeutically effective amount” as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.

[0055] As used herein, the term “treating” refers to the application or administration of a composition including one or more active agents to a subject, who is in need of the treatment, for example, having a target disease or disorder, a symptom of the disease / disorder, or a predisposition toward the disease / disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward the disease or disorder. Alleviating a target disease / disorder includes delaying the development or progression of the disease or reducing disease severity. Alleviating the disease does not necessarily require curative results. As used therein, “delaying” the development of a target disease or disorder means to defer, hinder, slow, retard, stabilize, and / or postpone progression of the disease. This delay can be of varying lengths of time, depending on the history of the disease and / or individuals being treated. A method that “delays” or alleviates the development of a disease, or delays the onset of the disease, is a method that reduces probability of developing one or more symptoms of the disease in a given time frame and / or reduces extent of the symptoms in a given time frame, when compared to304076022 - 15 -Atty. Docket No.: UTSDP4583WO-1001393863not using the method. Such comparisons are typically based on clinical studies, using a number of subjects sufficient to give a statistically significant result.

[0056] “Development” or “progression” of a disease means initial manifestations and / or ensuing progression of the disease. Development of the disease can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development or progression refers to the biological course of the symptoms. “Development” includes occurrence, recurrence, and onset. As used herein “onset” or “occurrence” of a target disease or disorder includes initial onset and / or recurrence.II. Composition

[0057] In some aspects, the current disclosure encompasses compositions comprising one or more inhibitors which directly or indirectly reduce, the amount of GPR75 localization in neuronal cilia. In some aspects, the disclosed composition directly or indirectly reduces the association between GPR75 and a ciliary trafficking protein. In some aspects, the ciliary trafficking protein comprises TLILP3. In some aspects, the disclosed composition directly or indirectly reduces GPR75 interactions with Gaq. In some aspects, the inhibitor reduces the translocation of Gaqinto primary cilia, thereby decreasing inositol trisphosphate (IP3) and diacylglycerol (DAG) levels in cilia of neurons. In some aspects, the inhibitor reduces the activity of other GPCRs in cilia of neurons. In some aspects, the disclosed composition directly or indirectly reduces the levels of proteolipid protein (myelin) 1 (Plp1 ).GPR75 Amino Acid and Nucleotide Sequences

[0058] GPR75 is a classical G protein-coupled receptor comprising an extracellular N-terminus followed by seven transmembrane domains, three intracellular loops, three extracellular loops and an intracellular C-terminus. For ease of reference, the amino acid sequences of human and mouse GPR75 are provided below as SEQ ID NOs: 1 and 2, respectively. SEQ ID NO: 2 (murine GPR75) is further annotated with residues, A110 and L144, bolded and underlined.SEQ ID NO: 1 (Human GPR75)

[0059] MNSTGHLQDAPNATSLHVPHSQEGNSTSLQEGLQDLIHTATLVTCTFLLAVIFCLGS YGNFIVFLSFFDPAFRKFRTNFDFMILNLSFCDLFICGVTAPMFTFVLFFSSASSIPDAFCFTF HLTSSGFIIMSLKTVAVIALHRLRMVLGKQPNRTASFPCTVLLTLLLWATSFTLATLATLKTSK SHLCLPMSSLIAGKGKAILSLYVVDFTFCVAVVSVSYIMIAQTLRKNAQVRKCPPVITVDASR PQPFMGVPVQGGGDPIQCAMPALYRNQNYNKLQHVQTRGYTKSPNQLVTPAASRLQLVS AINLSTAKDSKAVVTCVIIVLSVLVCCLPLGISLVQVVLSSNGSFILYQFELFGFTLIFFKSGLNP304076022 - 16 -Atty. Docket No.: UTSDP4583WO-1001393863FIYSRNSAGLRRKVLWCLQYIGLGFFCCKQKTRLRAMGKGNLEVNRNKSSHHETNSAYML SPKPQKKFVDQACGPSHSKESMVSPKISAGHQHCGQSSSTPINTRIEPYYSIYNSSPSQEE SSPCNLQPVNSFGFANSYIAMHYHTTNDLVQEYDSTSAKQIPVPSV (SEQ ID NO: 1) SEQ ID NO: 2 (Mouse GPR75)

[0060] MNTSAPLQNVPNATLLNMPPLHGGNSTSLQEGLRDFIHTATLVTCTFLLAIIFCLGSY GNFIVFLSFFDPSFRKFRTNFDFMILNLSFCDLFICGVTAPMFTFVLFFSSASSIPDSFCFTFH LTSSGFVIMSLKMVAVIALHRLRMVMGKQPNCTASFSCILLLTLLLWATSFTLATLATLRTNK SHLCLPMSSLMDGEGKAILSLYVVDFTFCVAWSVSYIMIAQTLRKNAQVKKCPPVITVDASR PQPFMGASVKGNGDPIQCTMPALYRNQNYNKLQHSQTHGYTKNINQMPIPSASRLQLVSAI NFSTAKDSKAWTCWIVLSVLVCCLPLGISLVQMVLSDNGSFILYQFELFGFTLIFFKSGLNP FIYSRNSAGLRRKVLWCLRYTGLGFLCCKQKTRLRAMGKGNLEINRNKSSHHETNSAYMLS PKPQRKFVDQACGPSHSKESAASPKVSAGHQPCGQSSSTPINTRIEPYYSIYNSSPSQQES GPANLPPVNSFGFASSYIAMHYYTTNDLMQEYDSTSAKQIPIPSV (SEQ ID NO: 2)

[0061] Also provided herein are coding sequences for both human and murine GPR75. These coding sequences can be targeted by the inhibitors of the present invention (e.g., siRNA). For ease of reference, nucleic acid sequences coding for human and mouse GPR75 are provided herein as SEQ ID NOs: 3 and 4, respectively.SEQ ID NO: 3 (Human GPR75 Nucleotide Sequence: complete CDS)

[0062] ATGAACTCAACAGGCCACCTTCAGGATGCCCCCAATGCCACCTCGCTCCATGTG CCTCACTCACAGGAAGGAAACAGCACCTCTCTCCAGGAGGGTCTTCAGGATCTCATCC ACACAGCCACCTTGGTGACCTGTACTTTTCTACTGGCGGTCATCTTCTGCCTGGGTTCC TATGGCAACTTCATTGTCTTCTTGTCCTTCTTCGATCCAGCCTTCAGGAAATTCAGAACC AACTTTGATTTCATGATCCTGAACCTGTCCTTCTGTGACCTCTTCATTTGTGGAGTGACA GCCCCCATGTTCACCTTTGTGTTATTCTTCAGCTCAGCCAGTAGTATCCCGGATGCTTT CTGCTTCACTTTCCATCTCACCAGTTCAGGCTTCATCATCATGTCTCTGAAGACAGTGG CAGTGATCGCCCTGCACCGGCTCCGGATGGTGTTGGGGAAACAGCCTAATCGCACGG CCTCCTTTCCCTGCACCGTACTCCTCACCCTGCTTCTCTGGGCCACCAGTTTCACCCTT GCCACCTTGGCTACCTTGAAAACCAGCAAGTCCCACCTCTGTCTTCCCATGTCCAGTCT GATTGCTGGAAAAGGGAAAGCCATTTTGTCTCTCTATGTGGTCGACTTCACCTTCTGTG TTGCTGTGGTCTCTGTCTCTTACATCATGATTGCTCAGACCCTGCGGAAGAACGCTCAA GTCAGAAAGTGCCCCCCTGTAATCACAGTCGATGCTTCCAGACCACAGCCTTTCATGG GGGTCCCTGTGCAGGGAGGTGGAGATCCCATCCAGTGTGCCATGCCGGCTCTGTATA GGAACCAGAATTACAACAAACTGCAGCACGTTCAGACCCGTGGATATACCAAGAGTCC CAACCAACTGGTCACCCCTGCAGCAAGCCGACTCCAGCTCGTATCAGCCATCAACCTC TCCACTGCCAAGGATTCCAAAGCCGTGGTCACCTGTGTGATCATTGTGCTGTCAGTCCT304076022 - 17 -Atty. Docket No.: UTSDP4583WO-1001393863GGTGTGCTGTCTTCCACTGGGGATTTCCTTGGTACAGGTGGTTCTCTCCAGCAATGGG AGCTTCATTCTTTACCAGTTTGAATTGTTTGGATTTACTCTTATATTTTTCAAGTCAGGAT TAAACCCTTTTATATATTCTCGGAACAGTGCAGGGCTGAGAAGGAAAGTGCTCTGGTGC CTCCAATACATAGGCCTGGGTTTTTTCTGCTGCAAACAAAAGACTCGACTTCGAGCCAT GGGAAAAGGGAACCTCGAAGTCAACAGAAACAAATCCTCCCATCATGAAACAAACTCTG CCTACATGTTATCTCCAAAGCCACAGAAGAAATTTGTGGACCAGGCTTGTGGCCCAAGT CATTCAAAAGAAAGTATGGTGAGTCCCAAGATCTCTGCTGGACATCAACACTGTGGTCA GAGCAGCTCGACCCCCATCAACACTCGGATTGAACCTTACTACAGCATCTATAACAGCA GCCCTTCCCAGGAGGAGAGCAGCCCATGTAACTTACAGCCAGTAAACTCTTTTGGATTT GCCAATTCATATATTGCCATGCATTATCACACCACTAATGACTTAGTGCAGGAATATGAC AGCACTTCAGCCAAGCAGATTCCAGTCCCCTCCGTTTAA (SEQ ID NO: 3)SEQ ID NO: 4 (Murine GPR75 Nucleotide Sequence: complete CDS)

[0063] ATGAACACAAGTGCCCCGCTTCAGAATGTCCCCAATGCCACCTTGCTAAACATG CCTCCCCTGCACGGGGGAAATAGCACTTCTCTCCAGGAAGGTCTTCGAGATTTTATCCA CACAGCCACCTTGGTGACCTGCACTTTTCTGCTTGCCATCATCTTCTGTCTAGGCTCTT ATGGAAATTTTATTGTCTTCTTGTCTTTCTTTGACCCATCCTTCAGGAAGTTCAGAACCA ACTTTGATTTCATGATCTTGAACCTGTCTTTCTGTGATCTGTTCATCTGTGGGGTCACAG CCCCCATGTTCACCTTCGTGCTGTTCTTCAGCTCAGCCAGTAGCATCCCAGATAGCTTC TGCTTCACCTTCCACCTTACCAGCTCAGGCTTCGTCATCATGTCCCTCAAGATGGTGGC TGTGATTGCTCTGCACCGGCTCCGGATGGTGATGGGGAAGCAGCCTAATTGTACAGCC TCCTTTTCCTGCATCTTGCTCCTTACCCTTCTTCTCTGGGCGACCAGCTTTACACTTGCC ACCTTGGCTACACTGAGAACCAATAAGTCCCACCTGTGTCTCCCCATGTCCAGTCTTAT GGATGGGGAAGGGAAAGCCATTCTGTCTCTGTATGTTGTTGACTTTACCTTCTGTGTTG CTGTGGTGTCTGTCTCTTATATTATGATTGCTCAAACCCTTCGGAAAAATGCTCAAGTAA AAAAGTGCCCCCCGGTGATCACAGTTGATGCTTCCAGACCACAGCCATTCATGGGGGC CTCTGTGAAGGGAAATGGAGATCCCATCCAGTGCACCATGCCAGCTCTGTATAGGAAC CAGAATTATAACAAACTGCAGCACAGTCAAACTCATGGATACACTAAGAATATCAACCA GATGCCAATCCCCTCAGCCAGTCGACTCCAGCTGGTATCAGCCATCAACTTCTCTACTG CCAAGGATTCCAAAGCCGTGGTCACCTGTGTGGTCATCGTGTTGTCAGTCCTGGTGTG CTGTCTTCCTCTTGGGATTTCCCTGGTGCAAATGGTTCTGTCTGACAATGGCAGTTTTAT CCTTTACCAGTTTGAACTGTTTGGATTTACTCTGATATTTTTCAAGTCAGGATTAAATCCT TTTATATATTCTCGGAACAGTGCTGGGCTGAGAAGGAAAGTACTCTGGTGCCTGAGATA CACTGGCCTGGGCTTTCTCTGCTGCAAACAGAAAACTCGACTTCGGGCCATGGGAAAA GGGAACCTTGAAATCAATAGAAACAAATCTTCTCATCATGAGACAAACTCTGCCTACATG CTGTCTCCAAAACCACAGAGAAAATTTGTGGACCAGGCTTGTGGCCCAAGTCACTCAAA GGAAAGTGCAGCGAGTCCCAAAGTTTCTGCTGGACATCAACCCTGTGGTCAAAGCAGT304076022 - 18 -Atty. Docket No.: UTSDP4583WO-1001393863TCCACACCCATCAACACTAGGATTGAACCTTACTATAGCATCTATAACAGCAGCCCTTC CCAGCAGGAGAGCGGTCCGGCAAACTTGCCTCCAGTGAACTCTTTTGGGTTTGCCAGT TCCTACATCGCCATGCACTATTACACCACCAATGATTTGATGCAGGAATATGACAGCAC GTCAGCAAAACAAATTCCTATCCCCTCTGTTTAA (SEQ ID NO: 4)Inhibitors

[0064] In some aspects, an inhibitor disclosed herein, is a small molecule or a macromolecule that can inhibit (repress, slow, interfere, reduce, suppress, modulate or block) localization of GPR75 on neuronal cilia. In some aspects, the inhibitor is a macromolecule, for example a protein, an antibody, or a polynucleotide sequence, for example an siRNA.

[0065] Antibody inhibitors: In some aspects, the inhibitor is an antibody, an antigen binding agent, or an epitope binding fragment thereof that directly or indirectly reduce, the amount of GPR75 localization in neuronal cilia. In some aspects, the antibody specifically targets a ciliary localization sequence (CLS) of GPR75 and / or one or more amino acid residues or domains in the sequence, for example A110 and / or L144 according to SEQ ID NO: 2, or an equivalent residue thereof (e.g., in SEQ ID NO: 1). It is within the skill of the art to identify a corresponding equivalent residue in protein sequences across species. In some aspects, an inhibitor disclosed herein, is a small molecule or a macromolecule that can inhibit (repress, slow, interfere, reduce, suppress, modulate or block) ciliary localization of GPR75. In some aspects, the antibody specifically binds to a polypeptide sequence or an epitope on GPR75. In some aspects, the antibody specifically binds to or inhibits or enhances the activity of another protein, for example TLILP3 that impacts or modulates one or more of the expression (transcription or translation), post-translational regulation, epigenetic regulation, or activity of one or more proteins, non-limiting examples of which include GPR75, other GPCRs, TLILP3. In some aspects, the antibody specifically targets the CLS of the disclosed proteins. In certain aspects, antibodies may have a suitable binding affinity for a target antigen (e.g. GPR75, other GPCRs, and / or TLILP3). In some aspects, an antibody described herein may have a binding affinity (KD) of at least about 1000 nM, at least about 100 nM, at least about 10 nM, at least about 1 nM, at least about 0.1 nM, or lower for an epitope. In some aspects, an antibody described herein may have a binding affinity (KD) between about 1000 nM to about 0.1 nM (e.g., about 1000 nM, about 750 nM, about 500 nM, about 250 nM, about 100 nM, about 75 nM, about 50 nM, about 25 nM, about 10 nM, about 5 nM, about 1 nM, about 0.75 nM, about 0.5 nM, about 0.25 nM, about 0.1 nM). In some aspects, an antibody described herein may have a binding affinity (KD) between about 50 nM to about 40 nM (e.g., about 50 nM, about 49 nM, about 48 nM, about 47 nM, about 46 nM, about 45 nM, about 44 nM, about 43 nM, about 42 nM, about 41 nM, about 40 nM) for an epitope disclosed herein. In some aspects, an antibody described herein may have a binding affinity (KD) between about 50 nM to about304076022 - 19 -Atty. Docket No.: UTSDP4583WO-100139386340 nM (e.g., about 50 nM, about 49 nM, about 48 nM, about 47 nM, about 46 nM, about 45 nM, about 44 nM, about 43 nM, about 42 nM, about 41 nM, about 40 nM). In some aspects, binding affinity (or binding specificity) can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, and / or spectroscopy (e.g., using a fluorescence assay).

[0066] Nucleic acid inhibitors: In some aspects, the inhibitor is a polynucleotide sequence that impacts one or more of the expression (transcription or translation) levels or activity of GPR75, other GPCRs, GNAQ, TLILP3, such that the ciliary localization of GPR75 is impacted. In some aspects, the polynucleotide sequence can be an RNA or a DNA sequence. In some aspects, the nucleic acid inhibitors, may be an antisense nucleic acid, an RNAi molecule (e.g., small interfering RNA (siRNA), small-hairpin RNA (shRNA), microRNA (miRNA)), an aptamer and / or a ribozyme. The nucleic acid and amino acid sequences of human and mouse GPR75 are known , (Gene ID: 10936 (human), Gene ID: 237716 (mouse), Uniprot Protein ID Q6X632 (mouse), 095800 (human), and thus nucleic acid inhibitors for use in accordance with methods of the present disclosure may be routinely made by the skilled artisan based on the knowledge in the art and teachings provided herein.

[0067] For example, antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are known in the art. The methods are based on binding of a polynucleotide to a complementary DNA or RNA. The antisense nucleic acids may comprise a single-stranded RNA or DNA sequence that is complementary to at least a portion of an RNA transcript of a desired gene. However, absolute complementarity, although preferred, is not required.

[0068] In some aspects, the nucleic acid inhibitor is an interfering RNA or RNAi molecule that target the expression of one or more genes for example GPR75, other GPCRs, and / or TLILP3 or regulators thereof. RNAi refers to the expression of an RNA which interferes with the expression of the targeted mRNA. Specifically, RNAi silences a targeted gene via interacting with the specific mRNA through a siRNA (small interfering RNA). The dsRNA complex is then targeted for degradation by the cell. An siRNA molecule is a double-stranded RNA duplex of 10 to 50 nucleotides in length, which interferes with the expression of a target gene which is sufficiently complementary (e.g. at least 80% identity to the gene). In some embodiments not covered by the disclosure, the siRNA molecule comprises a nucleotide sequence that is at least 85, 90, 95, 96, 97, 98, 99, or 100% identical to the nucleotide sequence of the target gene. In some aspects, the nucleic acid inhibitors may specifically target a 10-50 nucleotide sequence within a nucleic acid coding for human GPR75 (e.g., SEQ ID NO: 3) or mouse GPR75 (e.g., SEQ ID NO: 4) or a sequence at least 60%, at least 65%, at least 75%, at least304076022 - 20 -Atty. Docket No.: UTSDP4583WO-100139386380%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.

[0069] In some aspects, a disclosed nucleic acid inhibitor is an siRNA targeting GPR75. In some aspects, the siRNA comprises a guide strand comprising a nucleic acid sequence as set forth in any one of SEQ ID NOS: 11-15 (mouse) or SEQ ID NOS: 26-30 (human) , or a sequence with, or with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity to SEQ ID NOS: 11-15 or SEQ ID NOS: 26-30. In some aspects, the siRNA comprises a passenger strand comprising a nucleic acid sequence as set forth in any one of the passenger strand sequences set forth in SEQ ID NOS: 16-20 (mouse) or SEQ ID NOS: 31-35 (human), or a sequence with, or with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity to SEQ ID NOS: 16-20 or SEQ ID NOS: 31-35. In some aspects, the siRNA targets a sequence within a nucleic acid coding for human GPR75 (e.g., SEQ ID NO: 3) as set forth in any one of the target sequences for human siRNAs in SEQ ID NOS: 21-25, or a sequence at least about 80% identical thereto. In some aspects, the siRNA targets a sequence within a nucleic acid coding for mouse Gpr75 (e.g., SEQ ID NO: 4) as set forth in any one of the target sequences for mouse siRNAs in SEQ ID NOS: 6-10, or a sequence at least about 80% identical thereto. In some aspects, the siRNA comprises a guide strand and a passenger strand as set forth in Table 1, or sequences at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto.

[0070] In some aspects, a disclosed nucleic acid inhibitor is an siRNA targeting TLILP3. In some aspects, the siRNA comprises a guide strand comprising a nucleic acid sequence as set forth in any one of SEQ ID NOS: 38-39 (mouse), or a sequence with, or with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity to SEQ ID NOS: 38-39. In some aspects, the siRNA comprises a passenger strand comprising a nucleic acid sequence as set forth in any one SEQ ID NOS: 40-41 (mouse), or a sequence with, or with at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) identity to SEQ ID NOS: 40-41. In some aspects, the siRNA targets a sequence within a nucleic acid coding for mouse Tulp3 as set forth in any one of the target sequences for mouse siRNAs in SEQ ID NOS: 36-37, or a sequence at least about 80% identical thereto. In some aspects, the siRNA comprises a guide strand and a passenger strand as set forth in Table 1, or sequences at least about 80%, 81%,304076022 - 21 -Atty. Docket No.: UTSDP4583WO-100139386382%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical thereto.

[0071] In some aspects, the guide strand of a disclosed siRNA targeting GPR75 or TLILP3 comprises about 15 to 25 nucleotides, e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some aspects, the passenger strand comprises about 14 to 25 nucleotides, e.g., 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some aspects, the strands are fully complementary and the siRNA is blunt-ended when aligned. In other aspects, the strands align such that 1-, 2-, 3-, 4-, or 5-nucleotide 3' overhangs are generated. In some aspects, each siRNA comprises a 3'-overhang of 1 , 2, 3, 4, or 5 nucleotides. In some aspects, the siRNA does not comprise an overhang. In some aspects, the siRNA comprises 18-25, 19-24, or 20-23 nucleotides per strand and includes chemical modifications (e.g., alternating 2'-fluoro and 2'-O-methyl ribose substitutions) to enhance nuclease resistance and reduce immunostimulation. In some aspects, terminal regions of one or more strands include phosphorothioate-rich linkages and / or stabilized 5'-phosphate analogs (e.g., vinyl phosphonate) to improve metabolic stability and RISC loading.

[0072] In some aspects, the disclosed siRNAs targeting GPR75 or TLILP3 operate through the RNA interference (RNAi) pathway. Once inside a cell, the guide strand of the siRNA is selectively loaded into Argonaute 2 (Ago2), the catalytic core of the RNA-induced silencing complex (RISC). The guide strand directs RISC to the complementary GPR75 or Tulp3 mRNA sequence, resulting in endonucleolytic cleavage and degradation of the target transcript, thereby reducing GPR75 or TLILP3 expression, respectively. In some aspects, the guide strand is sufficiently complementary to a target sequence within a nucleic acid coding for human GPR75 (e.g., SEQ ID NO: 3) or mouse Gpr75 (e.g., SEQ ID NO: 4), or mouse Tulp3, to direct target-specific RNA interference. In some aspects, the siRNA is capable of reducing GPR75 orTULP3 expression in a cell by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% compared to a control cell that does not have the siRNA.

[0073] In some aspects, the guide strand of a disclosed siRNA targeting GPR75 is about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) complementary to an equal-length portion of a human GPR75 mRNA (e.g., SEQ ID NO: 3) or mouse Gpr75 mRNA (e.g., SEQ ID NO: 4). In some aspects, at least a 15-nucleotide sequence of the guide strand is 80% to 100% complementary to an equal-length portion of GPR75 mRNA. In some aspects, the guide strand targets a sequence corresponding to a 15-23 nucleotide sequence within the coding sequence of human GPR75 (e.g., SEQ ID NO: 3) or mouse Gpr75 (e.g., SEQ ID NO: 4). In some aspects, the guide strand of a disclosed siRNA304076022 - 22 -Atty. Docket No.: UTSDP4583WO-1001393863targeting TULP3 is about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derivable therein) complementary to an equal-length portion of a mouse Tulp3 mRNA. In some aspects, at least a 15-nucleotide sequence of the guide strand is 80% to 100% complementary to an equal-length portion of Tulp3 mRNA.

[0074] In some aspects, the disclosed siRNAs targeting GPR75 or TLILP3 may optionally be provided in a divalent siRNA (di-siRNA) format. In some aspects, a divalent siRNA comprises: (i) a first siRNA comprising a first guide strand and a first passenger strand; (ii) a second siRNA comprising a second guide strand and a second passenger strand; and (iii) a covalent linker joining the first passenger strand to the second passenger strand. In some aspects, the first and / or the second guide strand is 60% to 100% complementary to an equal-length portion of a human GPR75 mRNA (e.g., SEQ ID NO: 3) or mouse Gpr75 mRNA (e.g., SEQ ID NO: 4), or a mouse Tulp3 mRNA. In some aspects, the covalent linker is selected from polyethylene glycol (PEG), tetraethylene glycol (TEG), a peptide linker, a phosphodiester linker, a phosphorothioate linker, vinyl phosphonate linker, alkylene, polyamide, 1,2,3-triazole from click chemistry, disulfide, or an enzymatically cleavable peptide linker. In some aspects, the divalent architecture influences pharmacokinetics and stability, for example by providing enhanced resistance to exonucleases and improved retention in target tissues, including neuronal tissues, without altering the fundamental RISC-mediated silencing mechanism. In some aspects, the linker links the 3' end of the first passenger strand with the 3' end of the second passenger strand.

[0075] In some aspects, the nucleic acid inhibitor includes but not limited to, a decoy DNA, a double-stranded DNA, a single-stranded DNA, a complexed DNA, an encapsulated DNA, a viral DNA, a plasmid DNA, a naked RNA, an encapsulated RNA, a viral RNA, a doublestranded RNA, a molecule capable of generating RNA interference, or combinations thereof.

[0076] In some cases, genetic engineering systems such as CRISPR / Cas and other gene editing system may be utilized as inhibitors to make genome level edits in GPR75, minimizing localization of GPR75 in the cilia. A variety of enzymes can catalyze insertion of foreign DNA into a host genome. Non-limiting examples of gene editing tools and techniques include CRISPR, TALEN, zinc finger nuclease (ZFN), meganuclease, Mega-TAL, and transposonbased systems. A CRISPR system can be utilized to facilitate insertion of a polynucleotide sequence encoding a into a cell genome. For example, a CRISPR system can introduce a double stranded break at a target site in a genome. There are at least five types of CRISPR systems which all incorporate RNAs and CRISPR-associated proteins (Cas). Types I, III, and IV assemble a multi-Cas protein complex that is capable of cleaving nucleic acids that are304076022 - 23 -Atty. Docket No.: UTSDP4583WO-1001393863complementary to the crRNA. Types I and III both require pre-crRNA processing prior to assembling the processed crRNA into the multi-Cas protein complex. Types II and V CRISPR systems comprise a single Cas protein complexed with at least one guiding RNA.

[0077] In some aspects, the nucleic acid inhibitor may be aptamers. Aptamers are nucleic acid molecules, including double-stranded DNA and single-stranded RNA molecules, which bind to and form tertiary structures that specifically bind to a target molecule, such as DNA or RNA sequence of GPR75, other GPCRs, GNAQ or TLILP3. Nucleic acid aptamers are selected using methods known in the art, for example via the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) process. SELEX is a method for the in vitro evolution of nucleic acid molecules with highly specific binding to target molecules. The generation and therapeutic use of aptamers are well established in the art.

[0078] In some aspects, the nucleic acid inhibitor of the present disclosure is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of a gene of the disclosure. Such a vector would contain a sequence encoding the desired antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding desired genes of the instant disclosure, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region, the promoter contained in the 3' long terminal repeat of Rous sarcoma virus, the herpes thymidine promoter, and the regulatory sequences of the metallothionein gene.A. Modification of Nucleic Acids

[0079] In certain aspects, the nucleic acid of the disclosure may be modified. A "modified nucleic acid" refers to a molecule in which one or more of the components of the nucleic acid, namely sugars, bases, and phosphate moieties, are different from that which occur in nature, for example, different from that which occurs in the human body. Several modifications to nucleic acids are described in the art. These modifications may improve properties such as resistance to nucleases, permeability across biological membranes, solubility, stability, or modulation of pharmacokinetic and pharmacodynamic properties while maintaining specificity to the target mRNA. For example, the modifications on the nucleotides can include, but are not limited to, LNA, HNA, CeNA, 2'-methoxyethyl, 2'-O-alkyl, 2'-O-allyl, 2'-C-allyl, 2'-fluoro, 2'-304076022 - 24 -Atty. Docket No.: UTSDP4583WO-1001393863deoxy, 2'-hydroxyl, and combinations thereof. It is contemplated that one or more of these modifications may be excluded in an aspect.Modified Bases

[0080] Therapeutic nucleic acids targeting GPR75 may include natural (i.e. A, G, II, C, or T) or modified (e.g. 7-deazaguanosine, inosine, etc.) bases. Modification of bases includes the incorporation of modified bases (or modified nucleoside or modified nucleotides) that are variations of standard bases, sugars and / or phosphate backbone chemical structures occurring in ribonucleic (i.e., A, C, G and II) and deoxyribonucleic (i.e., A, C, G and T) acids. Included or excluded within this scope are, for example: Gm (2'-methoxyguanylic acid), Am (2'-methoxyadenylic acid), Cf (2'-fluorocytidylic acid), Ilf (2'-fluorouridylic acid), Ar (riboadenylic acid). The siRNAs may also include cytosine or any cytosine-related base including 5-methylcytosine, 4-acetylcytosine, 3-methylcytosine, 5-hydroxymethyl cytosine, 2-thiocytosine, 5-halocytosine (e.g., 5-fluorocytosine, 5-bromocytosine, 5-chlorocytosine, and 5-iodocytosine), 5-propynyl cytosine, 6-azocytosine, 5-trifluoromethylcytosine, N4,N4-ethanocytosine, phenoxazine cytidine, phenothiazine cytidine, carbazole cytidine or pyridoindole cytidine. The siRNA may further include guanine or any guanine-related base including 6-methylguanine, 1-methylguanine, 2,2-dimethylguanine, 2-methylguanine, 7-methylguanine, 2-propylguanine, 6-propylguanine, 8-haloguanine (e.g., 8-fluoroguanine, 8-bromoguanine, 8-chloroguanine, and 8-iodoguanine), 8-aminoguanine, 8-sulfhydrylguanine, 8-thioalkylguanine, 8-hydroxylguanine, 7-methylguanine, 8-azaguanine, 7-deazaguanine or 3-deazaguanine. The siRNA may still further include adenine or any adenine-related base including 6-methyladenine, N6-isopentenyladenine, N6-methyladenine, 1-methyladenine, 2-methyladenine, 2-methylthio-N6-isopentenyladenine, 8-haloadenine (e.g., 8-fluoroadenine, 8-bromoadenine, 8-chloroadenine, and 8-iodoadenine), 8-aminoadenine, 8-sulfhydryladenine, 8-thioalkyladenine, 8-hydroxyladenine, 7-methyladenine, 2-haloadenine (e.g., 2-fluoroadenine, 2-bromoadenine, 2-chloroadenine, and 2-iodoadenine), 2-aminoadenine, 8-azaadenine, 7-deazaadenine or 3-deazaadenine. Also included are uracil or any uracil-related base including 5-halouracil (e.g., 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil), 5-(carboxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, 1 -methylpseudouracil, 5-methoxyaminomethyl-2-thiouracil, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, 5-methyl-2-thiouracil, 2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, 5-methylaminomethyluracil, 5-propynyl uracil, 6-azouracil, or 4-thiouracil.304076022 - 25 -Atty. Docket No.: UTSDP4583WO-1001393863

[0081] The nucleic acids of the disclosure may include or exclude modified base variants. The modified base variant may include or exclude 4-acetylcytidine, 5-(carboxyhydroxylmethyl)uridine, 2'-methoxycytidine, 5-carboxymethylaminomethyl-2-thioridine, 5-carboxymethylaminomethyluridine, dihydrouridine, 2'-O-methylpseudouridine, b-D-galactosylqueosine, inosine, N6-isopentenyladenosine, 1 -methyladenosine, 1-methylpseudouridine, 1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine, 3-methylcytidine, 5-methylcytidine, N6-methyladenosine, 7-methylguanosine, 5-methylaminomethyluridine, 5-methoxyaminomethyl-2-thiouridine, b-D-mannosylqueosine, 5-methoxycarbonylmethyluridine, 5-methoxyuridine, 2-methylthio-N6-isopentenyladenosine, N-((9-b-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine, N-((9-b-D-ribofuranosylpurine-6-yl)N-methyl-carbamoyl)threonine, u rd ine- 5- oxy acetic acid methylester, uridine-5-oxyacetic acid (v), wybutoxosine, pseudouridine, queosine, 2-thiocytidine, 5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine, 5-methyluridine, N-((9-b-D-ribofuranosylpurine-6-yl)carbamoyl)threonine, 2'-O-methyl-5-methyluridine, 2'-O-methyluridine, and wybutosine, and 3-(3-amino-3-carboxypropyl)uridine. Also included are the modified nucleobases described in U.S. Pat. Nos. 3,687,808, 4,845,205, 5,130,302, 5,134,066, 5,175,273, 5,367,066, 5,432,272, 5,457,187, 5,459,255, 5,484,908, 5,502,177, 5,525,711, 5,552,540, 5,587,469, 5,594,121, 5,596,091, 5,614,617, 5,645,985, 5,830,653, 5,763,588, 6,005,096, and 5,681,941, each of which is incorporated herein by reference in its entirety.Modified Sugars

[0082] Modified sugar moieties for use in nucleic acids targeting GPR75 are well known in the art and are described for example in U.S. Pat. No. 9,045,754 which is incorporated by reference herein in its entirety. Modified sugars can be used to alter, typically increase, the affinity of the nucleic acid for its target and / or increase nuclease resistance. For example, in some aspects, the binding affinity of the nucleic acids to their target can be increased by incorporating substituent groups in the nucleoside subunits of the nucleic acids. In some aspects, the substituent groups are substituent groups located at the 2' position of the pentofuranosyl sugar moieties of the nucleoside subunits of the nucleic acids. Substituent groups include or exclude fluoro, alkoxy, amino-alkoxy, allyloxy, imidazolylalkoxy and polyethylene glycol. Alkoxy and aminoalkoxy groups generally include lower alkyl groups, particularly C1-C9 alkyl. In a particular aspect, the 2' substituent group is 2'-O-methyl. Polyethylene glycols are of the structure (O-CH2-CH2)n-O-alkyl. In a particular aspect, the substituent is a polyethylene glycol substituent of the formula (-O-CH2-CH2)n-O-alkyl, wherein n=1 and alkyl=CH3. This modification has been shown to increase both affinity of an oligonucleotide for its target and nuclease resistance of an oligonucleotide. See U.S. Pat. No.304076022 - 26 -Atty. Docket No.: UTSDP4583WO-10013938637,629,321 cited above. A further particularly useful 2'-substituent group for increasing the binding affinity is the 2'-fluoro group.

[0083] Examples of modified nucleoside and nucleotide sugar backbone variants known in the art include, without limitation, those having, e.g., 2' ribosyl substituents such as F, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2, CH3, ONO2, NO2, N3, NH2, OCH2CH2OCH3, O(CH2)2ON(CH3)2, OCH2OCH2N(CH3)2, O(C1-10 alkyl), O(C2-10 alkenyl), O(C2-10 alkynyl), S(C1-10 alkyl), S(C2-10 alkenyl), S(C2-10 alkynyl), NH(C1-10 alkyl), NH(C2-10 alkenyl), NH(C2-10 alkynyl), and O-alkyl-O-alkyl. Desirable 2' ribosyl substituents include 2'-methoxy (2'-OCH3), 2'-aminopropoxy (2' OCH2CH2CH2NH2), 2'-O-allyl (2'-CH2-CH=CH2), 2'-O-allyl (2'-O-CH2-CH=CH2), 2'-amino (2'-NH2), and 2'-fluoro (2'-F). The 2'-substituent may be in the arabino (up) position or ribo (down) position. One or more of these variants may be excluded from aspects of the disclosure.

[0084] Another class of modified nucleic acids known in the art and that may be utilized in the nucleic acids of the disclosure contain alkyl modifications at the 2' position of the ribose moiety. These nucleic acids were developed to improve the binding affinity and hybridization stability with target mRNA, and to increase the nuclease resistance of the nucleic acids. In this category, the most commonly used nucleic acids are 2'-O- Methyl (2-OME) and 2'-O-Methoxyethyl (2'-MOE) nucleic acids. Nucleic acids with this type of modification are incapable of activating RNAse H. Therefore, to induce RNAse H activation, chimeric nucleic acids have been developed in which a central gap region consisting of a phosphorothioate deoxyribose core is flanked with nuclease resistant arms such as 2-OME or 2'-MOE that possess greater nuclease resistance. A "gapmer" is produced as a result, in which RNAse H can sit in the central gap and activate target specific mRNA degradation, while the arms prevent the nucleic acid degradation. Nucleic acids in this category may possess higher affinity for mRNA, show better tissue uptake, and have increased resistance to nucleases, longer in vivo half-life, and lesser toxicity, as compared to the modified nucleic acids of the first class.

[0085] A further class of nucleic acids known in the art and that may be utilized in the nucleic acids of the disclosure contain modifications of the furanose ring along with modifications of the phosphate linkage, the ribose moiety, or the nucleotides. These modifications were designed to improve the nuclease stability, target affinity and pharmacokinetic profiles of the nucleic acids. Common examples of this category of nucleic acids are Locked nucleic acid (LNA), Peptide nucleic acid (PNA) and Morpholino phosphoroamidates (MF). Nucleic acids in this category are more stable in biological fluids because of their high resistance to degradation by nucleases and peptidases. They also exhibit a strong hybridization affinity with the mRNA. Further, PNAs recognize double stranded DNA, and are able to modulate gene expression or induce mutation by strand invasion of chromosomal duplex DNA. Nucleic acids304076022 - 27 -Atty. Docket No.: UTSDP4583WO-1001393863in this category also do not activate RNAse H and rely on sterically hindering the ribosomal machinery to cause translational arrest. They do not bind to serum proteins as they are uncharged. Lack of charge reduces the odds of non-specific interactions but increases the rate of clearance from the body. Their electrostatically neutral backbones may reduce solubility and make uptake more difficult.

[0086] A representative list of preferred modified sugars includes but is not limited to bicyclic modified sugars (BNA's), including methyleneoxy (4'-CH2-O-2') BNA and ethyleneoxy (4-(CH2)2-O-2' bridge) BNA; substituted sugars, especially 2'-substituted sugars having a 2'-F, 2'-OCH3 or a 2'-O(CH2)2-OCH3 substituent group; and 4'-thio modified sugars. Sugars can also be replaced with sugar mimetic groups among others. Methods for the preparations of modified sugars are well known to those skilled in the art.Modified Internucleotide Linkages

[0087] Nucleic acid therapeutics targeting GPR75 may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand or antisense strand or both (in nucleic acid therapeutics including a sense strand) in any position of the strand. For instance, the internucleotide linkage modification may occur on every nucleotide on the sense strand or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand may contain both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand.

[0088] In certain aspects, the nucleic acids of the disclosure comprise or exclude one or more nucleoside subunits connected by phosphorus linkages including phosphodiester, phosphorothioate, 3'(or -5')deoxy-3'-(or -5')thio-phosphorothioate, phosphorodithioate, phosphoroselenates, 3'-(or -5')deoxy phosphinates, borano phosphates, 3'-(or 5'-)amino phosphoramidates, hydrogen phosphonates, borano phosphate esters, phosphoramidates, alkyl or aryl phosphonates and phosphotriester phosphorus linkages. In some aspects, the nucleic acids of the disclosure comprise nucleoside subunits connected by carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetyl, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino linkages.304076022 - 28 -Atty. Docket No.: UTSDP4583WO-1001393863

[0089] For example, one class of modified nucleic acids described in the art and that may be utilized in the nucleic acids of the disclosure are those that have one of the non-bridging oxygen atoms in the phosphate group of the nucleic acids replaced with either a sulfur group (phosphorothioates), a methyl group (methyl phosphonates) or an amine group (phosphoramidates). These nucleic acids have greater resistance to nucleases and longer plasma half-life as compared with phosphodiester oligonucleotides. They are capable of activating RNAse H, carry negative charges which facilitate their delivery to cells, and have suitable pharmacokinetics. Among these modifications, phosphorothioate modifications are used most widely. For example, Vitravene, an FDA approved ASO drug, and most of the other ASO drugs in clinical trials are phosphorothioate ASOs.

[0090] In addition, the bases in nucleotide may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, inhibitory nucleic acids may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. The inhibitory nucleic acids may be prepared by converting the RNA to cDNA using known methods (see, e.g., Ausubel et. al., Current Protocols in Molecular Biology Wiley 1999). The inhibitory nucleic acids can also be cRNA (see, e.g., Park et. al., (2004) Biochem. Biophys. Res. Commun. 325(4): 1346-52).Covalent Linkers

[0091] Conjugate moieties are attached to oligonucleotides targeting GPR75 through covalent linkers. In certain oligomeric compounds, the covalent linker is a single chemical bond (i.e. , the conjugate moiety is attached directly to an oligonucleotide through a single bond). In certain oligomeric compounds, a conjugate moiety is attached to an oligonucleotide via a more complex covalent linker comprising one or more covalent linker moieties, which are sub-units making up a covalent linker. In certain aspects, the covalent linker comprises a chain structure, such as a hydrocarbyl chain, or an oligomer of repeating units such as ethylene glycol, nucleosides, or amino acid units.

[0092] In certain aspects, a covalent linker comprises pyrrolidine. In certain aspects, a covalent linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such aspects, the covalent linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain aspects, the covalent linker comprises groups selected from alkyl and amide groups. In certain aspects, the covalent linker comprises groups selected from alkyl and ether groups. In certain aspects, the covalent linker comprises at least one phosphorus moiety. In certain aspects, the covalent linker comprises at least one phosphate group. In certain aspects, the covalent linker includes at least one neutral linking group.304076022 - 29 -Atty. Docket No.: UTSDP4583WO-1001393863

[0093] In certain aspects, covalent linkers, including the covalent linkers described above, are bifunctional linking moieties, e.g., those known in the art to be useful for attaching conjugate groups to parent compounds, such as the oligonucleotides provided herein. In general, a bifunctional linking moiety comprises at least two functional groups. One of the functional groups is selected to bind to a particular site on a parent compound and the other is selected to bind to a conjugate group. Examples of functional groups used in a bifunctional linking moiety include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In certain aspects, bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.

[0094] Examples of covalent linkers include but are not limited to polyethylene glycol (PEG), tetraethylene glycol (TEG), a peptide linker, a phosphodiester linker, a phosphorothioate linker, vinyl phosphonate linker, alkylene, polyamide, 1,2,3-triazole from click chemistry, disulfide, or an enzymatically cleavable peptide linker, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane- 1 -carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other covalent linkers include but are not limited to substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C2-C10 alkenyl or substituted or unsubstituted C2-C10 alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

[0095] In certain aspects, covalent linkers comprise 1-10 linker-nucleosides. In certain aspects, covalent linkers comprise 2-5 linker-nucleosides. In certain aspects, covalent linkers comprise exactly 3 linker-nucleosides. In certain aspects, covalent linkers comprise the TCA motif. In certain aspects, such linker-nucleosides are modified nucleosides. In certain aspects such linker-nucleosides comprise a modified sugar moiety. In certain aspects, linker-nucleosides are unmodified. In certain aspects, linker-nucleosides comprise an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain aspects, a cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine and 2-N-isobutyrylguanine. It is typically desirable for linker-nucleosides to be cleaved from the oligomeric compound after it reaches a target tissue. Accordingly, linker-nucleosides are typically linked to one another and to the remainder of the oligomeric compound through cleavable bonds. In certain aspects, such cleavable bonds are phosphodiester bonds.

[0096] Herein, linker-nucleosides are not considered to be part of the oligonucleotide. Accordingly, in aspects in which an oligomeric compound comprises an oligonucleotide304076022 - 30 -Atty. Docket No.: UTSDP4583WO-1001393863consisting of a specified number or range of linked nucleosides and / or a specified percent complementarity to a reference nucleic acid and the oligomeric compound also comprises a conjugate group comprising a covalent linker comprising linker-nucleosides, those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid. For example, an oligomeric compound may comprise (1) a modified oligonucleotide consisting of 8-30 nucleosides and (2) a conjugate group comprising 1-10 linker-nucleosides that are contiguous with the nucleosides of the modified oligonucleotide. The total number of contiguous linked nucleosides in such an oligomeric compound is more than 30. Alternatively, an oligomeric compound may comprise a modified oligonucleotide consisting of 8-30 nucleosides and no conjugate group. The total number of contiguous linked nucleosides in such an oligomeric compound is no more than 30. Unless otherwise indicated covalent linkers comprise no more than 10 linker-nucleosides. In certain aspects, covalent linkers comprise no more than 5 linker-nucleosides. In certain aspects, covalent linkers comprise no more than 3 linker-nucleosides. In certain aspects, covalent linkers comprise no more than 2 linker-nucleosides. In certain aspects, covalent linkers comprise no more than 1 linker-nucleoside.

[0097] In certain aspects, it is desirable for a conjugate group to be cleaved from the oligonucleotide. For example, in certain circumstances oligomeric compounds comprising a particular conjugate moiety are better taken up by a particular cell type, but once the oligomeric compound has been taken up, it is desirable that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Thus, certain covalent linkers may comprise one or more cleavable moieties. In certain aspects, a cleavable moiety is a cleavable bond. In certain aspects, a cleavable moiety is a group of atoms comprising at least one cleavable bond. In certain aspects, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds. In certain aspects, a cleavable moiety is selectively cleaved inside a cell or subcellular compartment, such as a lysosome. In certain aspects, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases.

[0098] In certain aspects, a cleavable bond is selected from among an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide. In certain aspects, a cleavable bond is one or both of the esters of a phosphodiester. In certain aspects, a cleavable moiety comprises a phosphate or phosphodiester. In certain aspects, the cleavable moiety is a phosphate or phosphodiester linkage between an oligonucleotide and a conjugate moiety or conjugate group.

[0099] In certain aspects, a cleavable moiety comprises or consists of one or more linker-nucleosides. In certain such aspects, the one or more linker-nucleosides are linked to one304076022 - 31 -Atty. Docket No.: UTSDP4583WO-1001393863another and / or to the remainder of the oligomeric compound through cleavable bonds. In certain aspects, such cleavable bonds are unmodified phosphodiester bonds. In certain aspects, a cleavable moiety is 2'-deoxynucleoside that is attached to either the 3' or 5'-terminal nucleoside of an oligonucleotide by a phosphodiester internucleoside linkage and covalently attached to the remainder of the covalent linker or conjugate moiety by a phosphate or phosphorothioate internucleoside linkage. In certain such aspects, the cleavable moiety is 2'-deoxyadenosine.Terminal Groups

[0100] In certain aspects, oligomeric compounds targeting GPR75 comprise one or more terminal groups. In certain such aspects, oligomeric compounds comprise a stabilized 5'-phosphate. Stabilized 5'-phosphates include, but are not limited to 5'-phosphonates, including, but not limited to 5'-vinylphosphonates. In certain aspects, terminal groups comprise one or more abasic nucleosides and / or inverted nucleosides. In certain aspects, terminal groups comprise one or more 2'-linked nucleosides. In certain such aspects, the 2'-linked nucleoside is an abasic nucleoside.Conjugated Functional Moieties

[0101] In other aspects, the nucleic acid inhibitors of the present disclosure, including siRNAs targeting GPR75, may be modified with one or more functional moieties. A functional moiety is a molecule that confers one or more additional activities to the nucleic acid inhibitor. In certain aspects, the functional moieties enhance cellular uptake by target cells (e.g., neuronal cells). Thus, the disclosure includes nucleic acid inhibitors which are conjugated or unconjugated (e.g., at their 5' and / or 3' terminus) to another moiety (e.g. a non-nucleic acid moiety such as a peptide), an organic compound (e.g., a dye), or the like. The conjugation can be accomplished by methods known in the art, e.g., using the methods of Lambert et al., Drug Deliv. Rev.: 47(1), 99-112 (2001) (describes nucleic acids loaded to polyalkylcyanoacrylate (PACA) nanoparticles); Fattal et al., J. Control Release 53(1 -3): 137-43 (1998) (describes nucleic acids bound to nanoparticles); Schwab et al., Ann. Oncol. 5 Suppl. 4:55-8 (1994) (describes nucleic acids linked to intercalating agents, hydrophobic groups, polycations or PACA nanoparticles); and Godard et al., Eur. J. Biochem. 232(2):404-10 (1995) (describes nucleic acids linked to nanoparticles).

[0102] In a certain aspect, the functional moiety is a hydrophobic moiety. In a certain aspect, the hydrophobic moiety is selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides and nucleoside analogs, endocannabinoids, and vitamins. In a certain aspect, the steroid is selected from the group consisting of cholesterol and Lithocholic acid (LCA). In a certain aspect, the fatty acid is selected from the group consisting304076022 - 32 -Atty. Docket No.: UTSDP4583WO-1001393863of Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) and Docosanoic acid (DCA). In some aspects, the vitamin is selected from the group comprising choline, vitamin A, vitamin E, or derivatives or metabolites thereof. In a certain aspect, the vitamin is selected from the group consisting of retinoic acid and alpha-tocopheryl succinate.

[0103] In a certain aspect, a nucleic acid inhibitor of the present disclosure is conjugated to a lipophilic moiety. In one aspect, the lipophilic moiety is a ligand that includes a cationic group. In certain aspects, the lipophilic moiety is selected from the group consisting of cholesterol, vitamin E, vitamin K, vitamin A, folic acid, a cationic dye (e.g., Cy3). In an exemplary aspect, the lipophilic moiety is cholesterol. Other lipophilic moieties include cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, di methoxytrityl, or phenoxazine.

[0104] In certain aspects, the functional moieties may comprise one or more ligands tethered to a nucleic acid inhibitor to improve stability, hybridization thermodynamics with a target nucleic acid, targeting to a particular tissue or cell-type, or cell permeability, e.g., by an endocytosis-dependent or -independent mechanism. Ligands and associated modifications can also increase sequence specificity and consequently decrease off-site targeting. A tethered ligand can include one or more modified bases or sugars that can function as intercalators. These can be located in an internal region, such as in a bulge of a nucleic acid inhibitor / target duplex. The intercalator can be an aromatic, e.g., a polycyclic aromatic or heterocyclic aromatic compound. A polycyclic intercalator can have stacking capabilities, and can include systems with 2, 3, or 4 fused rings. In one aspect, the ligand can include a cleaving group that contributes to target gene inhibition by cleavage of the target nucleic acid. The cleaving group can be, for example, a bleomycin (e.g., bleomycin-A5, bleomycin-A2, or bleomycin-B2), pyrene, phenanthroline (e.g., O-phenanthroline), a polyamine, a tripeptide (e.g., lys-tyr-lys tripeptide), or a metal ion chelating group. The metal ion chelating group can include, e.g., an Lu(lll) or Ell(lll) macrocyclic complex, a Zn(ll) 2,9-dimethylphenanthroline derivative, a Cu(ll) terpyridine, or acridine, which can promote the selective cleavage of target RNA at the site of the bulge by free metal ions, such as Lu(lll). A tethered ligand can be an aminoglycoside ligand, which can cause a nucleic acid inhibitor to have improved hybridization properties or improved sequence specificity. Exemplary aminoglycosides include glycosylated polylysine, galactosylated polylysine, neomycin B, tobramycin, kanamycin A, and acridine conjugates of aminoglycosides, such as Neo-N-acridine, Neo-S-acridine, Neo-C-acridine, Tobra-N-acridine, and KanaA-N-acridine. A tethered ligand can be a poly-arginine peptide, peptoid or peptidomimetic, which can enhance the cellular uptake of an oligonucleotide agent.304076022 - 33 -Atty. Docket No.: UTSDP4583WO-1001393863

[0105] Exemplary ligands are coupled, either directly or indirectly, via an intervening tether, to a ligand-conjugated carrier. In certain aspects, the coupling is through a covalent bond. In certain aspects, the ligand is attached to the carrier via an intervening tether. In certain aspects, a ligand alters the distribution, targeting or lifetime of a nucleic acid inhibitor into which it is incorporated. In certain aspects, a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand.

[0106] Exemplary ligands can improve transport, hybridization, and specificity properties and may also improve nuclease resistance of the resultant natural or modified nucleic acid inhibitor, or a polymeric molecule comprising any combination of monomers described herein and / or natural or modified ribonucleotides. Ligands in general can include therapeutic modifiers, e.g., for enhancing uptake; diagnostic compounds or reporter groups e.g., for monitoring distribution; cross-linking agents; nuclease-resistance conferring moieties; and natural or unusual nucleobases. General examples include lipophiles, lipids, steroids (e.g., uvaol, hecigenin, diosgenin), terpenes (e.g., triterpenes, e.g., sarsasapogenin, Friedelin, epifriedelanol derivatized lithocholic acid), vitamins (e.g., folic acid, vitamin A, biotin, pyridoxal), carbohydrates, proteins, protein binding agents, integrin targeting molecules, polycationics, peptides, polyamines, and peptide mimics. Ligands can include a naturally occurring substance, (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); amino acid, or a lipid. The ligand may also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrenemaleic acid anhydride copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymers, or polyphosphazine. Examples of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptidepolyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

[0107] Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine (GalNAc) or derivatives thereof, N-acetyl-glucosamine, multivalent mannose, multivalent304076022 - 34 -Atty. Docket No.: UTSDP4583WO-1001393863fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, or an RGD peptide or RGD peptide mimetic. Other examples of ligands include dyes, intercalating agents (e.g. acridines and substituted acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine, phenanthroline, pyrenes), lys-tyr-lys tripeptide, aminoglycosides, guanidium aminoglycosides, artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol (and thio analogs thereof), cholic acid, cholanic acid, lithocholic acid, adamantane acetic acid, 1 -pyrene butyric acid, dihydrotestosterone, glycerol (e.g., esters (e.g., mono, bis, or tris fatty acid esters, e.g., C10, C11, C12, C13, 014, 015, 016, 017, 018, 019, or 020 fatty acids) and ethers thereof, e.g., 010, 011, 012, 013, 014, 015, 016, 017, 018, 019, or 020 alkyl; e.g., 1,3-bis-O(hexadecyl)glycerol, 1,3-bis-O(octadecyl)glycerol), geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, stearic acid (e.g., glyceryl distearate), oleic acid, myristic acid, 03-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, di methoxytrityl, or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]2, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport / absorption facilitators (e.g., aspirin, naproxen, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP or AP. In certain aspects, the ligand is GalNAc or a derivative thereof.

[0108] Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell. Ligands may also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide.

[0109] The ligand can be a substance, e.g., a drug, which can increase the uptake of the nucleic acid inhibitor into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, and / or intermediate filaments. The drug can be, for example, taxol, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin. The ligand can increase the uptake of the nucleic acid inhibitor into the cell by activating an inflammatory response, for304076022 - 35 -Atty. Docket No.: UTSDP4583WO-1001393863example. A lipid based ligand can be used to modulate, e.g., control the binding of the conjugate to a target tissue.

[0110] In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These can be useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include B vitamins, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by cancer cells. Also included are HSA and low-density lipoprotein (LDL).

[0111] In another aspect, the ligand is a cell-permeation agent, such as a helical cellpermeation agent. In certain aspects, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent can be an alpha-helical agent, which may have a lipophilic and a lipophobic phase.

[0112] The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to oligonucleotide agents can affect pharmacokinetic distribution, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long. A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. The peptide moiety can be an L-peptide or D-peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature 354:82-84, 1991). In exemplary aspects, the peptide or peptidomimetic tethered to a nucleic acid inhibitor via an incorporated monomer unit is a cell targeting peptide such as an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties.

[0113] Peptide inhibitors: In some aspects, the inhibitor is a peptide inhibitor, for example a decoy peptide. In some aspects, a decoy peptide may emulate parts of the target site for CLS,304076022 - 36 -Atty. Docket No.: UTSDP4583WO-1001393863specific residues on GPR75, for instance A110 and / or L144. In some aspects, the decoy peptide may comprise chemical changes that enhance affinity and / or decrease dissociation such that the cathepsin enzymatic activity is no longer available to cleave native proteins.

[0114] Small molecule inhibitors: In some aspects, the inhibitor is a small molecule or a combination of small molecules, for example a drug that directly or indirectly inhibits one or more of the expression, ciliary localization, or activity of one or more of GPR75, other GPCRs, or TLILP3 or activity thereof. In some aspects, the ability for a small molecule, or combination of small molecules, to inhibit the levels, or localization of one or more of GPR75, other GPCRs, or TLILP3, or activity thereof may be determined in a cell-based assay including, for example, those described herein, or assays known in the art. In some aspects, the small molecule inhibitor can be direct or indirect inhibitors. For example, a GPR75, other GPCRs, or TLILP3 inhibitory small molecule, or combination of small molecules, may inhibit the expression (e.g., transcription, translation, ciliary localization, or combinations thereof) of at least one or more of GPR75, other GPCRs, or TLILP3. Alternatively, a direct GPR75, other GPCRs, or TLILP3 small molecule inhibitor may directly bind to GPR75, other GPCRs, or TLILP3. Combinations of one or more indirect and one or more direct small molecule inhibitor may be used in accordance with the methods disclosed herein.

[0115] Binding organic small molecule inhibitors may be identified and chemically synthesized using known methodology. In general, small molecule inhibitors are usually less than about 2000 Daltons in size, alternatively less than about 1500, 750, 500, 250 or 200 Daltons in size, wherein such small organic molecules are capable of binding, preferably specifically, to a polypeptide as described herein. Such small molecule inhibitors may be identified without undue experimentation using well-known techniques. In this regard, it is noted that techniques for screening organic small molecule libraries for molecules that are capable of binding to a polypeptide target are well-known in the art.

[0116] Binding organic small molecules may be, for example, aldehydes, ketones, oximes, hydrazones, semicarbazones, carbazides, primary amines, secondary amines, tertiary amines, sugars, N-substituted hydrazines, hydrazides, alcohols, ethers, thiols, thioethers, disulfides, carboxylic acids, esters, amides, ureas, carbamates, carbonates, ketals, thioketals, acetals, thioacetals, aryl halides, aryl sulfonates, alkyl halides, alkyl sulfonates, aromatic compounds, heterocyclic compounds, anilines, alkenes, alkynes, diols, amino alcohols, oxazolidines, oxazolines, thiazolidines, thiazolines, enamines, sulfonamides, epoxides, aziridines, isocyanates, sulfonyl chlorides, diazo compounds, and acid chlorides.

[0117] In some aspects, the current disclosure also encompasses pharmaceutical compositions comprising one or more of the inhibitors disclosed herein and at least one304076022 - 37 -Atty. Docket No.: UTSDP4583WO-1001393863excipient. Compositions, in particular pharmaceutical compositions of the present invention can include, without limitation, saline, buffered solutions, lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, cells transfected with viral vectors (e.g., for transplantation into a subject), nanoparticle mimics and combinations thereof. In some aspects, the compositions disclosed herein are chemical vectors, such as a lipid complex or naked DNA. “Naked DNA” or “naked nucleic acid” refers to a nucleic acid molecule that is not contained in encapsulating means that facilitates delivery of a nucleic acid into the cytoplasm of a target host cell. Naked DNA may be circular or linear (linearized DNA sequence). Optionally, a naked nucleic acid can be associated with standard means used in the art for facilitating its delivery of the nucleic acid to the target host cell, for example to facilitate the transport of the nucleic acid through the cell membrane. In some aspects, the composition is a pharmaceutical composition comprising one or more excipients as disclosed herein below.

[0118] A pharmaceutical composition in accordance with the present disclosure may be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. As used herein, a “unit dose” refers to a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient (for example, one or more GPR75 activators or inhibitors). The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and / or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

[0119] Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and / or any additional ingredients in a pharmaceutical composition in accordance with the present disclosure may vary, depending upon the identity, size, and / or condition of the subject being treated and further depending upon the route by which the composition is to be administered. For example, the composition may comprise between 0.1% and 99% (w / w) of the active ingredient. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w / w) active ingredient.

[0120] In some aspects, a pharmaceutically acceptable excipient may be at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some aspects, an excipient is approved for use for humans and for veterinary use. In some aspects, an excipient may be approved by United States Food and Drug Administration. In some aspects, an excipient may be of pharmaceutical grade. In some aspects, an excipient may meet the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.304076022 - 38 -Atty. Docket No.: UTSDP4583WO-1001393863

[0121] In certain aspects, compositions disclosed herein may comprise one or more pharmaceutically acceptable excipient(s), diluents, and / or carrier(s). As used herein, a pharmaceutically acceptable diluent, excipient, or carrier, refers to a material suitable for administration to a subject without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained. Pharmaceutically acceptable diluents, carriers, and excipients can include, but are not limited to, physiological saline, Ringer’s solution, phosphate solution or buffer, buffered saline, and other carriers known in the art.

[0122] In some aspects, pharmaceutical compositions herein may include stabilizers, antioxidants, colorants, other medicinal or pharmaceutical agents, carriers, adjuvants, preserving agents, stabilizing agents, wetting agents, emulsifying agents, solution promoters, salts, solubilizers, antifoaming agents, antioxidants, dispersing agents, surfactants, or any combination thereof. Herein, the term “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. Techniques for formulation and administration of drugs may be found in “Remington’s Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., latest edition, which is incorporated herein by reference.

[0123] In certain aspects, pharmaceutical compositions described herein may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries to facilitate processing of genetically modified endothelial progenitor cells into preparations which can be used pharmaceutically. In some aspects, any of the well-known techniques, carriers, and excipients may be used as suitable and / or as understood in the art.

[0124] In certain aspects, pharmaceutical compositions described herein may be an aqueous suspension comprising one or more polymers as suspending agents. In some aspects, polymers that may comprise pharmaceutical compositions described herein include: water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose; waterinsoluble polymers such as cross-linked carboxyl-containing polymers; mucoadhesive polymers, selected from, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methyl methacrylate), polyacrylamide, polycarbophil, acrylic acid / butyl acrylate copolymer, sodium alginate, and dextran; or a combination thereof. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% total amount of polymers as suspending304076022 - 39 -Atty. Docket No.: UTSDP4583WO-1001393863agent(s) by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of polymers as suspending agent(s) by total weight of the composition.

[0125] In certain aspects, pharmaceutical compositions disclosed herein may comprise a viscous formulation. In some aspects, viscosity of composition herein may be increased by the addition of one or more gelling or thickening agents. In some aspects, compositions disclosed herein may comprise one or more gelling or thickening agents in an amount to provide a sufficiently viscous formulation to remain on treated tissue. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% total amount of gelling or thickening agent(s) by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of gelling or thickening agent(s) by total weight of the composition. In some aspects, suitable thickening agents for use herein can be hydroxypropyl methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium chondroitin sulfate, sodium hyaluronate. In other aspects, viscosity enhancing agents can be acacia (gum arabic), agar, aluminum magnesium silicate, sodium alginate, sodium stearate, bladderwrack, bentonite, carbomer, carrageenan, Carbopol, xanthan, cellulose, microcrystalline cellulose (MCC), ceratonia, chitin, carboxymethylated chitosan, chondrus, dextrose, furcellaran, gelatin, Ghatti gum, guar gum, hectorite, lactose, sucrose, maltodextrin, mannitol, sorbitol, honey, maize starch, wheat starch, rice starch, potato starch, gelatin, sterculia gum, xanthum gum, gum tragacanth, ethyl cellulose, ethyl hydroxyethyl cellulose, ethylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, poly(hydroxyethyl methacrylate), oxypolygelatin, pectin, polygeline, povidone, propylene carbonate, methyl vinyl ether / maleic anhydride copolymer (PVM / MA), poly(methoxyethyl methacrylate), poly(methoxyethoxyethyl methacrylate), hydroxypropyl cellulose, hydroxypropylmethyl-cellulose (HPMC), sodium carboxymethyl-cellulose (CMC), silicon dioxide, polyvinylpyrrolidone (PVP: povidone), Splenda (dextrose, maltodextrin and sucralose), or any combination thereof.

[0126] In certain aspects, pharmaceutical compositions disclosed herein may comprise additional agents or additives selected from a group including surface-active agents, detergents, solvents, acidifying agents, alkalizing agents, buffering agents, tonicity modifying agents, ionic additives effective to increase the ionic strength of the solution, antimicrobial agents, antibiotic agents, antifungal agents, antioxidants, preservatives, electrolytes,304076022 - 40 -Atty. Docket No.: UTSDP4583WO-1001393863antifoaming agents, oils, stabilizers, enhancing agents, and the like. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50% total amount of one or more agents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more agents by total weight of the composition. In some aspects, one or more of these agents may be added to improve the performance, efficacy, safety, shelflife and / or other property of the muscarinic antagonist composition of the present disclosure. In some aspects, additives may be biocompatible, without being harsh, abrasive, and / or allergenic.

[0127] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more acidifying agents. As used herein, “acidifying agents” refers to compounds used to provide an acidic medium. Such compounds include, by way of example and without limitation, acetic acid, amino acid, citric acid, fumaric acid and other alpha hydroxy acids, such as hydrochloric acid, ascorbic acid, and nitric acid and others known to those of ordinary skill in the art. In some aspects, any pharmaceutically acceptable organic or inorganic acid may be used. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% total amount of one or more acidifying agents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more acidifying agents by total weight of the composition.

[0128] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more alkalizing agents. As used herein, “alkalizing agents” are compounds used to provide alkaline medium. Such compounds include, by way of example and without limitation, ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium bicarbonate, sodium hydroxide, triethanolamine, and trolamine and others known to those of ordinary skill in the art. In some aspects, any pharmaceutically acceptable organic or inorganic base can be used. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% total amount of one or more alkalizing agents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%,304076022 - 41 -Atty. Docket No.: UTSDP4583WO-1001393863or about 15% to about 90% total amount of one or more alkalizing agents by total weight of the composition.

[0129] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more antioxidants. As used herein, “antioxidants” are agents that inhibit oxidation and thus can be used to prevent the deterioration of preparations by the oxidative process. Such compounds include, by way of example and without limitation, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite and other materials known to one of ordinary skill in the art. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% total amount of one or more antioxidants by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more antioxidants by total weight of the composition.

[0130] In certain aspects, pharmaceutical compositions disclosed herein may comprise a buffer system. As used herein, a “buffer system” is a composition comprised of one or more buffering agents wherein “buffering agents” are compounds used to resist change in pH upon dilution or addition of acid or alkali. Buffering agents include, by way of example and without limitation, potassium metaphosphate, potassium phosphate, monobasic sodium acetate and sodium citrate anhydrous and dihydrate and other materials known to one of ordinary skill in the art. In some aspects, any pharmaceutically acceptable organic or inorganic buffer can be used. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% total amount of one or more buffering agents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more buffering agents by total weight of the composition.

[0131] In some aspects, the amount of one or more buffering agents may depend on the desired pH level of a composition. In some aspects, pharmaceutical compositions disclosed herein may have a pH of about 6 to about 9. In some aspects, pharmaceutical compositions disclosed herein may have a pH greater than about 8, greater than about 7.5, greater than about 7, greater than about 6.5, or greater than about 6.304076022 - 42 -Atty. Docket No.: UTSDP4583WO-1001393863

[0132] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more preservatives. As used herein, “preservatives” refers to agents or combination of agents that inhibits, reduces or eliminates bacterial growth in a pharmaceutical dosage form. Non-limiting examples of preservatives include Nipagin, Nipasol, isopropyl alcohol and a combination thereof. In some aspects, any pharmaceutically acceptable preservative can be used. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% total amount of one or more preservatives by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more preservatives by total weight of the composition.

[0133] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more surface-acting reagents or detergents. In some aspects, surface-acting reagents or detergents may be synthetic, natural, or semi-synthetic. In some aspects, compositions disclosed herein may comprise anionic detergents, cationic detergents, zwitterionic detergents, ampholytic detergents, amphoteric detergents, nonionic detergents having a steroid skeleton, or a combination thereof. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% total amount of one or more surface-acting reagents or detergents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more surface-acting reagents or detergents by total weight of the composition.

[0134] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more stabilizers. As used herein, a “stabilizer” refers to a compound used to stabilize an active agent against physical, chemical, or biochemical process that would otherwise reduce the therapeutic activity of the agent. Suitable stabilizers include, by way of example and without limitation, succinic anhydride, albumin, sialic acid, creatinine, glycine and other amino acids, niacinamide, sodium acetyltryptophonate, zinc oxide, sucrose, glucose, lactose, sorbitol, mannitol, glycerol, polyethylene glycols, sodium caprylate, and sodium saccharin and others known to those of ordinary skill in the art. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% total amount of one or more stabilizers by total weight304076022 - 43 -Atty. Docket No.: UTSDP4583WO-1001393863of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more stabilizers by total weight of the composition.

[0135] In some aspects, pharmaceutical compositions disclosed herein may comprise one or more tonicity agents. As used herein, a “tonicity agents” refers to a compound that can be used to adjust the tonicity of the liquid formulation. Suitable tonicity agents include, but are not limited to, glycerin, lactose, mannitol, dextrose, sodium chloride, sodium sulfate, sorbitol, trehalose and others known to those or ordinary skill in the art. Osmolarity in a composition may be expressed in milliosmoles per liter (mOsm / L). Osmolarity may be measured using methods commonly known in the art. In some aspects, a vapor pressure depression method is used to calculate the osmolarity of the compositions disclosed herein. In some aspects, the amount of one or more tonicity agents comprising a pharmaceutical composition disclosed herein may result in a composition osmolarity of about 150 mOsm / L to about 500 mOsm / L, about 250 mOsm / L to about 500 mOsm / L, about 250 mOsm / L to about 350 mOsm / L, about 280 mOsm / L to about 370 mOsm / L or about 250 mOsm / L to about 320 mOsm / L. In some aspects, a composition herein may have an osmolality ranging from about 100 mOsm / kg to about 1000 mOsm / kg, from about 200 mOsm / kg to about 800 mOsm / kg, from about 250 mOsm / kg to about 500 mOsm / kg, or from about 250 mOsm / kg to about 320 mOsm / kg, or from about 250 mOsm / kg to about 350 mOsm / kg or from about 280 mOsm / kg to about 320 mOsm / kg. In some aspects, a pharmaceutical composition described herein may have an osmolarity of about 100 mOsm / L to about 1000 mOsm / L, about 200 mOsm / L to about 800 mOsm / L, about 250 mOsm / L to about 500 mOsm / L, about 250 mOsm / L to about 350 mOsm / L, about 250 mOsm / L to about 320 mOsm / L, or about 280 mOsm / L to about 320 mOsm / L. In some aspects, pharmaceutical compositions disclosed herein may comprise at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% total amount of one or more tonicity modifiers by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more tonicity modifiers by total weight of the composition.III. Delivery particles

[0136] In some aspects, the composition as disclosed herein may comprise a delivery particle. The delivery particle compositions may encapsulate or be associated with one or more active agents (e.g., GPR75 inhibitor), which may be, but are not limited to: polynucleotides, engineered protein compositions, and / or small molecules. In some aspects, polynucleotides,304076022 - 44 -Atty. Docket No.: UTSDP4583WO-1001393863engineered protein compositions, and / or small molecules formulated in the delivery particles can have improved pharmacokinetic and / or pharmacodynamic properties. In some aspects, polynucleotides, engineered protein compositions, and / or small molecules delivery particles are better tolerated by a patient. In some aspects, polynucleotides, engineered protein compositions, and / or small molecules are formulated in the delivery particles, and in some aspects, are more effectively delivered to cells to affect their function, than naked engineered proteins, polynucleotides, and / or small molecules. In some aspects, a delivery particle composition confers water solubility to hydrophobic agents, to combinations of hydrophobic agents, and / or to combinations of hydrophobic and hydrophilic agents. In some aspects, a delivery particle composition comprises a liposomal and / or nano-emulsion composition of a therapeutic agent. In some aspects, the delivery particle is a nanoparticle or a microparticle.

[0137] In several aspects, as disclosed elsewhere herein, a nanoparticle composition (e.g., a mixed micelle composition, a liposomal composition, solid lipid particles, oil-in-water emulsions, water-in-oil-in-water emulsions, water-in-oil emulsions, oil-in-water-in-oil emulsions, etc.) is provided to aid in the delivery of therapeutic agents. In certain aspects, pharmaceutical compositions described herein may be formulated in the form of a nanoparticle. The nanoparticle may have a monolayer enclosing the nanoparticle core, wherein the polynucleotide construct is disposed within the nanoparticle core. In an aspect, the nanoparticle core includes a solid lipid (i.e., lipid that remains solid at room temperature and body temperature) or a liquid lipid (i.e., oil, which remains liquid at room temperature and body temperature, for example, vegetable oil or a lipid extracted from human adipose tissue). In particular, aspects of the present disclosure include nanoparticles and compositions for the controlled and / or sustained release (e.g., release at a predetermined rate to maintain a certain concentration for a certain period of time) of an agent, such as a polynucleotide construct from the nanoparticle. In some aspects, the nanoparticles comprise one or more therapeutic agents. In some aspects, a composition comprising the nanoparticles disclosed herein comprises a therapeutically effective amount of one or more therapeutic agents.

[0138] In several aspects, when formulated, the dry weight % of one or more therapeutic agents present in the nanoparticle compositions is equal to or at least about: 0.1%, 0.5%, 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, or any ranger derivable therein. In several aspects, the therapeutic agents are provided in an aqueous composition. In several aspects, the wet weight % of one or more therapeutic agents present in the composition (with water included) is equal to or at least about: 0.5%, 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, or any range derivable therein. In several aspects, the one or more therapeutic agents may be provided in the wet composition at a concentration of greater304076022 - 45 -Atty. Docket No.: UTSDP4583WO-1001393863than or equal to about: 0.001 mg / mL, 0.005 mg / mL, 0.01 mg / mL, 0.05 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, 5 mg / mL, 20 mg / mL, 30 mg / mL, 50 mg / mL, 100 mg / mL, or any range derivable therein.

[0139] In several aspects, the therapeutic agents, collectively or individually, are present in the aqueous nanoparticle composition at a concentration of less than or equal to about: 150 mg / mL, 100 mg / mL, 75 mg / mL, 50 mg / mL, 25 mg / mL, 20 mg / mL, 10 mg / mL, 5 mg / mL, 2.5 mg / mL, 2 mg / mL, 1.5 mg / mL, 1 mg / mL, 0.5 mg / mL, 0.1 mg / mL, 0.05 mg / mL, 0.01 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more therapeutic agents, collectively or individually, are present in the aqueous composition at a concentration of greater than or equal to about: 150 mg / mL, 100 mg / mL, 75 mg / mL, 50 mg / mL, 25 mg / mL, 20 mg / mL, 10 mg / mL, 5 mg / mL, 2.5 mg / mL, 2 mg / mL, 1.5 mg / mL, 1 mg / mL, 0.5 mg / mL, 0.1 mg / mL, 0.05 mg / mL, 0.01 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more therapeutic agents, collectively or individually, are present in the composition at a dry wt. % of equal to or at least about: 0.1%, 0.5%, 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more therapeutic agents, collectively or individually, are present in the composition at a wet wt. % of equal to or at least about: 0.1%, 0.5%, 1%, 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%, 47.5%, 50%, 52.5%, 55%, 57.5%, 60%, or ranges including and / or spanning the aforementioned values. In several aspects, as disclosed elsewhere herein, the composition is aqueous, while in others it has been dried into a powder (that is free of or substantially free of water). In several aspects, where the composition has been dried, it comprises a water content of less than or equal to 20%, 15%, 10%, 7.5%, 5%, 2.5%, 1%, or ranges including and / or spanning the aforementioned values.

[0140] In several aspects, as disclosed elsewhere herein, the composition is aqueous (e.g., contains water) while in other aspects, the composition is dry (lacks water or substantially lacks water). In several aspects, the composition has been dried (e.g., has been subjected to a process to remove most or substantially all water). In several aspects, the composition comprises nanoparticles in water (e.g., as a solution, suspension, or emulsion). In other aspects, the composition is provided as a powder (e.g., that may be constituted or reconstituted in water). In several aspects, as disclosed elsewhere herein, the water content (in wt. %) of the composition is less than or equal to about: 30%, 20%, 10%, 5%, 2.5%, 1%, 0.5%, 0.1%, 0%, or ranges including and / or spanning the aforementioned values. In several aspects, as disclosed elsewhere herein, the water content (in wt. %) of the composition is greater than or equal to about: 50%, 60%, 70%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, or304076022 - 46 -Atty. Docket No.: UTSDP4583WO-1001393863ranges including and / or spanning the aforementioned values. In several aspects, the water is nanopure, deionized, USP grade, WFI, and / or combinations of the foregoing. In some aspects, the composition is a dried composition comprising a nanoparticle having weight ratios of a first therapeutic agent: a nanoscale coordination polymer NCP: optionally a lipid source, and optionally a surfactant of 1 to 50:1 to 50:1 to 50:0 to 17.5.

[0141] In some aspects, a nanoparticle composition provides an oil-in-water emulsion (e.g., a nanoemulsion), water-in-oil emulsion, a water-in-oil-in-water emulsion, an oil-in-water-in-oil emulsion, a liposome (and variants including multi-lamellar, double liposome preparations, etc.), micelle, and / or solid lipid particles. Any one of these structures may be provided as a nanoparticle or microparticle.

[0142] In some aspects, the nanoparticle composition comprises a lipid source. In some aspects, the lipid source comprises a charged lipid, which can impart a charge to the nanoparticle. In some aspects, the lipid source comprises a neutral lipid. In some aspects, the lipid source comprises one or more phospholipids. In some aspects, the one or more phospholipids comprises one or more of phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylinositol phosphate, phosphatidylinositol bisphosphate, phosphatidylinositol trisphosphate, lipoid H 100-3, phospholipon 90H, phospholipon 80H, lipoid 100-3, lipoid P75-3, 1,2-dioleoyl-sn-glycero-3-phosphate (DOPA), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-diastearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] (DSPE-PEG2000) or any combination of the foregoing. In some aspects, the lipid source is a phosphatidylcholine. In some aspects, the one or more lipid source lipid(s) (collectively or individually) are present in the composition at a dry wt. % of equal to or less than about: 0%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, or ranges including and / or spanning the aforementioned values. In some aspects, the one or more lipid source lipid(s) (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0%, 0.1%, 0.5%, 1.0%, 2.5%, 4%, 5%, 6%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or ranges including and / or spanning the aforementioned values. In some aspects, the one or more lipid source lipid(s) (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7.5 mg / mL, 10 mg / mL, 12.5 mg / mL, 15 mg / mL, 17.5 mg / mL, 20 mg / mL, 25 mg / mL, 30 mg / mL, 35 mg / mL, 40 mg / mL, 45 mg / mL, 50 mg / mL, or ranges including and / or spanning the aforementioned values. In some aspects, the composition is aqueous, while in others it has been dried into a powder. For instance, in several aspects, the composition is aqueous (wet), while in others it has been dried into a powder (dry). In some aspects, the one or more lipid(s) of the lipid source are synthetic,304076022 - 47 -Atty. Docket No.: UTSDP4583WO-1001393863derived from sunflower, soy, egg, or mixtures thereof. In some aspects, the one or more lipids of the lipid source can be hydrogenated or non-hydrogenated. In some aspects, the lipid source exceeds requirements of the United States Pharmacopeia (is USP grade) and / or is National Formulary (NF) grade.

[0143] In some aspects, the one or more lipids of the lipid source has a purity of greater than or equal to about: 92.5%, 95%, 96%, 96.3%, 98%, 99%, 100%, or ranges including and / or spanning the aforementioned values. In several aspects, the one or more lipids of the lipid source has a total % impurity content by weight of less than or equal to about: 8.5%, 5%, 4%, 3.7%, 2%, 1%, 0%, or ranges including and / or spanning the aforementioned values.

[0144] In some aspects, a nanoparticle composition comprises a surfactant. In certain aspects, a nanoparticle composition does not comprise a surfactant. In some aspects, the surfactant is a pharmaceutically acceptable surfactant. In some aspects, the surfactant is a food surfactant. In some aspects, the surfactant comprises one or more of a polyoxyethylene sorbitan esters (e.g., polysorbates / tweens, including polysorbate 80, polysorbate 20, etc.), cremophor (e.g., a non-ionic solubilizer and emulsifier that is made by reacting ethylene oxide with castor oil), propylene oxide-modified polymethylsiloxane, dodecyl betaine, lauramidopropyl betaine, cocoamido-2-hydroxypropyl sulfobetaine, sodium stearate (or other stearate salts), polyoxyethylene alcohol, lecithins, mono- and diglycerides of fatty acids (MDG), acetic acid esters of MDG, lactic acid esters of MDG, citric acid esters of MDG, mono-and diacetyl tartaric acid esters of MDG, sucrose esters of fatty acids, polyglycerol esters of fatty acids (e.g., polyglycerol esters), polyglycerol polyricinoleate, propane-1, 2-diol esters of fatty acids, propylene glycol esters, sodium stearoyl-2-lactylate, calcium stearoyl-2-lactylate, sorbitan fatty acid esters, quillaja extract surfactant, yucca extract surfactant, saponins, silicone emulsifiers, sorbitan trioleate, soya lecithin, dioctyl sodium sulfosuccinate, dioctyl sodium sulfonate, polyoxyethylene, hydrogenated castor oil, sucrose fatty acid ester, or combinations of any of the foregoing. Natural or synthetic surfactants can be used, including polyethylene glycol and dextrans, such as cyclodextran. In some aspects, the one or more surfactants are present in a nanoparticle composition (collectively or individually) at a dry wt. % of equal to or less than about: 0%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, or ranges including and / or spanning the aforementioned values. In some aspects, surfactants can include cationic, anionic, non-ionic, and zwitterionic surfactants. In some aspects, one or more surfactants (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0%, 0.1%, 0.5%, 1.0%, 2.5%, 4%, 5%, 6%, 7.5%, 10%, 12.5%, 15%, 17.5%, or ranges including and / or spanning the aforementioned values. In some aspects, one or more surfactants (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL,304076022 - 48 -Atty. Docket No.: UTSDP4583WO-10013938635 mg / mL, 6 mg / mL, 7.5 mg / mL, 10 mg / mL, 12.5 mg / mL, 15 mg / mL, 17.5 mg / mL, or ranges including and / or spanning the aforementioned values. In some aspects, a surfactant exceeds requirements of the United States Pharmacopeia (is USP grade) and / or is National Formulary (NF) grade.

[0145] In several aspects, one or more co-emulsifiers are used. In certain aspects, a nanoparticle composition does not comprise a co-emulsifier. In some aspects, a co-emulsifier is a pharmaceutically acceptable co-emulsifier. In some aspects, a co-emulsifier is selected from the group consisting of oleic acid, miglyol 812N (all versions), cetearyl olivate, isoprpyle myristate, celluloses, polysaccharides (e.g., methylcellulose, propylmethylcellulose, hydroxypropyl methylcellulose, xanthan gum, etc.), capric acid, caprylic acid, triglycerides (e.g., triglycerides of oleic acid, capric acid, caprylic acid (Captex 8000, Captex GTO, Captex 1000)), glycerol monooleate, glyceryl stearate, glycerol monostearate (Geleol™ Mono and Diglyceride NF), omega-3 fatty acids (a-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), Tonalin, Pronova Pure® 46:38, free fatty acid Tonalin FFA 80), conjugated linoleic acid (CLA), alpha glycerylphosphorylcholine (alpha GPC), palmitoylethanolamide (PEA), cetyl alcohol, or emulsifying wax and / or combinations of any of the foregoing. In some aspects, one or more co-emulsifiers are present in the nanoparticle composition (collectively or individually) at a dry wt. % of equal to or less than about: 0%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, or ranges including and / or spanning the aforementioned values. In some aspects, one or more co-emulsifiers (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0%, 0.1%, 0.5%, 1.0%, 2.5%, 4%, 5%, 6%, 7.5%, 10%, 12.5%, 15%, 17.5%, or ranges including and / or spanning the aforementioned values. In some aspects, one or more co-emulsifiers (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7.5 mg / mL, 10 mg / mL, 12.5 mg / mL, 15 mg / mL, 17.5 mg / mL, or ranges including and / or spanning the aforementioned values. In some aspects, a co-emulsifier exceeds requirements of the United States Pharmacopeia (is USP grade) and / or is National Formulary (NF) grade. In some aspects, a co-emulsifier component comprises a medium chain triglyceride (MCT). In some aspects, a medium chain triglyceride comprises a fatty acid selected from one or more of caproic acid, octanoic acid, capric acid, caprylic acid, and / or lauric acid (e.g., is formed from). In some aspects, a medium chain triglyceride comprises a fatty acid 6-12 carbons in length (e.g., 6, 7, 8, 9, 10, 11, or 12). In some aspects, a co-emulsifier component comprises a long chain triglyceride (LCT). In some aspects, a long chain triglyceride comprises a fatty acid greater than 12 carbons in length (e.g., greater than or equal to 13, 14, 15, 16, 17, 18, 19, or 20 carbons in length, or ranges including and / or spanning the aforementioned values).304076022 - 49 -Atty. Docket No.: UTSDP4583WO-1001393863In some aspects, a co-emulsifier component is a single lipid. In some aspects, a co-emulsifier component is highly pure. In some aspects, a co-emulsifier component has a purity by weight % of equal to or greater than about: 90%, 95%, 97%, 98%, 99%, 100%, or ranges including and / or spanning the aforementioned values. In some aspects, a co-emulsifier component is present in the nanoparticle composition at dry weight % of equal to or greater than about: 10%, 20%, 30%, 35%, 40%, 45%, 50%, or ranges including and / or spanning the aforementioned values.

[0146] In some aspects, a nanoparticle composition comprises one or more sterols. In certain aspects, a nanoparticle composition does not comprise a sterol. In some aspects, one or more sterols comprise one or more cholesterols, ergosterols, hopanoids, hydroxysteroids, phytosterols (e.g., vegapure), ecdysteroids, and / or steroids. In some aspects, a sterol comprises a cholesterol. In some aspects, a sterol component is a single sterol. In some aspects, a sterol component is cholesterol. In some aspects, cholesterol (or other sterol) is highly pure. In some aspects, one or more sterol(s) (e.g., cholesterol, and / or other sterols), collectively or individually, are present in the aqueous composition at a concentration of less than or equal to about: 50 mg / mL, 40 mg / mL, 20 mg / mL, 10 mg / mL, 5 mg / mL, or ranges including and / or spanning the aforementioned values. In some aspects, one or more sterol(s) are present in the composition at a dry wt. % of equal to or less than about: 0.25%, 0.5%, 1%, 5%, 7.5%, 10%, 15%, 20%, 25%, or ranges including and / or spanning the aforementioned values. In some aspects, one or more sterol(s) (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0.1%, 0.25%, 0.5%, 1%, 2%, 3%, 4%, 5%, 7.5%, 10%, or ranges including and / or spanning the aforementioned values. In some aspects, cholesterol used in the composition comprises cholesterol from one or more sheep’s wool, synthetic cholesterol, or semisynthetic cholesterol from plant origin. In some aspects, a sterol has a purity of greater than or equal to about: 92.5%, 95%, 96%, 98%, 99%, 99.9%, 100.0%, or ranges including and / or spanning the aforementioned values. In some aspects, a sterol has a total % impurity content by weight of less than or equal to about: 8.5%, 5%, 4%, 3.7%, 2%, 1%, 0%, or ranges included and / or spanning the aforementioned values. In some aspects, sterol is not cholesterol.

[0147] In some aspects, a nanoparticle composition comprises a preservative. In certain aspects, a nanoparticle composition does not comprise a preservative. In several aspects, a preservative includes one or more benzoates (such as sodium benzoate or potassium benzoate), nitrites (such as sodium nitrite), sulfites (such as sulfur dioxide, sodium or potassium sulphite, bisulphite or metabisulphite), sorbates (such as sodium sorbate, potassium sorbate), ethylenediaminetetraacetic acid (EDTA) (and / or the disodium salt thereof), polyphosphates, organic acids (e.g., citric, succinic, malic, tartaric, benzoic, lactic304076022 - 50 -Atty. Docket No.: UTSDP4583WO-1001393863and propionic acids), and / or antioxidants (e.g., vitamins such as vitamin E and / or vitamin C, butylated hydroxytoluene). In several aspects, sorbates and benzoates may be used in acidic pH formulations. In several aspects, one or more preservatives (collectively or individually) are present in the composition at a dry wt. % of equal to or at less than about: 0.01 %, 0.1 %, 0.25%, 0.5%, 1%, 5%, 7.5%, 10%, 15%, 20%, 25%, or ranges including and / or spanning the aforementioned values. In several aspects, one or more preservatives (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0.001%, 0.01%, 0.025%, 0.05%, 0.1%, 0.5%, 0.75%, 1.0%, 1.5%, 2.0%, 2.5%, 5%, or ranges including and / or spanning the aforementioned values. In several aspects, one or more preservatives (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.001 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, or ranges including and / or spanning the aforementioned values. In several aspects, as disclosed elsewhere herein, the composition is aqueous, while in others it has dried into a powder. For instance, as disclosed elsewhere herein, in several aspects, the composition is aqueous (wet), while in others it has been dried into a powder (dry). In several aspects, preservatives inhibit or prevent growth of mold, bacteria, and / or fungus.

[0148] In some aspects, a nanoparticle composition comprises a metal. In some aspects, a metal may be zinc. In certain aspects, a nanoparticle composition does not comprise a metal. In several aspects, one or more metals (collectively or individually) are present in the composition at a dry wt. % of equal to or at less than about: 0.01%, 0.1%, 0.25%, 0.5%, 1%, 5%, 7.5%, 10%, 15%, 20%, 25%, or ranges including and / or spanning the aforementioned values. In several aspects, one or more metals (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0.001%, 0.01%, 0.025%, 0.05%, 0.1%, 0.5%, 0.75%, 1.0%, 1.5%, 2.0%, 2.5%, 5%, or ranges including and / or spanning the aforementioned values. In several aspects, one or more metals (collectively or individually) are present in the composition at a wet w / v of equal to or less than about: 0 mg / mL, 0.001 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 4 mg / mL, 5 mg / mL, or ranges including and / or spanning the aforementioned values. In some aspects, metals may be combined with metalloligands to generate a nanoscale coordination polymer. In some aspects, nanoscale coordination polymers may comprise metal-connecting points and organic bridging ligands. In some aspects, a nanoscale coordination polymer (NCP) may self-assemble into nanoparticles.

[0149] In several aspects, as disclosed elsewhere herein, a nanoparticle composition provides particles in the nano-measurement range. In several aspects, a nanoparticle is spherical or substantially spherical. In several aspects, a solid lipid nanoparticle possesses a solid lipid core matrix that can solubilize lipophilic molecules. In several aspects, a lipid core304076022 - 51 -Atty. Docket No.: UTSDP4583WO-1001393863is stabilized by surfactants and / or emulsifiers as disclosed elsewhere herein, while in other aspects, surfactants are absent. In several aspects, the size of the particle is measured as a mean diameter. In several aspects, the size of the particle can be measured by dynamic light scattering. In several aspects, the size of the particle can be measured using a zeta-sizer. In several aspects, the size of the particle can be measured using Scanning Electron Microscopy (SEM). In several aspects, the size of the particle can be measured using a cryogenic SEM (cryo-SEM). Where the size of a nanoparticle is disclosed elsewhere herein, any one or more of these instruments or methods may be used to measure such sizes.

[0150] In several aspects, a nanoparticle composition may comprise nanoparticles having an average size of less than or equal to about: 10 nm, 25 nm, 40 nm, 50 nm, 100 nm, 250 nm, 500 nm, 1000 nm, or ranges including and / or spanning the aforementioned values. In several aspects, a composition comprises nanoparticles having an average size of between about 50 nm and 150 nm or between about 50 and about 250 nm. In several aspects, the size distribution of the nanoparticles for at least 50%, 75%, 80%, 90% (or ranges including and / or spanning the aforementioned percentages) of the particles present is equal to or less than about: 20 nm, 40 nm, 60 nm, 80 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 160 nm, 180 nm, 200 nm, 300 nm, 400 nm, 500 nm, or ranges including and / or spanning the aforementioned nm values. In several aspects, a composition comprises nanoparticles having an average size of less than or equal to about: 10 nm, 50 nm, 100 nm, 250 nm, 500 nm, 1000 nm, or ranges including and / or spanning the aforementioned values. In several aspects, the size distribution of the nanoparticles for at least 90% of the particles present is equal to or less than about: 20 nm, 40 nm, 60 nm, 80 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 160 nm, 180 nm, 200 nm, 300 nm, 400 nm, 500 nm, or ranges including and / or spanning the aforementioned nm values. In several aspects, the size distribution of the nanoparticles for at least 90% of the particles present is equal to or less than about: 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 160 nm, 180 nm, 200 nm, or ranges including and / or spanning the aforementioned nm values. In several aspects, the D90 of the particles present is equal to or less than about: 80 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 160 nm, 180 nm, 200 nm, 300 nm, 400 nm, 500 nm, or ranges including and / or spanning the aforementioned values. In several aspects, the size of the nanoparticle is the diameter of the nanoparticle as measured using any of the techniques as disclosed elsewhere herein. For instance, in some aspects, the size of the nanoparticle is the measured using dynamic light scattering. In several aspects, the size of the nanoparticle is the measured using a zeta sizer. In several aspects, consistency in size over time, or within a sample, allows predictable stability for the active agent encapsulated therein.304076022 - 52 -Atty. Docket No.: UTSDP4583WO-1001393863

[0151] In several aspects, over 50%, 75%, 95% (or ranges spanning and or including the aforementioned values) of nanoparticles prepared by methods disclosed herein have a particle size of between about 20 to about 500 nm (e.g., as measured by zeta sizing (e.g., refractive index)). In several aspects, over 50%, 75%, 95% (or ranges spanning and or including the aforementioned values) of nanoparticles prepared by methods disclosed herein have a particle size of between about 50 nm to about 200 nm (e.g., as measured by zeta sizing (e.g., refractive index)). In several aspects, over 50%, 75%, 95% (or ranges spanning and or including the aforementioned values) of nanoparticles prepared by methods disclosed herein have a particle size of between about 90 nm to about 150 nm (e.g., as measured by zeta sizing (e.g., refractive index)). In several aspects, maintaining consistency in size allows predictable delivery to subjects. In several aspects, the D90 particle size measurement varies between 150 and 500 nm.

[0152] In several aspects, the average size of the nanoparticles of a composition as disclosed herein may be substantially constant and / or does not change significantly over time (e.g., it is a stable nanoparticle). In several aspects, after formulation and storage for a period of at least about 1 month (30 days), about 3 months (90 days), or about 6 months (180 days) (e.g., at ambient conditions, at 25 °C with 60% relative humidity, or under the other testing conditions disclosed elsewhere herein), the average size of nanoparticles comprising the composition changes less than or equal to about: 1%, 5%, 10%, 20%, or ranges including and / or spanning the aforementioned values.

[0153] In several aspects, the polydispersity index (PDI) of the nanoparticles of a composition as disclosed herein is less than or equal to about: 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, or ranges including and / or spanning the aforementioned values. In several aspects, the size distribution of the nanoparticles is highly monodisperse with a polydispersity index of less than or equal to about: 0.05, 0.10, 0.15, 0.20, 0.25, or ranges including and / or spanning the aforementioned values.

[0154] In several aspects, the zeta potential of the nanoparticles of a composition as disclosed herein is less than or equal to about: 1 mV, 3 mV, 4 mV, 5 mV, 6 mV, 7 mV, 8 mV, 10 mV, 20 mV, or ranges including and / or spanning the aforementioned values. In several aspects, the zeta potential of the nanoparticles is greater than or equal to about: -3 mV, -1 mV, 0 mV, 1 mV, 3 mV, 4 mV, 5 mV, 6 mV, 7 mV, 8 mV, 4 mV, 10 mV, 20 mV, or ranges including and / or spanning the aforementioned values. In several aspects, the zeta potential and / or diameter of the particles (e.g., measured using dynamic light scattering) is acquired using a zetasizer (e.g., a Malvern ZS90 or similar instrument).304076022 - 53 -Atty. Docket No.: UTSDP4583WO-1001393863

[0155] In several aspects, as disclosed elsewhere herein, a nanoparticle composition is an oil-in-water emulsion, water-in-oil emulsion, water-in-oil-in-water emulsion, oil-in-water-in-oil emulsion, liposome, solid lipid particles formulation, etc. For brevity, these may just be referred to as the composition. In several aspects, a nanoparticle composition can be processed to comprises one or more of solid lipid nanoparticles, liposomes (and variants including multi-lamellar, double liposome preparations, etc.), niosomes, ethosomes, electrostatic particulates, microemulsions, nanoemulsions, microsuspensions, nanosuspensions, or combinations thereof. In several aspects, polymeric nanoparticles may be formed. In several aspects, cyclodextrin is added.

[0156] In several aspects, a solid lipid nanoparticle composition comprises a lipid core matrix. In several aspects, the lipid core matrix is solid. In several aspects, the solid lipid comprises one or more ingredients as disclosed elsewhere herein. In several aspects, the core of the solid lipid comprises one or more lipids, surfactants, active ingredients, etc. In several aspects, the surfactant acts as an emulsifier. In several aspects, emulsifiers can be used to stabilize the lipid dispersion (with respect to charge and molecular weight). In several aspects, the core ingredients (e.g., the components of the core) are present in the composition (collectively or individually) at a dry wt. % of equal to or less than about: 0.5%, 1.0%, 2.5%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 80% or ranges including and / or spanning the aforementioned values. In several aspects, the core ingredients and / or the emulsifiers (collectively or individually) are present in the composition at a wet wt. % of equal to or less than about: 0.5%, 1.0% 2.5%, 5%, 7.5%, 10%, 12.5%, 15%, 20%, 30%, 40%, 60% or ranges including and / or spanning the aforementioned values.

[0157] In several aspects, a nanoparticle composition (e.g., when in water or dried) comprises multilamellar nanoparticle vesicles, unilamellar nanoparticle vesicles, multivesicular nanoparticles, emulsion particles, irregular particles with lamellar structures and bridges, partial emulsion particles, combined lamellar and emulsion particles, and / or combinations thereof. In certain aspects, the nanoparticle compositions do not comprise multilamellar nanoparticle vesicles, unilamellar nanoparticle vesicles, multivesicular nanoparticles, emulsion particles, irregular particles with lamellar structures and bridges, partial emulsion particles, combined lamellar and emulsion particles, and / or combinations thereof. In several aspects, the composition is characterized by having multiple types of particles (e.g., lamellar, emulsion, irregular, etc.). In other aspects, a majority of the particles are emulsion particles. In several aspects, a majority of the particles present are lamellar (multilamellar and / or unilamellar). In other aspects, a majority of the particles present are irregular particles. In still other aspects, a minority of the particles present are emulsion particles. In several aspects, a304076022 - 54 -Atty. Docket No.: UTSDP4583WO-1001393863minority of the particles present are lamellar (multilamellar and / or unilamellar). In other aspects, a minority of the particles present are irregular particles.

[0158] In several aspects, multilamellar nanoparticles comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). For example, in some aspects, between about 5% and about 10% of the particles present are multilamellar. In several aspects, unilamellar nanoparticles comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 20%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). For example, in some aspects, between about 10% and about 15% of the particles present are unilamellar.

[0159] In several aspects, emulsion particles comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 25%, 50%, 60%, 65%, 70%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). For example, in some aspects, between about 60% to about 75% of the particles present are emulsion particles.

[0160] In several aspects, micelle particles comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 25%, 50%, 60%, 65%, 70%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). In several aspects, liposomes comprise equal to or at least about 5%, 8%, 9%, 10%, 15%, 25%, 50%, 60%, 65%, 70%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). In several aspects, irregular particles (including particles with lamellar structures and / or bridges) comprise equal to or at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). For example, in some aspects, between about 1% to about 5% of the particles present are irregular particles. In several aspects, combined lamellar and emulsion particles comprise equal to or at least about 5%, 6%, 7%, 8%, 9%, 10%, 15%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition). In several aspects, mixed-micelle particles comprise equal to or at least about 5%, 6%, 7%, 8%, 9%, 10%, 15%, 25%, 50%, 75%, 85%, 95%, or 100% (or ranges spanning and / or including the aforementioned values) of the particles present in the composition (e.g., the aqueous composition).304076022 - 55 -Atty. Docket No.: UTSDP4583WO-1001393863

[0161] The nanoparticle compositions can comprise, but are not limited to, combinations of multilamellar nanoparticles, unilamellar nanoparticles, emulsion nanoparticles, micelle nanoparticles, irregular particles, and / or liposomes.

[0162] The percentages and / or concentrations of particles present in the composition may be purposefully modified. In some aspects, the percentage and / or concentration of the particles present in the composition are tailored to the active compound and / or the liquid comprising the particles. Such tailoring may lead to more homogenization and / or dispersion in the liquid. The tailoring may stabilize dispersion in the liquid.

[0163] In several aspects, the formulations and / or compositions disclosed herein are stable during sterilization. In several aspects, the sterilization may include one or more of ozonation, LIV treatment, and / or heat treatment. In several aspects, the particle size and / or PDI after sterilization (e.g., exposure to techniques that allow sterilization of the composition) varies by less than or equal to about: 1%, 5%, 10%, 20%, 30%, or ranges including and / or spanning the aforementioned values. In several aspects, the therapeutic agent concentration after sterilization (e.g., exposure to techniques that allow sterilization of the composition) varies (e.g., drops) by less than or equal to about: 1%, 5%, 10%, 15%, or ranges including and / or spanning the aforementioned values.

[0164] In several aspects, the nanoparticle compositions (including after stabilization) disclosed herein have a shelf life of equal to or greater than 1 month, 3 months, 6 months, 12 months, 14 months, 16 months, 18 months, 19 months, or ranges including and / or spanning the aforementioned values. The shelf-life can be determined as the period of time in which there is 95% confidence that at least 50% of the response (active agent(s) concentration or particle size) is within the specification limit. This refers to a 95% confidence interval and when linear regression predicts that at least 50% of the response is within the set specification limit.IV. Dosage formulations

[0165] In certain aspects, the present disclosure provides compositions comprising one or more inhibitors disclosed herein, formulated for one or more routes of administration. Suitable routes of administration may, for example, include intravenous, intramuscular, intraperitoneal, oral, subcutaneous, intranasal route, cranial, transmucosal, trans-nasal, intestinal, and / or parenteral delivery. In some aspects, compositions herein formulated can be formulated for parenteral delivery, specifically intravenous delivery. In some aspects, compositions can be formulated for intramuscular, subcutaneous, intramedullary, intravenous, intraperitoneal, and / or intranasal injections.

[0166] In certain aspects, one may administer a composition herein in a local or systemic manner, for example, via local injection of the pharmaceutical composition directly into a tissue304076022 - 56 -Atty. Docket No.: UTSDP4583WO-1001393863region of a patient. In some aspects, a pharmaceutical composition disclosed herein can be administered parenterally, e.g., by intravenous injection, intracerebroventricular injection, intra-cisterna magna injection, intra-parenchymal injection, or a combination thereof. In some aspects, a pharmaceutical composition disclosed herein can administered to a subject as disclosed herein. In some aspects, a pharmaceutical composition disclosed herein can be administered to a human patient. In some aspects, a pharmaceutical composition disclosed herein can be administered to a human patient via at least two administration routes.

[0167] In certain aspects, pharmaceutical compositions of the present disclosure may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[0168] In certain aspects, pharmaceutical compositions for use in accordance with the present disclosure, thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. For injection, the active ingredients of a pharmaceutical composition herein may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, physiological salt buffer, or any combination thereof.

[0169] In certain aspects, pharmaceutical compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection herein may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. In some aspects, compositions herein may be suspensions, solutions or emulsions in oily or aqueous vehicles, and / or may contain formulatory agents such as suspending, stabilizing and / or dispersing agents.

[0170] In certain aspects, pharmaceutical compositions herein formulated for parenteral administration may include aqueous solutions of the active preparation (e.g., a polynucleotide construct) in water-soluble form. In some aspects, compositions herein comprising suspensions of the active preparation may be prepared as oily or water-based injection suspensions. Suitable lipophilic solvents and / or vehicles for use herein may include, but are not limited to, fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. In some aspects, compositions herein comprising aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and / or dextran. In some aspects, compositions herein comprising a suspension may also contain one or more suitable304076022 - 57 -Atty. Docket No.: UTSDP4583WO-1001393863stabilizers and / or agents which increase the solubility of the active ingredients (e.g., a polynucleotide construct / vector molecule) to allow for the preparation of highly concentrated solutions.

[0171] In some aspects, compositions herein may comprise the active ingredient in a powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water-based solution, before use.

[0172] Pharmaceutical compositions suitable for use in context of the present disclosure may include compositions wherein the active ingredients can be contained in an amount effective to achieve the intended purpose. In some aspects, a therapeutically effective amount means an amount of active ingredients (e.g., a polynucleotide construct molecule) effective to prevent, slow, alleviate or ameliorate symptoms of a disorder (e.g., EDE) or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. For any preparation used in the methods of the present disclosure, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays and or screening platforms disclosed herein. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

[0173] In some aspects, toxicity and therapeutic efficacy of the active ingredients disclosed herein (e.g., a polynucleotide construct / vector) can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. In some aspects, data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in a human subject. In some aspects, a dosage for use herein may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient’s condition.

[0174] In certain aspects, dosage amounts and / or dosing intervals may be adjusted individually to brain or blood levels of the active ingredient that are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). In some aspects, the MEC for an active ingredient (e.g., a polynucleotide construct / vector molecule or composition disclosed herein) may vary for each preparation but can be estimated from in vitro data. In some aspects, dosages necessary to achieve the MEC herein may depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.304076022 - 58 -Atty. Docket No.: UTSDP4583WO-1001393863

[0175] In certain aspects, depending on the severity and responsiveness of the condition to be treated, dosing with compositions herein can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

[0176] In certain aspects, the amounts of a composition herein to be administered will be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, and the like. In some aspects, effective doses may be extrapolated from dose-responsive curves derived from in vitro or in vivo test systems.

[0177] The active ingredient may be administered at once or may be divided into a number of smaller doses to be administered at intervals of time. The precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. Concentration and dosage values may also vary with the severity of the condition to be alleviated. For any particular subject, specific dosage regimens can be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.V. Method of treatment

[0178] GPR75 is a G protein-coupled receptor (GPCR) that traffics to neuronal cilia and is important in maintaining IP3 and DAG levels therein. It is expressed in several brain regions including the hypothalamus, and other tissues, playing a crucial role in regulating metabolism, energy homeostasis, and appetite control. Its localization to cilia is mediated by an adaptor protein, TLILP3. Modulating the localization of GPR75 to the cilia (e.g., by disrupting or promoting its interaction with TLILP3), and / or modulating its activity in the cilia, thereby modulating IP3 and DAG levels and directly or indirectly affecting other GPCRs activity, can have therapeutically beneficial effects. Accordingly, methods are provided below for treating various diseases or conditions using GPR75 inhibitors provided herein.

[0179] In some aspects, the current disclosure encompasses a method of treating a disease or a disorder, in a subject in need thereof, by decreasing levels of GPR75 (e.g., levels of GPR75 on a cell surface), reducing GPR75 localization to cilia, and / or reducing GPR75 activity in the cilia, as measured by GPR75 ciliary localization and / or IP3 and DAG levels. In various aspects, the methods may comprise administering a GPR75 inhibitor of the present disclosure to the subject. In various aspects, administering the GPR75 inhibitor may decrease IP3 and DAG levels in the cilia. In various aspects, administering the GPR75 inhibitor may decrease304076022 - 59 -Atty. Docket No.: UTSDP4583WO-1001393863IP3 and DAG levels in the primary cilia of hypothalamic neurons. In various aspects, administration of the inhibitor may decrease translocation of Gaqinto primary cilia (e.g., primary cilia of hypothalamic neurons). In various aspects, the inhibitor directly or indirectly reduces the association between GPR75 and a ciliary trafficking protein (e.g., TLILP3). In various aspects, the inhibitor directly or indirectly modulates GPR75 interactions with G«q.

[0180] In some aspects, administration of the GPR75 inhibitor into a subject in need thereof, may decrease the level of functional GPR75 by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% compared to baseline, wherein the baseline corresponds to the level of GPR75 in the subject prior to administration. In some aspects, administration of the GPR75 inhibitor into a subject in need thereof, may decrease the level of ciliary IP3 and DAG by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% compared to baseline, wherein the baseline corresponds to the level of IP3 and DAG in the subject prior to administration.

[0181] In various aspects, administering the GPR75 inhibitor may reduce body weight (e.g., excess body weight), prevent body weight gain, induce weight loss, decrease body fat, or reduce food intake in a subject (e.g., a subject in need thereof). In some aspects, the weight increase in a subject may be attributed to excessive ingestion of food or unbalanced diets or may be weight increase derived from a concomitant drug (e.g., insulin sensitizers having a PPARy agonist-like action, such as troglitazone, rosiglitazone, englitazone, ciglitazone, pioglitazone and the like). In some aspects, the weight increase may be weight increase before reaching obesity or maybe weight increase in an obese subject. In some aspects, the weight increase may also be medication-induced weight gain or weight gain subsequent to cessation of smoking. In some aspects, the weight increase in the subject may be associated with an eating disorder, such as hyperphagia, binge eating, bulimia, or compulsive eating.

[0182] Accordingly, in various aspects, methods for treating obesity in a subject are provided, the methods comprising administering a GPR75 inhibitor to the subject. Likewise, methods of reducing food intake or treating hyperphagia in a subject are provided, the methods comprising: administering a GPR75 inhibitor to the subject. In any of these methods, the inhibitor may reduce the ciliary localization of GPR75 and / or decrease IP3 and DAG levels in the primary cilia of neurons, (e.g., in primary cilia of hypothalamic neurons).

[0183] In various aspects, the disease or a disorder treated with a GPR75 inhibitor can comprise a metabolic disease. Accordingly, methods are also provided for treating and / or reducing risks of one or more metabolic diseases, the methods comprise administering a GPR75 inhibitor to the subject. In various aspects, metabolic diseases comprise type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension,304076022 - 60 -Atty. Docket No.: UTSDP4583WO-1001393863cardiovascular disease, obesity, or any combination thereof. These and other diseases and conditions that can be treated using the compositions of the present disclosure are described below.

[0184] In some aspects, the condition, disease or disorder is obesity and conditions, diseases or disorders that are associated with or related to obesity. Non-limiting examples of obesity and obesity related conditions include symptomatic obesity, simple obesity, childhood obesity, morbid obesity, and abdominal obesity (central obesity characterized by abdominal adiposity). Non-limiting examples of symptomatic obesity include endocrine obesity (e.g., Cushing syndrome, hypothyroidism, insulinoma, obese type II diabetes, pseudohypoparathyroidism, hypogonadism), hypothalamic obesity, hereditary obesity (e.g., Prader-Willi syndrome, Laurence-Moon-Biedl syndrome), and drug-induced obesity (e.g., steroid, phenothiazine, insulin, sulfonylurea agent, or p-blocker-induced obesity).

[0185] In some aspects, the condition, disease or disorder is associated with obesity. Examples of such conditions, diseases or disorders include, without limitation, glucose tolerance disorders, diabetes (e.g., type 2 diabetes, obese diabetes), lipid metabolism abnormality, hyperlipidemia, hypertension, cardiac failure, hyperuricemia, gout, fatty liver (including non-alcoholic steatohepatitis (NASH)), coronary heart disease (e.g., myocardial infarction, angina pectoris), cerebral infarction (e.g., brain thrombosis, transient cerebral ischemic attack), bone or articular disease (e.g., knee osteoarthritis, hip osteoarthritis, spondylitis deformans, lumbago), sleep apnea syndrome, obesity hypoventilation syndrome (Pickwickian syndrome), menstrual disorder (e.g., abnormal menstrual cycle, abnormality of menstrual flow and cycle, amenorrhea, abnormal catamenial symptom), visceral obesity syndrome, and metabolic syndrome. In some aspects, the chemical compound and pharmaceutical compositions described herein can be used to treat subjects exhibiting symptoms of both obesity and insulin deficiency.Diabetes

[0186] In some aspects, the condition, disease or disorder is diabetes. Non-limiting examples of diabetes include type 1 diabetes mellitus, type 2 diabetes mellitus (e.g., diet-treated type 2-diabetes, sulfonylurea-treated type 2-diabetes, a far-advanced stage type 2-diabetes, longterm insulin-treated type 2-diabetes), diabetes mellitus (e.g., non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus), gestational diabetes, obese diabetes, autoimmune diabetes, and borderline type diabetes. In some aspects, the condition, disease or disorder is type 2 diabetes mellitus (e.g., diet-treated type 2-diabetes, sulfonylurea-treated304076022 - 61 -Atty. Docket No.: UTSDP4583WO-1001393863type 2-diabetes, a far-advanced stage type 2-diabetes, long-term insulin-treated type 2-diabetes).

[0187] In some aspects, compositions and methods for treating a subject with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce fasting plasma glucose levels. In some aspects, compositions and methods for treating a subject with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce nonfasting plasma glucose levels. In some aspects, compositions and methods for treating a subject with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce HbA1c levels. In some aspects, compositions and methods for treating a subject with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce glucagon levels. In some aspects, compositions and methods for treating a subject with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein increase insulin levels. In some aspects, compositions and methods for treating a subject with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce BMI.

[0188] In some aspects, a reduction in fasting plasma glucose levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in fasting plasma glucose levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in fasting plasma glucose levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in fasting plasma glucose levels to about or below 126 mg / dL, about or below 110 mg / dL, or about or below 90 mg / dL indicates treatment of the type 2 diabetes mellitus.

[0189] In some aspects, a reduction in non-fasting plasma glucose levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in nonfasting plasma glucose levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in non-fasting plasma glucose levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in non-fasting plasma glucose levels to about or below 200 mg / dL, about or below 150 mg / dL, or about or below 130 mg / dL indicates treatment of type 2 diabetes mellitus.

[0190] In some aspects, a reduction in HbA1c levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in HbA1c levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in HbA1c levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some aspects, reduction in HbA1c levels to about or below 6.5%, about or below 6.0%, or about or below 5.0% indicates treatment of type 2 diabetes mellitus.304076022 - 62 -Atty. Docket No.: UTSDP4583WO-1001393863

[0191] In some aspects, a reduction in glucagon levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in glucagon levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in glucagon levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some aspects, an increase in insulin levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some aspects, an increase in insulin levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some aspects, an increase in insulin levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus.

[0192] In some aspects, a reduction in BMI of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in BMI of about 15% to about 80% indicates treatment of the type 2 diabetes mellitus. In some aspects, a reduction in BMI of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in BMI of about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% indicates treatment of type 2 diabetes mellitus. In some aspects, a reduction in BMI to about or below 40, about or below 30, or about or below 20 indicates treatment of type 2 diabetes mellitus.

[0193] In some aspects, the condition, disease or disorder is associated with diabetes (e.g., a complication of diabetes). Non-limiting examples of disorders associated with diabetes include obesity, obesity-related disorders, metabolic syndrome, neuropathy, nephropathy (e.g., diabetic nephropathy), retinopathy, diabetic cardiomyopathy, cataract, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious disease (e.g., respiratory infection, urinary tract infection, gastrointestinal infection, dermal soft tissue infections, inferior limb infection), diabetic gangrene, xerostomia, hypacusis, cerebrovascular disorder, diabetic cachexia, delayed wound healing, diabetic dyslipidemia peripheral blood circulation disorder, cardiovascular risk factors, (e.g., coronary artery disease, peripheral artery disease, cerebrovascular disease, hypertension, and risk factors related to unmanaged cholesterol and / or lipid levels, and / or inflammation), NASH, bone fracture, and cognitive dysfunction.

[0194] Other non-limiting examples of disorders related to diabetes include pre-diabetes, hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, high LDL-cholesterol, low HDL-cholesterol, postprandial hyperlipemia), metabolic syndrome (e.g., metabolic disorder where activation of GLP-1R is beneficial, metabolic syndrome X), hypertension, impaired glucose tolerance (IGT), insulin resistance, and sarcopenia.304076022 - 63 -Atty. Docket No.: UTSDP4583WO-1001393863

[0195] In some aspects, the condition, disease or disorder is diabetes and obesity (diabesity). In some aspects, the compounds described herein are also useful in improving the therapeutic effectiveness of metformin.Disorders of Metabolically Important Tissues

[0196] In some aspects, the condition, disease or disorder is a disorder of a metabolically important tissue. Non-limiting examples of metabolically important tissues include liver, fat, pancreas, kidney, and gut.

[0197] In some aspects, the condition, disease or disorder is a fatty liver disease. Fatty liver diseases include, but are not limited to, non-alcoholic fatty acid liver disease (NAFLD), steatohepatitis, non-alcoholic steatohepatitis (NASH), fatty liver disease resulting from hepatitis, fatty liver disease resulting from obesity, fatty liver disease resulting from diabetes, fatty liver disease resulting from insulin resistance, fatty liver disease resulting from hypertriglyceridemia, Abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolman’s disease, acute fatty liver of pregnancy, and lipodystrophy.

[0198] Other non-limiting examples of disorders in metabolically important tissues include joint disorders (e.g., osteoarthritis, secondary osteoarthritis), steatosis (e.g. in the liver); gall stones; gallbladder disorders; gastroesophageal reflux; sleep apnea; hepatitis; fatty liver; bone disorder characterized by altered bone metabolism, such as osteoporosis, including postmenopausal osteoporosis, poor bone strength, osteopenia, Paget's disease, osteolytic metastasis in cancer subjects, osteodystrophy in liver disease and the altered bone metabolism caused by renal failure or hemodialysis, bone fracture, bone surgery, aging, pregnancy, protection against bone fractures, and malnutrition polycystic ovary syndrome; renal disease (e.g., chronic renal failure, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal disease); muscular dystrophy, angina pectoris, acute or chronic diarrhea, testicular dysfunction, respiratory dysfunction, frailty, sexual dysfunction (e.g., erectile dysfunction), and geriatric syndrome. In some aspects, compositions described herein can be used for treating surgical trauma by improving recovery after surgery and / or by preventing the catabolic reaction caused by surgical trauma.Cardiovascular and Vascular Diseases

[0199] In some aspects, the condition, disease or disorder is a cardiovascular disease. Nonlimiting examples of cardiovascular disease include congestive heart failure, atherosclerosis, arteriosclerosis, coronary heart disease, coronary artery disease, congestive heart failure, coronary heart disease, hypertension, cardiac failure, cerebrovascular disorder (e.g., cerebral infarction), vascular dysfunction, myocardial infarction, elevated blood pressure (e.g., 130 / 85304076022 - 64 -Atty. Docket No.: UTSDP4583WO-1001393863mm Hg or higher), and prothrombotic state (exemplified by high fibrinogen or plasminogen inhibitor in the blood).

[0200] In some aspects, the condition, disease or disorder is related to a vascular disease. Non-limiting examples of vascular diseases include peripheral vascular disease, macrovascular complications (e.g., stroke), vascular dysfunction, peripheral artery disease, abdominal aortic aneurysm, carotid artery disease, cerebrovascular disorder (e.g., cerebral infarction), pulmonary embolism, chronic venous insufficiency, critical limb ischemia, retinopathy, nephropathy, and neuropathy.Insulin-Related

[0201] In some aspects, the condition, disease or disorder is impaired fasting glucose (IFG), impaired fasting glycemia (IFG), hyperglycemia, insulin resistance (impaired glucose homeostasis), hyperinsulinemia, elevated blood levels of fatty acids or glycerol, a hypoglycemic condition, insulin resistant syndrome, paresthesia caused by hyperinsulinemia, hyperlipidemia, hypercholesteremia, impaired wound healing, leptin resistance, glucose intolerance, increased fasting glucose, dyslipidemia (e.g., hyperlipidemia, atherogenic dyslipidemia characterized by high triglycerides and low HDL cholesterol), glucagonoma, hyperuricacidemia, hypoglycemia (e.g., nighttime hypoglycemia), and concomitant comatose endpoint associated with insulin.

[0202] In some aspects, compositions described herein can reduce or slow down the progression of borderline type, impaired fasting glucose or impaired fasting glycemia into diabetes.Diseases

[0203] In some aspects, the condition, disease or disorder is an inflammatory disorder. Nonlimiting examples of inflammatory disorders include chronic rheumatoid arthritis, spondylitis deformans, arthritis deformans, lumbago, gout, post-operational or post-traumatic inflammation, bloating, neuralgia, laryngopharyngitis, cystitis, pneumonia, pancreatitis, enteritis, inflammatory bowel disease (including inflammatory large bowel disease), inflammation in metabolically important tissues including liver, fat, pancreas, kidney and gut, and a proinflammatory state (e.g., elevated levels of proinflammatory cytokines or markers of inflammation-like C-reactive protein in the blood).Administration

[0204] As used herein, “an effective amount” refers to the amount of each active agent required to confer therapeutic effect on the subject, either alone or in combination with one or more other active agents. An effective amount may refer to a dose of compound sufficient to304076022 - 65 -Atty. Docket No.: UTSDP4583WO-1001393863provide circulating or local concentrations high enough to impart a beneficial effect on the recipient thereof. The precise amount to be administered can be determined by the skilled practitioner in view of desired dosages, side effects, and medical history of the patient. Determination of whether an amount of the nucleic acids, the small molecules, or the polypeptides / peptide, disclosed herein has achieved a therapeutic effect would be evident to one of skill in the art. Effective amounts vary, as recognized by those skilled in the art, depending on the condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size, gender and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. In some aspects, a maximum dose of the individual components or combinations thereof may be used, that is, the highest safe dose according to sound medical judgment. In some aspects, empirical considerations, such as the half-life, generally will contribute to the determination of the dosage. In some aspects, frequency of administration may be determined and adjusted over the course of therapy, and is generally, but not necessarily, based on treatment and / or suppression and / or amelioration and / or delay of a target disease / disorder. In some aspects, sustained continuous release formulations of an antibody herein may be appropriate. Various formulations and devices for achieving sustained release are known in the art and provided herein.

[0205] In some aspects, dosages as described herein may be determined empirically in individuals who have been given one or more administration(s) of an activator disclosed herein. In accordance with some aspects herein, individuals can be given incremental dosages. To assess efficacy of the antibody, polynucleotide or small molecule, an indicator of the disease / disorder can be followed.

[0206] In some aspects, for administration of any of the pharmaceutical compositions described herein, an initial candidate dosage can be about 2-200 mg / kg. For the purpose of the present disclosure, a typical daily dosage may range from about any of 0.1 pg / kg to 3 pg / kg to 30 pg / kg to 300 pg / kg to 3 mg / kg, to 30 mg / kg to 300 mg / kg weight of the subject or more, depending on the factors mentioned above. In some aspects, a typical daily dosage may be 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 20 mg / kg, 21 mg / kg, 22 mg / kg, 23 mg / kg, 24 mg / kg, 25 mg / kg, 26 mg / kg, 27 mg / kg, 28 mg / kg, 29 mg / kg, 30 mg / kg, 31 mg / kg, 32 mg / kg, 33 mg / kg, 34 mg / kg, 35 mg / kg, 36 mg / kg, 37 mg / kg, 38 mg / kg, 39 mg / kg, 40 mg / kg, 41 mg / kg, 42 mg / kg, 43 mg / kg, 44 mg / kg, 45 mg / kg, 46 mg / kg, 47 mg / kg, 48 mg / kg, 49 mg / kg, 50 mg / kg weight of the subject. In some aspects, for an adult patient of normal304076022 - 66 -Atty. Docket No.: UTSDP4583WO-1001393863weight, doses ranging from about 0.5 to about 200 mg / kg may be administered. In some aspects, the dosage described herein can be less than, more than, equal to or about 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 20 mg / kg, 21 mg / kg, 22 mg / kg, 23 mg / kg, 24 mg / kg, 25 mg / kg, 26 mg / kg, 27 mg / kg, 28 mg / kg, 29 mg / kg, 30 mg / kg, 31 mg / kg, 32 mg / kg, 33 mg / kg, 34 mg / kg, 35 mg / kg, 36 mg / kg, 37 mg / kg, 38 mg / kg, 39 mg / kg, 40 mg / kg, 41 mg / kg, 42 mg / kg, 43 mg / kg, 44 mg / kg, 45 mg / kg, 46 mg / kg, 47 mg / kg, 48 mg / kg, 49 mg / kg, 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg, 150 mg / kg, 200 mg / kg, or more. The particular dosage regimen, i.e., dose, timing and repetition, can depend on the particular individual and that individual’s medical history, as well as the properties of the individual agents (such as the half-life of the agent, and other considerations well known in the art). For repeated administration over several days or longer, depending on the condition, treatment methods of the present disclosure may be sustained until a desired suppression of symptoms occurs and / or until sufficient therapeutic levels are achieved to alleviate a target disease or disorder, or a symptom thereof. In some aspects, a dosing regimen herein may comprise administering a dose of about 2-200 mg / kg. In some aspects, other dosage regimens may be useful, depending on the pattern of pharmacokinetic decay that the practitioner wishes to achieve. In accordance with some aspects herein, dosing from one-four times a week is contemplated. In some aspects, dosing ranging from about 0.5 mg / kg to about 200 mg / kg may be used. In some aspects, dosing frequency may be more than, less than, about or equal to twice daily, once daily, twice weekly, once every week, every 2 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, or every 10 weeks; or once every month, every 2 months, or every 3 months, or longer. In some aspects, the progress of this therapy can be easily monitored by conventional techniques and assays. In some aspects, a dosing regimen (including the disclosed antibody used) suitable for use herein can vary over time.

[0207] In some aspects, the pharmaceutical compositions disclosed herein may be administered to the subject by a variety of routes. For example, one or more of the compositions disclosed herein may be administered orally via a solid or liquid dosage form (tablet, gel cap, time release capsule powder, solution, or suspension in aqueous or nonaqueous liquid), parenterally (i.e., subcutaneously, intradermally, intravenously, (i.e., as a solution, suspension, or emulsion in a carrier), and / or intramuscularly, intracranially, or intraperitoneally). In one aspect, the compounds may be administered in saline or with a pharmaceutically acceptable excipient as described above. In some aspects, the disclosed compositions may be administered in various dosage and may be suitably administered in an oral form.304076022 - 67 -Atty. Docket No.: UTSDP4583WO-1001393863

[0208] The composition may be administered at various doses and in various ways, for example, once a day or several times by dividing daily doses, depending on a patient's body weight, age, sex, health condition, a diet, administration time, an administration method, and the severity of a disease. In some aspects, administration of a disclosed composition as described herein is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In some aspects, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. For example, the period of administration of the disclosed composition followed by a period where administration is stopped is repeated for a determined or undetermined period of time. In some aspects, a period of administration is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In some aspects, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.

[0209] In some aspects, the composition is for administration at least, at most, about 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 60 min, 70 min, 80 min, 90 min prior to intake of a meal (for example, breakfast, lunch, or dinner). In some aspects, the composition is for administration at least, at most, about 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 60 min, 70 min, 80 min, 90 min after intake of a meal (for example, breakfast, lunch, or dinner). In some aspects, the composition is formulated for oral intake as a once daily, twice daily, thrice daily or 4 times daily intake.

[0210] Generally, the composition will be administered in a therapeutically effective amount which includes prophylactic amounts or lower dosages for example, when combined with another agent. In certain aspects, a compound disclosed herein may be administered to a subject intravenously at a concentration ranging from about 0.5 mg / kg to about 200 mg / kg. In some aspects, a compound disclosed herein may be administered to a subject intravenously at a concentration of about less than, more than, equal to or about 0.5 mg / kg, 1 mg / kg, 2304076022 - 68 -Atty. Docket No.: UTSDP4583WO-1001393863mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, 40 mg / kg, about 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg, 150 mg / kg, 200 mg / kg, or more. In some aspects, a compound disclosed herein may be administered to a subject intravenously at least once a day, at least twice a day, at least three times a day, or more.

[0211] In certain aspects, a compound disclosed herein may be administered to a subject orally at a concentration ranging from about 5 mg / kg to about 500 mg / kg. In some aspects, a compound disclosed herein may be administered to a subject orally at a concentration of about less than, more than, equal to or about 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg, 40 mg / kg, about 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg, 150 mg / kg, 200 mg / kg, or more. In some aspects, a compound disclosed herein may be administered to a subject orally at least once a day, at least twice a day, at least three times a day or more.

[0212] In certain aspects, treatments administered according to the methods disclosed herein reduce symptoms and / or can improve patient life expectancy compared to the life expectancy and / or symptoms an untreated subject with identical disease condition and predicted outcome. As used herein, “patient life expectancy” is defined as the time at which 50 percent of subjects are alive and 50 percent have passed away. In some aspects, patient life expectancy can be indefinite following treatment according to the methods disclosed herein. In other aspects, patient life expectancy can be increased at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, at least about 40% or greater to at least about 60% or greater compared to an untreated subject with identical disease condition and predicted outcome. In some aspects, patient life expectancy can be increased at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, at least about 100% compared to an untreated subject with identical disease condition and predicted outcome. In some aspects, patient life expectancy can be increased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45%304076022 - 69 -Atty. Docket No.: UTSDP4583WO-1001393863or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about 85% or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or greater, at least about 95% or greater to at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.

[0213] In some aspects, a suitable subject, or a subject in need thereof is a subject diagnosed with, showing symptoms of, suspected of having, or having susceptibility to any disease or condition described herein. In Suitable subjects may include, without limit, humans, as well as companion animals such as cats, dogs, rodents, and horses; research animals such as rabbits, sheep, pigs, dogs, primates, mice, rats, and other rodents; agricultural animals such as cows, cattle, pigs, goats, sheep, horses, deer, chickens, other fowl; zoo animals; and primates such as chimpanzees, monkeys, and gorillas. The subject can be of any age without limitation. Although in some aspects, the subject is from two years of age to 12 years of age, or 12 years of age through 21 years of age, 21 years of age to 31 years of age, 31 years of age to 41 years of age, 41 years of age to 51 years of age, 51 years of age to 61 years of age, 61 years of age to 71 years of age, 71 years of age to 81 years of age, 81 years of age to 91 years of age, 91 years of age to 101 years of age or more. In some aspects, the subject is an adult subject. In some aspects, the subject is a non-human animal. In some aspects, the subject is a human.Additional therapies

[0214] In some aspects, the one or more of the pharmaceutical compositions disclosed herein may be administered together with other therapeutic interventions. In some aspects, the compositions disclosed herein can be administered before, after or along with additional therapeutics and treatment methods. In some aspects, the additional therapeutic or treatment method may be administered concurrently. As used herein, a therapy or therapeutic that is administered “concurrently” with another drug is administered within 1 day of the other drug. In some aspects, a therapy or therapeutic that is administered concurrently with another drug is administered at about the same time, within about 5 minutes, within about 10 minutes, within about 15 minutes, within about 20 minutes, within about 30 minutes, within about 45 minutes, within about 1 hour, within about 2 hours, within about 3 hours, within about 4 hours, within about 5 hours, within about 6 hours, within about 7 hours, within about 8 hours, within about 9 hours, within about 10 hours, within about 1 1 hours, within about 12 hours, within about 13304076022 - 70 -Atty. Docket No.: UTSDP4583WO-1001393863hours, within about 14 hours, within about 15 hours, within about 16 hours, within about 17 hours, within about 18 hours, within about 19 hours, within about 20 hours, within about 21 hours, within about 22 hours, within about 23 hours, or within about 24 hours of administration of the other drug. In some aspects, additional therapies or therapeutics aim to alleviate symptoms, slow disease progression, and improve the quality of life for subjects in need thereof, for example a subject diagnosed with, showing symptoms of, suspected of having, or having susceptibility to any disease or disorder described herein. These additional therapies may include, but are not limited to pharmacological treatments, non-pharmacological interventions, and emerging experimental therapies.

[0215] In some aspects, the one or more additional therapies may include one or more of a diet therapy (e.g., dietary monitoring, diet therapy for diabetes), an exercise therapy (e.g., physical activity), blood sugar monitoring, gastric electrical stimulation (e.g., TANTALUS), and diet modifications. In some aspects, the additional therapy may comprise administering a weight loss drug, drugs to control blood pressure, blood glucose levels, cardiovascular diseases etc. Non-limiting examples of such drugs include Semaglutide (Wegovy®), Liraglutide (Saxenda®), Tirzepatide (Zepbound®), Orlistat (Alli®, Xenical®), Phentermine-Topiramate (Qsymia®), Naltrexone-Bupropion (Contrave®), Metformin, Empagliflozin (Jardiance®), Dapagliflozin (Farxiga®), Sitagliptin (Januvia®), Insulin (Lantus®, Humalog®, Novolog®), Atorvastatin (Lipitor®), Rosuvastatin (Crestor®), Ezetimibe (Zetia®), PCSK9 inhibitors (Repatha®, Praluent®), ACE inhibitors (Lisinopril, Ramipril), Beta-blockers (Metoprolol, Carvedilol), Anticoagulants (Warfarin, Apixaban), and Aspirin (low dose for heart health).VI. Mouse Model

[0216] Disclosed herein is a mouse model for studying obesity comprising a mutation in the GPR75 gene wherein the GPR gene comprises a nucleotide sequence as set forth in SEQ ID NOs: 3 or 4, or a codon optimized version thereof, or a sequence at least about 60% identical thereto.EXAMPLESExample 1 : Introduction to the Examples

[0217] Mice are the most widely used animal model to study human obesity due to their physiologic similarity to humans. Since the positional cloning of the mouse obese (ob) gene, many studies with different mouse models have provided fundamental insights into the development of obesity. However, the genetic basis for obesity remains poorly understood, largely due to the complex physiological processes that lead to obesity. To identify new genes and pathways associated with obesity, a / V-ethyl-ZV-nitrosourea (ENU)-based phenotype-304076022 - 71 -Atty. Docket No.: UTSDP4583WO-1001393863driven forward genetic screening coupled with automated meiotic mapping (AMM) in mice was undertaken. Both body weight and body composition were measured in these mice carrying different mutations, which has allowed us to identify both obese and lean phenotypes.

[0218] GPR75 is a human orphan G protein-coupled receptor that maps to chromosome 2p16. The molecular mechanism of GPR75 in the regulation of body weight is poorly understood. Described herein is a lean phenotype that was caused by a point mutation in Gpr75 from the mouse screening disclosed herein. Furthermore, the underlying cause of the phenotype was explored and potential GPR75 ligands involved in regulating body weight were examined.Example 2: Identification of the Thinner allele

[0219] The Thinner phenotype is observed among third generation (G3) C57BL / 6J mice heterozygous or homozygous for mutations induced by ENll. Thinner mice have decreased body weight, decreased fat mass, and slightly decreased lean mass compared to wild type (WT) mice (FIGS. 1A-1C). The Thinner phenotype was mapped as a quantitative trait. AMM implicated a missense allele of Gpr75 as the causative mutation, displaying the strongest linkage in an additive model of inheritance (FIGS. 1D-1F). The Thinner mutation was a single nucleotide transition from T to C, causing substitution of a lysine for a proline at position 144 (L144P) in the GPR75 protein (FIG. 8A). These data suggest an association between GPR75 and leanness in mice.Example 3: GPR75-deficient mice exhibit a lean phenotype

[0220] The Thinner mutation (L144P) did not affect the stability of GPR75 as revealed by a similar expression level as the WT protein in 293T cells (FIG. 8). It was suspected that the mutation affects the function of GPR75 protein. By CRISPR / Cas9 gene targeting, a null allele of Gpr75 was introduced, encoding the first 6 amino acids (aa) followed by 9 aberrant aa and a termination codon, into the germline of C57BL / 6J mice (FIGS. 8A and 8C). Homozygous Gpr75 knockout (Gpr75- / -) mice had no reproductive and developmental defects, and both male and female Gpr75- / - mice were fertile. There was no difference in the body weight, fat weight, and lean weight between WT and Gpr75- / - mice at 6 weeks of age (FIGS. 2A-2C).However, after only 2 weeks of HFD feeding, Gpr75- / - mice began to exhibit significantly decreased fat weight compared to WT mice (FIG. 2B). After 4 weeks of HFD feeding, Gpr75~ mice had decreased body weight (FIG. 2A). No difference in lean weight was observed between WT and Gpr75- / - mice over the course of 8 weeks HFD feeding (FIG. 2C). The lean phenotype of Gpr75- / - mice fed with HFD for 8 weeks was obvious, with a smaller size of epididymal white adipose tissue (eWAT), interscapular white adipose tissue (iWAT), interscapular brown adipose tissue (iBAT), and liver (FIGS. 2D-2E). Additionally, Gpr75-- mice304076022 - 72 -Atty. Docket No.: UTSDP4583WO-1001393863had decreased liver weight and liver triglyceride (FIGS. 2F-2G). Hematoxylin and eosin (H&E) staining further revealed smaller adipocyte size in the adipose tissues and reduced fat content in the liver of Gpr75~- mice (FIG. 2H). The HFD used in our study contains high levels of saturated fatty acids (lard), which are known to rapidly induce obesity in susceptible C57BL / 6J mice. To explore whether different types of fatty acids influence the phenotype of Gpr75~- mice, HFD rich mice were fed with unsaturated fatty acids (safflower oil). Interestingly, Gpr75~ mice also exhibited decreased fat weight compared to WT mice, with no change in body weight and lean weight (FIGS. 2I-2K). Unlike on a HFD, Gpr75-- mice on a regular chow diet displayed very weak body weight change and fat weight change compared to WT mice. Only a slight difference was observed in the fat weight of WT and Gpr75-- mice at 16 weeks of age (FIGS. 2L-2N).

[0221] To further check other metabolic profiles of Gpr75~7- mice, the fasting serum of WT and Gpr75-- mice were checked after 4 weeks of HFD feeding. There was no difference in blood glucose, insulin, cholesterol, and triglycerides between WT and Gpr75-- mice (FIGS. 9A-9D).However, Gpr75-- mice had significantly decreased levels of leptin, which is likely caused by the decreased fat mass (FIG. 9E). Both the glucose tolerance test and insulin tolerance test were performed on the WT and Gpr75~- mice, and no notable difference was observed (FIGS.9F-9G). These data suggest that there is no change in glucose / insulin metabolism between the WT and Gpr75~- mice at the onset of the lean phenotype development.Example 4: The lean phenotype of Gpr757' mice is due to decreased food intake

[0222] Food intake of WT and Gpr75~- mice was monitored beginning at 6 weeks of age on a chow diet and a HFD (FIGS. 3A-3D). On the chow diet, no difference in food intake was observed between Gpr75~- mice and WT littermates (FIGS. 3A and 3B). However, food intake was significantly decreased in Gpr75~- mice compared to WT mice after HFD feeding for 10 days (FIGS. 3C and 3D). To check if the decreased food intake was the cause of the lean phenotype in GPR75-deficient mice, WT mice were pair-fed with the same amount of HFD as Gpr75-- mice beginning at 6 weeks of age when the body weight, fat weight, and lean weight of the mice were similar (FIGS. 3E-3G). Three weeks after pair-feeding with HFD, WT, and Gpr75-- mice gained similar body weight, fat weight, and lean weight (FIGS. 3E-3G), implying the decreased food intake directly contributes to the development of the lean phenotype in GPR75-deficient mice.

[0223] To check if there were other factors beyond the decreased food intake that contributed to the lean phenotype of GPR75-deficient mice, metabolic cage experiments were conducted on WT and Gpr75'- mice after 2 weeks of HFD feeding (FIGS. 10A-10D). At this stage, Gpr75~ mice exhibited decreased body weight and fat weight but similar lean weight compared to304076022 - 73 -Atty. Docket No.: UTSDP4583WO-1001393863WT mice (FIGS. 10A-10C). No significant differences were observed in energy expenditure, respiratory exchange ratio, and physical activities between WT and Gpr75~- mice (FIGS. 10D- IOI). Furthermore, Gpr75~- mice also demonstrated a comparable ability to maintain body temperature compared to WT mice during an acute cold stress experiment without food (FIG. IOJ). To eliminate the impact of difference in food intake on the metabolic cage experiments, WT mice were pair-fed with the same amount of HFD as Gpr75~- mice every day when conducting the metabolic cage experiments. Despite this standardization, no differences were found between WT and Gpr75-- mice (FIGS. 11A-11I). Additionally, Gpr75-- mice showed no deficiencies in food digestion and absorption as revealed by a similar fecal energy density compared to WT mice (FIG. 11 J). Taken together, these findings strongly suggest that reduced food intake is the sole determinant contributing to the lean phenotype observed in GPR75-deficient mice.Example 5: GPR75 is predominantly expressed in the brain and interacts with Gaq to signal in the brain

[0224] To understand why GPR75-deficient mice experienced reduced food intake, the mRNA levels of Gpr75 in various mouse tissues was examined. The expression of Gpr75 mRNA was notably higher in the brain compared to all other tested tissues, indicating a potential role of GPR75 in the brain (FIG.4A). Using the single-cell RNA sequencing (scRNA-seq) data from Allen Brain Cell Atlas, the expression of Gpr75 mRNA in different cells of the mouse brain were thoroughly analyzed. Among 4.04 million brain cells, Gpr75 was expressed in 0.327 million cells, accounting for 8.09% of all cells in the brain (FIG. 12A). The majority of Gpr75+ cells belong to neuronal classes (88.68%), with only small portions represented by granule and immature neuronal classes (4.57%) and non-neuronal classes (6.75%) (FIGS.12B-12C). Gpr75+ cells were widely distributed among all neuronal classes and various brain regions, with a relatively higher percentage among serotonergic neurons (36.60%) (FIGS.12B-12G).

[0225] To check the relative expression of the endogenous GPR75 protein, 3xFlag-Gpr75 knock-in mice were generated using CRISPR-mediated homologous replacement (FIG. 4B).The endogenous GPR75 protein expression was exclusively detected in the Flag immunoprecipitates of brain lysates, aligning with the Gpr75 mRNA expression profile (FIG.4C). Different parts of the brain have diverse functions, and the hypothalamus plays a crucial role in the regulation of food intake. Hence, the expression of endogenous GPR75 protein in various brain regions was evaluated. Consistent with the scRNA-seq data (FIGS. 12D-12E), GPR75 protein was expressed throughout different parts of the brain without clear regional differences (FIG. 4D).304076022 - 74 -Atty. Docket No.: UTSDP4583WO-1001393863

[0226] To investigate the molecular mechanism underlying GPR75’s role in the regulation of food intake, 3xFlag-Gpr75 knock-in mice were utilized to pull down GPR75 in brain lysates for the identification of interacting proteins by mass spectrometry (FIG. 4E). GNAQ (aka Gaq), a guanine nucleotide-binding protein, was identified as a GPR75 interacting protein (FIG. 4E).The interaction between GPR75 and Gaq was further confirmed by immunoprecipitation assays (FIG. 4F). Prior studies have indicated that Gaqmediates GPR75 signaling. Thus, it’s plausible that GPR75 also functions through Gaqin modulating food intake centrally.

[0227] To gain insights into the role of GPR75 in the central regulation of feeding, a transcriptomics analysis (RNA-seq) of the hypothalamus from WT and Gpr75~- mice under a chow diet or 2 weeks of HFD was performed. For false discovery rate (FDR) < 0.05, only a total of 8 genes were significantly changed in the hypothalamus of chow diet-fed Gpr75~- mice, including 5 increased genes and 3 decreased genes (FIGS. 4G and 4H). While on HFD feeding, a total of 30 genes were significantly changed in the hypothalamus of Gpr75~- mice for FDR < 0.05, including 5 increased genes and 25 decreased genes (FIGS. 4G and 4I). It is worth noting that only one gene, proteolipid protein (myelin) 1 (Plp1), was significantly decreased in both chow diet- and HFD- fed Gpr75-- mice. The major transcriptome change observed only in HFD-fed Gpr75-- mice is consistent with the appearance of a strong lean phenotype of Gpr75-- mice driven by the HFD. To facilitate interpretation and identify relevant signaling pathways associated with loss of GPR75 in the hypothalamus, overrepresentation analyses mapping significant genes was performed to the Reactome and Wikipathways databases included in the ConsensusPathDB (FIGS. 4J and 4K). An overrepresentation of pathways with important roles in the regulation of energy homeostasis was found, including TGF-p signaling and signaling by receptor tyrosine kinases, and development and function of neurons, including extracellular matrix organization, signaling by Neurotrophic tyrosine receptor kinases (NTRKs), and glial cell differentiation. These data suggest that GPR75 regulates various signaling pathways after HFD feeding.Example 6: GPR75 is localized in the primary cilia

[0228] Primary cilia are present in various cell types and play a crucial role in cell signaling. Dysregulation of cilia or ciliary proteins is closely linked to obesity. Many GPCRs are cilia-associated proteins, and their functions within the cilia are essential for regulating food intake and energy expenditure. To explore whether GPR75 is a cilia-associated protein, 3xFlag-Gpr75 in mouse inner medullary collecting duct (mlMCD)-3 cells was overexpressed and its subcellular localization observed. Immunofluorescence staining results clearly indicated that the GPR75 protein was localized in the cilia (FIG. 5A). TUB like protein 3 (TULP3) is known to mediate the trafficking of GPCRs into the primary cilia. Indeed, GPR75 interacted with304076022 - 75 -Atty. Docket No.: UTSDP4583WO-1001393863TLILP3 when expressed in 293T cells (FIG. 13). In Tulp3 knockout (Tulp3~-) mlMCD3 cells, GPR75 protein failed to localize in the cilia, suggesting that the ciliary localization of GPR75 is dependent on TLILP3 (FIG. 5B). Considering the specific expression of the GPR75 protein in the brain, it would be interesting to check the ciliary localization of GPR75 in brain neuron-derived cell lines. Therefore, the mouse embryonic hypothalamic cell line N11 was used to examine the subcellular localization of GPR75. Similar to mlMCD3 cells, GPR75 was executively localized in the cilia of N11 cells (FIG. 5C). However, the L144P mutant form of GPR75 identified in Thinner mice failed to localize in the cilia (FIG. 5D), suggesting that ciliary localization is important for the role of GPR75 in energy homeostasis. Besides cell lines, overexpressed GPR75 was also localized in the cilia of mouse primary hypothalamic neurons (FIG. 5E). To assess the subcellular localization of endogenous GPR75 protein, primary hypothalamic neurons were isolated from WT control and 3xFlag-Gpr75 knock-in mice. As shown in FIGS. 5F and 5G, endogenous GPR75 protein co-localized with the cilia marker ADCY3, confirming its presence in the cilia. While human GPR75 protein is reported to express on the cell surface and localize in the plasma membrane in human embryonic kidney (HEK) 293 cells, two loss-of-function mutations of GPR75 (p.Ala110fs and p.Gln234*) were unable to localize in the plasma membrane. However, whether human GPR75 is localized in the primary cilia remains unknown. Similar to mouse GPR75, human GPR75 was specifically localized in the cilia of N11 cells (FIG. 5H). Additionally, two mutations of human GPR75 (p.Ala110fs and p.Gln234*) that are associated with lower BMI failed to localize in the cilia (FIGS. 5I and 5J). In conclusion, GPR75 is a cilia-associated protein, and its localization in the primary cilia is crucial for its function in regulating body weight in both mice and humans.Example 7: Loss of GPR75 has no effect on the development of obesity in Lepobmice and Adcy3 mutant mice

[0229] Leptin signaling in the brain plays an important role in the regulation of food intake. Gpr75-- mice were crossed to Lepobmutant mice to determine whether GPR75 is involved in leptin signaling and whether loss of GPR75 would attenuate the obesity phenotype of Lepobmutant mice. As expected, Lepob / +and Lepoh / ohmice had increased body weight, fat weight, and lean weight than WT mice at 4 weeks of age (FIGS. 6A-6C). Completely knockout of Gpr75 didn’t weaken the exacerbated fat and lean weight in both Lepob / +and Lepoh / ohmice (FIGS. 6A-6C). ADCY3 catalyzes the synthesis of cAMP and its functions within the primary neuronal cilia are essential in regulating body weight. To check the genetic interaction between GPR75 and ADCY3, Gpr75-- mice to Adcy3-- mice were needed to crossed. Unfortunately, Adcy3-- mice are known to be anosmic and have a very high fatality rate within 48 hours after birth. During the genetic screening, a viable hypomorphic mutant of Adcy3 (Adcy3L278H / L278H) was identified with massive obesity. As shown in FIGS. 6D-6F, Adcy3L278H7L278Hmice had304076022 - 76 -Atty. Docket No.: UTSDP4583WO-1001393863increased body weight and fat weight compared with WT mice at 8 weeks of age. Loss of Gpr75 failed to reduce the development of obesity in Adcy3L278H / L278Hmice (FIGS. 6D-6F).Taken together, these findings demonstrate that loss of Gpr75 didn’t attenuate the obesity phenotype of Lepobmice and Adcy3 mutation mice.Example 8: Testing the ligands of GPR75

[0230] At present, CCL5 and 20-HETE, are reported to be ligands of GPR75. Two distinct assays were conducted to test the effect of CCL5 and 20-HETE on GPR75. Initially, a luciferase report construct was generated that contains a multiple-response element (MRE), a cAMP-response element (CRE), a serum-response element (SRE), and a luciferase gene. The MRE / CRE / SRE luciferase assay is capable of detecting agonist effects from Gi-, Gs-, and Gq-coupled receptors as well as the activities of most GPCRs. Human GPR75 and the luciferase reporter construct were co-transfected in 293T cells to check the luciferase activity with different concentrations of these ligands. The second assay employed was PRESTO-tango assay which is designed to identify ligands through the G protein-independent p-arrestin recruitment pathway. However, a strong activation of human GPR75 by CCL5 or 20-HETE was not observed, no matter whether in MRE / CRE / SRE luciferase assay or in PRESTO-tango assay (FIGS. 7A and 7B). Since 20-HETE is prone to oxidation, a stable synthetic analog, sodium 20-hydroxyeicosa-5(Z),14(Z)-dienoate (5,14-HEDE) was used, to explore its potency to activate GPR75. In MRE / CRE / SRE luciferase assay, a modest induction of GPR75 with concentrations exceeding 1 pg / ml of 5,14-HEDE (FIG. 7C) was observed; while in PRESTO-tango assay, only high concertation (> 1 pg / ml) of 5,14-HEDE appeared to activate GPR75 (FIG. 7D). However, 5,14-HEDE didn’t increase intracellular cAMP level via GPR75 (FIG. 7E) and a very high concentration (50 pg / ml) of 5,14-HEDE seemed to increase intracellular level of inositol monophosphate (I P 1 ) (FIG. 7F). These findings do not conclusively establish CCL5, 20-HETE, and 5,14-HEDE as definitive ligands of GPR75. The pursuit of novel GPR75 ligands is worthwhile, particularly those that could potentially regulate food intake.Example 9: Discussion

[0231] To identify new regulators of obesity, ENU-based phenotype-driven forward genetic screening was utilized to identify mutations that change body weight in mice. A missense allele of Gpr75, named Thinner, was detected in this screen. Gpr75-'- mice exhibited decreased body fat both under HFD and chow diet. Apart from food intake, there were no differences in energy expenditure, physical activities, and food digestion and absorption between WT and Gpr75-- mice. Though there are conflicting results regarding the contribution of food intake and energy expenditure in the development of the lean phenotype in GPR75-deficient mice, pair-feeding304076022 - 77 -Atty. Docket No.: UTSDP4583WO-1001393863experiment clearly showed that decreased food intake mainly caused the lean phenotype in Gpr75~- mice.

[0232] Protein-truncating variants in GPR75 have been linked to lower BMI and Gpr75~- mice have shown resistance to HFD-induced obesity. This study revealed that Gpr75~- mice exhibited reduced food intake, confirming the decreased food intake as the primary cause of the observed lean phenotype. However, the mechanism through which GPR75 regulates food intake remains unknown. Utilizing the Flag tag knock-in mice, the endogenous protein level of GPR75 was detected. Its notably higher expression in the brain compared to other tissues suggests its involvement in regulating energy homeostasis through the central nervous system. Simultaneously, the uniform expression of GPR75 protein across various brain regions makes it challenging to pinpoint the specific brain area (s) in which GPR75 works to regulate body weight. Additionally, it has been reported that GPR75 plays a role in regulating hippocampal activity, and Gpr75 knockout mice display altered contextual memory and anxiety-like behaviors. Further studies to specific knockout Gpr75 in distinct brain regions could provide insights into its role in obesity and anxiety.

[0233] Despite reports identifying 20-HETE and CCL5 as potential ligands for GPR75, the experimental results failed to validate these findings in this system. A modest activation of GPR75 was observed with high concentrations of 5,14-HEDE; however, high concentrations of the compound might also affect normal cellular activities, thereby influencing experimental results. Previous studies have suggested that 20-HETE impairs insulin signaling through GPR75 activation and contributes to the development of insulin resistance. In addition, several studies also indicated that deficiency in GPR75 protects against the onset of insulin resistance. All mice used in these studies have been on HFD for longer than 14 weeks, while the data showed that the glucose and insulin metabolism in Gpr75~- mice under HFD for 8 weeks had no abnormalities. This suggests that the improved insulin sensitivity observed in Gpr75~- mice under prolonged HFD feeding is a secondary effect of the reduced adiposity, and the resistance of Gpr75-- mice to HFD-induced obesity is not due to enhanced insulin sensitivity but rather decreased food intake. Thus, at least 20-HETE does not seem to act as a ligand involved in the activation of GPR75 to regulate food intake and body weight. Further investigation is essential to identify the specific ligand for GPR75 in the context of obesity.

[0234] Primary cilia, particularly in neuronal cells, play an essential role in the regulation of energy homeostasis. Mutations in many cilia-associated proteins lead to obesity. Surprisingly, both human and mouse GPR75 were found to be situated in primary cilia, marking GPR75 as the first identified cilia-associated protein whose loss-of-function mutations do not induce obesity but instead lead to leanness in both mice and humans. The presence and function of GPR75 suggest that abnormalities in the ciliary signaling may not always lead to obesity.304076022 - 78 -Atty. Docket No.: UTSDP4583WO-1001393863Disruption of distinct cilia signaling pathways may affect energy balance in both directions. In contrast to the obesity phenotype associated with many cilia-associated proteins, the leanness observed in Gpr75'- mice is relatively weak under a chow diet. It takes approximately 16 weeks for Gpr75-- mice to exhibit a reduction in body fat, whereas obese mice typically exhibit increased body fat accumulation within 4 to 8 weeks. It’s plausible that additional “weak” cilia signals capable of decreasing food intake, enhancing energy expenditure, and promoting a leaner state might exist but are currently overlooked and concealed. This phenomenon also suggests that organisms exercise a more cautious and precise regulation of reduced food intake.

[0235] The appearance of the lean phenotype of Gpr75-- mice requires HFD feeding, as the lean phenotype is very weak on a regular chow diet. Even on a chow diet, Lepoband Adcy3 mutant mice are known to accumulate massive amounts of fat by 6-8 weeks of age, largely due to increased food intake. However, the loss of GPR75 (Gpr75--) fails to inhibit the development of obesity in these chow diet-fed Lepoband Adcy3 mutant mice. These data suggest that GPR75 does not function downstream of leptin signaling, or alternatively, GPR75 operates in a novel pathway that runs parallel to the classic leptin-melanocortin signaling to regulate appetite. Another intriguing hypothesis is that GPR75 may somehow “sense” the HFD and activate to increase feeding, serving as an evolutionarily conserved mechanism for ancestors to store more animal fats when they are available. It would be interesting to study the potential role of GPR75 as a sensor of fatty foods, which might help to understand why humans prefer consuming fatty foods and consequently become obese.

[0236] In summary, the close association of GPR75 deficiency with obesity and food intake in both mice and humans makes it a promising drug target for treating obesity. The localization of GPR75 in primary cilia may help us better understand the function of cilia in obesity and eating behavior in the future.Example 10: MethodsSex as a biological variable

[0237] Only male animals were used for the CRISPR knockout studies, with the rationale that male mice are more susceptible to diet-induced obesity. However, both male and female animals were examined in the genetic screening, and similar findings were reported for both sexes. Thus, the findings are expected to be relevant for both sexes, and sex was not considered as a biological variable.304076022 - 79 -Atty. Docket No.: UTSDP4583WO-1001393863Mice

[0238] C57BL / 6J mice (stock# 000664) and the ob strain (B6.Cg-Lepob / J, stock# 000632) were purchased from The Jackson Laboratory. The Thinner strain (C57B 6J-Gpr75Thinner) and the Adcy3L278H / L278Hmice were generated by ENU mutagenesis and are described at http: / / mutagenetix.utsouthwestern.edu. Gpr75 knockout (Gpr75--) mice and 3xFlag tag Gpr75 knock-in (3xFlag-Gpr75) were generated in the laboratory using the CRISPR / Cas9 system as described previously with the Gpr75 (5’-ATTGGGGACATTCTGAAGCG-3’-SEQ ID NO: 5) small base-pairing guide RNA (sgRNA) and oligo template with 3xFlag tag and flanking sequence: 5’- TGAGCTGAGATCCTGACTCTTTTCCTGCTGAATTTATTTTTTTGAGAACACAAGAAAGAG ACACCTCTCTCTGAAGatggactacaaagaccatgacggtgattataaagatcatgatatcgattacaaggatgacg atgacaagATGAACACAAGTGCCCCGCTTCAGAATGTCCCCAATGCCACCTTGCTAAACAT GC-3’ (SEQ ID NO: 42). The sex and age of each mouse used in the experiment is specified in the corresponding figure legends and experiment descriptions. Littermate controls were used throughout the study and are clearly mentioned in the results and figure legends. All mice were fed a standard chow diet (2016 Teklad Global 16% Protein Rodent Diet) except mice with diet-induced obesity, which were fed a high-fat diet (60 kcal% fat, D12492, Research Diets) or unsaturated high-fat diet [45 kcal% fat (Mostly safflower oil), D05122101, Research Diets] from 6 weeks of age. All mice were housed at room temperature (23°C) unless indicated. Mice were observed daily to ensure good health status. Mice were maintained at The University of Texas Southwestern Medical Center and studies were performed in accordance with institutionally approved protocols.Plasmids

[0239] PCR was carried out using mouse brain cDNA as the template and oligonucleotide primers designed to obtain the coding DNA sequence (CDS) of the mouse Gpr75 (NM_175490.4) and Gnaq (NM_008139.6). Human Hela cell cDNA was used to obtain the CDS of the human GPR75 (NM_006794.4). These genes were cloned into the HA-tagged or 3xFlag-tagged pCMV vector for transient expression. The mouse Gpr75 and human GPR75 mutants were generated with PCR mutagenesis. pGL3-MRE / CRE / SRE-luciferase vector was constructed as previously reported. The MRE / CRE / SRE fragment was artificially synthesized and inserted into the pGL3-basic vector. The GPR75-Tango plasmid was a gift from Bryan Roth (Addgene plasmid #66372; http: / / n2t.net / addqene:66372: RRID: Addgene_66372). All constructs were verified by sequencing.304076022 - 80 -Atty. Docket No.: UTSDP4583WO-1001393863Cell culture and transfection

[0240] The 293T cells were purchased from American Type Culture Collection (ATCC). The N11 cells were obtained from Dr. Xiaoyong Yang at Yale University. The mlMCD3 WT and Tulp3-- cells were obtained from Dr. Saikat Mukhopadhyay at the University of Texas Southwestern Medical Center. The HTLA cells were obtained from Dr. Gilad Barnea at Brown University. These cells were grown in culture medium [DMEM (Gibco), 10% (vol / vol) FBS (ATCC), 1% Pen-Strep antibiotics (Gibco)] at 37 °C with 5% CO2. Transfection of plasmids was carried out using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s instructions. Cells were harvested between 36 and 48 h post transfection.Isolation of primary hypothalamic neurons

[0241] Primary hypothalamic neurons were isolated following standard protocol. First, culture dishes are coated with poly-D-Lysine to prepare for cell attachment. Surgical tools were sterilized and kept in ethanol, and wash mediums [DMEM (Gibco), 1% Pen-Strep antibiotics (Gibco)] were prepared and kept on ice. Pregnant mice (16-19 days) were euthanized, and embryos were collected. The brains were isolated from the embryos, with careful dissection to avoid damage and contamination. Hypothalamus was specifically identified and isolated, rinsed and washed with PBS, and digested with Papain-Trypsin buffer [2 mg / ml Papain (Sigma) + 0.05% Trypsin-EDTA (Gibco) in wash medium]. After neutralizing the enzyme activity, tissues were dissociated into single cells, and the cell density was calculated. Isolated cells are seeded into the coated culture plates with plating medium [Neurobasal medium (Gibco), 10% (vol / vol) FBS (ATCC), 1% Pen-Strep antibiotics (Gibco), 2 mM L-glutamate (Gibco)] and allowed to attach. Finally, the neurons were maintained in complete culture medium [Neurobasal medium (Gibco), 1% N2 supplement (Gibco), 2% B27 supplement (Gibco), 2 mM L-glutamate (Gibco), 1% Pen-Strep antibiotics (Gibco)]. The medium was refreshed by replacing half of it every 3-4 days.Metabolic analysis of mice

[0242] The mice underwent a 6-hour fasting period (from 7:00 AM to 1:00 PM) for both the glucose tolerance test (GTT) and insulin tolerance test (ITT). Blood glucose levels were assessed using the AlphaTRAK glucometer and test strips. Following the initial blood glucose measurement, the GTT was initiated by an intraperitoneal injection of a 10% glucose solution (1 g / kg; Sigma-Aldrich), and blood glucose levels were monitored at set time points over the next 2 hours. The ITT was initiated by an intraperitoneal injection of human insulin (0.75 U / kg; Sigma-Aldrich), and blood glucose levels were measured at designated time points over the subsequent 2 hours. Magnetic resonance spectroscopy (MRS) was conducted on live mice304076022 - 81 -Atty. Docket No.: UTSDP4583WO-1001393863using EchoMRI Body Composition Analyzers with default settings. Cold tolerance test was performed as previously described. In brief, internal body temperatures of the mice were tracked by implanting a temperature transponder (IPTT-300) under the skin and recording temperatures with a portable reader (DAS-8007-IUS, BioMedic Data Systems). To subject the mice to acute cold exposure, they were individually housed in 6°C cold chambers without access to food, and body temperature was assessed at specified time points. Metabolic cage measurements were performed using the TSE PhenoMaster system. Mice were acclimatized for 5 days in metabolic cages before the actual measurement. For the pair-feeding experiment, WT mouse (pair-fed group) was offered the amount of HFD eaten by the Gpr75-- mouse (comparison group) on the previous day beginning at 6 weeks of age.Serum chemistries and ELISA

[0243] The mice underwent a 6-hour fasting period (from 7:00 AM to 1 :00 PM) before all blood sample collections. Insulin and leptin levels in the serum were measured using ELISA kits from Crystal Chem, following the manufacturer’s instructions. Triglyceride levels were assessed using the Infinity Triglycerides Liquid Stable Reagent from Thermo Fisher Scientific, with the Matrix Plus Chemistry Reference Kit from Verichem Laboratories as the standard for measurement. Cholesterol levels were determined using the Infinity Cholesterol Liquid Stable Reagent from Thermo Fisher Scientific, with the Matrix Plus Cholesterol Reference Kit from Verichem Laboratories used as the measurement standard.Immunohistochemistry and immunostaininq

[0244] Tissue samples for routine histology and special stains were obtained from anesthetized mice and fixed following standard protocols with adjustments made for tissue size and staining requirements. Samples for Hematoxylin and Eosin (H&E) staining were fixed for 48 h in 10% (vol / vol) neutral-buffered formalin and stored briefly in 75% (vol / vol) ethanol. These sections were stained for histopathological evaluation by regressive H&E on a Sakura Finetek DRS-601 robotic staining system using Leica SelecTech reagents (hematoxylin 560 and alcoholic eosin Y 515).

[0245] For immunostaining, mlMCD3 cells and N11 cells cultured in chambers were washed with PBS, fixed in freshly prepared 4% formaldehyde in PBS buffer for 10 minutes at room temperature, rinsed again with PBS, and then blocked with PBSA (PBS and 3% BSA by weight) for 1 hour. Following this, the cells were incubated with a primary antibody diluted in PBSA overnight at 4°C, washed with PBS, incubated with a secondary antibody diluted in PBSA for 30 minutes at room temperature, and finally mounted using a mounting medium (Life Technologies). The following primary antibodies were used in this study: mouse anti-Flag (M2,304076022 - 82 -Atty. Docket No.: UTSDP4583WO-1001393863Sigma-Aldrich, 1:500) and rabbit anti-Ac-Tubulin [D20G3, Cell Signaling Technology (CST), 1:800], The following secondary antibodies were used in the study: Alexa Fluor 488 Goat antiMouse IgG (H + L) (115-545-166, Jackson ImmunoResearch, 1:500) and Rhodamine Red-X Goatanti-Rabbit IgG (H + L) (111-295-144, Jackson ImmunoResearch, 1:500). Hoechst (CST) was used to stain nuclei.and western blot

[0246] For western blot analysis, cells were collected in 1*NuPAGE LDS sample buffer (Life Technologies) containing 2.5% 2-mercaptoethanol (Sigma-Aldrich). For immunoprecipitation, tissues or cells underwent lysis in Nonidet P-40 lysis buffer (50 mM Tris-CI, pH 8.0, 0.1 M NaCI, 10 mM sodium fluoride, 1 mM sodium vanadate, 1% Nonidet P-40, 10% glycerol, 1.5 mM EDTA, and Protease Inhibitor Mixture) for 30 minutes at 4°C. After centrifugation, lysates were incubated with Flag antibody-conjugated beads for 2 hours at 4°C. The beads were subsequently washed three times with 1 mL of Nonidet P-40 lysis buffer and eluted using 3xFlag peptides for 30 minutes at 4°C. For immunoprecipitation intended for mass spectrometric analysis, the procedure was similar except for the higher cell count and longer lysis time. Mass spectrometric analysis was carried out following established methods. In a standard Western blot, samples were separated using NuPAGE 4-12% Bis-Tris gels (Thermo Fisher Scientific), transferred onto NC membranes (Bio-Rad), probed with primary antibody overnight at 4°C, followed by incubation with the secondary antibody for 1 hour at room temperature, and finally visualized using a chemiluminescent substrate (Thermo Fisher Scientific). The following primary antibodies were used in this study: mouse anti-HA (HA-7, Sigma-Aldrich, 1:5000), anti-Flag (M2, Sigma-Aldrich, 1:5000), and rabbit anti-Gapdh (D16H11, CST, 1:2000). The following secondary antibodies were used in this study: Goat anti-Mouse IgG (H + L) HRP (115-035-146, Jackson ImmunoResearch, 1:5000) and Goat antiMouse IgG (light chain specific) HRP (115-035-174, Jackson ImmunoResearch, 1:5000). RNA isolation, reverse transcription, and RT-qPCR

[0247] Tissue samples or cells were lysed in TRIzol (Invitrogen) for RNA isolation with PureLink RNA Mini Kit (Invitrogen) following a standard protocol. Reverse transcription was carried out by SuperScript III First-Strand Synthesis SuperMix (Life Technologies) following standard protocol. RT-qPCR was conducted using the ABI StepOnePlus system with Powerup SYBR Green Master Mix (Life Technologies). Relative quantification was carried out using the 2-AAGf method. The following primer pairs were used: Gpr75, 5’-GGCGATGATGACTCTAGCCC-3’ (forward - SEQ ID NO: 43), 5’- GTGCCAAAGAAGATAAGCCAGC-3’ (reverse - SEQ ID NO: 44); Polr2a, 5’- CAAGATGCAAGAGGAGGAA GAG-3’ (forward - SEQ ID NO: 45), 5’-304076022 - 83 -Atty. Docket No.: UTSDP4583WO-1001393863TGTTGTCTGTCTGAGGTAAGTG-3’ (reverse - SEQ ID NO: 46); Gpr75 #1, 5’-GATGAACACAAGTGCCCCGC-3’ (forward - SEQ ID NO: 47), 5’- GGCAAGCAGAAAAGTGCAGG-3’ (reverse - SEQ ID NO: 48); Gpr75 #2, 5’- CTTCTTTGGCACATGCTCGTC-3’ (forward - SEQ ID NO: 49), 5’- GTGGCATTGGGGACATTCTGAAG-3’ (reverse - SEQ ID NO: 50).I P-1 assay

[0248] Inositol phosphate (IP-1) accumulation was measured utilizing the IP-One Gq kit (62IPAPEB, Cisbio, Bedford, MA) following the manufacturer's instructions. Briefly, HTI_A cells were seeded onto 96-well plates (Corning) at 5x104cells / well in 100 pl medium and transfected with pCMV-human-GPR75. 24h after the transfection, the HTI_A cells were starved in serum-free DM EM for 2 h. Subsequently, cells were rinsed and exposed to specific reagents and their corresponding controls for 2 hours. Each well received the I P-1 d2 reagent (acceptor) followed by the IP-1 Tb Cryptate antibody (donor), and the plate was sealed and incubated for 1 hour. Standards and samples were read using a SpectraMax iD5 multimode microplate reader (Molecular Devices, San Jose, CA) employing a homogeneous time-resolved fluorescence (HTRF) protocol (Ex 350 nm, Em 665 / 620 nm HTRF).cAMP assay

[0249] 293T cells were seeded onto a 24-well plate and transfected with pCMV-human-GPR75. 24 hours after transfection, 293T cells were treated with the appropriate reagents for 2-4 h. Cells were treated with 0.5 mM IBMX for 30 minutes, then were either left untreated or treated with 1 uM forskolin for 15 minutes. The cAMP concentrations of all wells were assessed with the Cyclic AMP XP® Assay Kit (4339S, Cell signaling) following the manufacturer’s protocol.8-Arrestin recruitment assay (PRESTO-Tanqo)

[0250] The PRESTO-Tango system was utilized to screen ligand-receptor activation via the G protein-independent p-arrestin-recruitment pathway. HTLA cells were plated onto 96-well plates (Corning) at 5x104cells / well in 100 pl medium and transfected with GPR75-Tango for 24 hours. Subsequently, the cells underwent a 2-hour serum-free DMEM starvation period. Post-starvation, the cells were rinsed and exposed to various reagents, incubating at 37°C with 5% CO2 for 2 hours. Following this incubation, the treatment was removed, and fresh complete media (DMEM supplemented with 20% FBS) was replenished, allowing overnight incubation at 37°C with 5% CO2. The next day, the plates were retrieved, and luminescence was measured using the Steady-Gio Luciferase Assay System (E2520, Promega) following the standard protocol.304076022 - 84 -Atty. Docket No.: UTSDP4583WO-1001393863Luciferase

[0251] Cells were seeded into 96-well plates (Corning) at a density of 5x104cells per well in 100 pl of medium and left to incubate at 37°C overnight. Ligands at different concentrations were dissolved in 11 pl medium and added to each well. The cells were incubated at 37 °C for 6 h. Then, the luminescence signal was measured immediately using and luminescence was measured using the Steady-Gio Luciferase Assay System (E2520, Promega).RNA-;

[0252] Total RNA was extracted from tissues by TRIzol and PureLink RNA Mini Kit (Invitrogen) following a standard protocol. cDNA synthesis and library preparation were carried out by the SMART-Seq mRNA LP kit (Takara, 634768). The sequencing was carried out on the Illumina NovaSeq 6000 platform (PE150, raw data > 6 GB / sample). Sequencing data was analyzed using Astrocyte, which is a scientific workflow platform developed by BioHPC at UT Southwestern Medical Center. Differentially expressed genes were analyzed with DESeq2 using raw counts. Overrepresentation analyses were performed with ConsensusPathDB. Statistics

[0253] Data are presented as mean ± SD in all graphs depicting error bars. The statistical significance of differences between experimental groups was determined by two-tailed unpaired Student’s t test, one-way ANOVA with Holm-Sidak’s multiple comparisons test, mixed-effects model with Holm-Sidak’s multiple comparisons test, or a linear correlation with a two-tailed comparison of slope and intercept using GraphPad Prism 10. *P < 0.05; **P < 0.01 ; ***P < 0.001 ; ****p < 0.0001 ; ns, not significant with P > 0.05.

[0254] All mouse experiments in this study were approved by the University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee (IACUC).Data

[0255] The RNA-seq data generated in this publication were deposited into the NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE254239. The corresponding author will provide all requested materials, data sets, and protocols, without restriction, upon request. See the Supporting Data Values file for all data shown.304076022 - 85 -Atty. Docket No.: UTSDP4583WO-1001393863Example 11: siRNA-Mediated Knockdown of GPR75 and Reduction of Ciliary Localization in N11 Cells

[0256] Matched-species human siRNAs (see Table 1) were transfected into N11 cells stably expressing human GPR75-3xFlag. As shown in FIGS. 14A-14C, matched-species human siRNAs reduced human GPR75 mRNA and Flag-tagged protein in the human stable line. The strongest mRNA knockdown was observed with hGpr75_294-316 (12.1% mRNA remaining relative to control), and the strongest protein reductions were observed with hGpr75_1439-1461 (16.8%) and hGpr75_1503-1525 (16.0%). The cross-species mouse siRNA mGpr75_811-833 showed partial activity in the human line (54.3% mRNA, 37.9% protein remaining). The results are summarized in Table 2.Table 1:Name Specie Target sequence (5'- Guide strand (5'- Passenger strand s >3') >3') (5'->3') mGpr75_ Mouse ttcggaaaaatgctcaagtaaa UUACUUGAGCA CGGAAAAAUGC 686-708 a UUUUUCCGAA UCAAGUAAAA mGpr75_ Mouse ctgtataggaaccagaattata AUAAUUCUGGU GUAUAGGAACC 811-833 a UCCUAUACAG AGAAUUAUAA mGpr75_ Mouse ctcatggatacactaagaatatc UAUUCUUAGUG CAUGGAUACAC 854-876 UAUCCAUGAG UAAGAAUAUC mGpr75_ Mouse caggattaaatccttttatatat AUAUAAAAGGAU GGAUUAAAUCC 1106- UUAAUCCUG UUUUAUAUAU 1128mGpr75_ Mouse accttactatagcatctataaca UUAUAGAUGCU CUUACUAUAGC 1440- AUAGUAAGGU AUCUAUAACA 1462hGpr75_2 Human ccccatgttcacctttgtgttat AACACAAAGGU CCAUGUUCACC 94-316 GAACAUGGGG UUUGUGUUAU hGpr75_1 Human gtcaggattaaacccttttatat AUAAAAGGGUU CAGGAUUAAAC 104-1126 UAAUCCUGAC CCUUUUAUAU hGpr75_1 Human tcccatcatgaaacaaactctg AGAGUUUGUUU CCAUCAUGAAAC 267-1289 c CAUGAUGGGA AAACUCUGC hGpr75_1 Human aaccttactacagcatctataac UAUAGAUGCUG CCUUACUACAG 439-1461 UAGUAAGGUU CAUCUAUAAC hGpr75_1 Human gccagtaaactcttttggatttg AAUCCAAAAGAG CAGUAAACUCU 503-1525 UUUACUGGC UUUGGAUUUG mm.Ri.Tu Mouse tgcaggttttacatgaattctattt AUAAAUAGAAUU CAGGUUUUACA Ip3.13.1 at CAUGUAAAACCU UGAAUUCUAUU GCA UATmm.Ri.Tu Mouse cgggaggagaaccgcaagat AAGAAAUAUCUU GGAGGAGAACC Ip3.13.2 atttctt GCGGUUCUCCU GCAAGAUAUUUCCCG CTT

[0257] Table 2. Knockdown of human GPR75-3xFlag in N11 stable cells by human and crossspecies mouse siRNAs.304076022 - 86 -Atty. Docket No.: UTSDP4583WO-1001393863Condition Species match mRNA remaining Protein remaining (%) (%) Control siRNA — 100.0 100.0 hGpr75_294-316 Matched 12.1 25.7hGpr75_1104-1126 Matched 37.7 30.0 hGpr75_1267-1289 Matched 62.5 21.0 hGpr75_1439-1461 Matched 36.0 16.8hGpr75_1503-1525 Matched 38.7 16.0mGpr75_811-833 Cross-species 54.3 37.9

[0258] Matched-species mouse siRNAs were transfected into N11 cells stably expressing mouse Gpr75-3xFlag. As shown in FIGS. 15A-15C, matched-species mouse siRNAs reduced mouse Gpr75 mRNA and Flag-tagged protein in the mouse stable line. The strongest overall matched-species hit was mGpr75_1440-1462 (25.7% mRNA and 1.7% protein remaining). mGpr75_811-833, mGpr75_854-876, and mGpr75_1106-1128 also showed strong protein knockdown. The cross-species human siRNA hGpr75_1104-1126 showed weaker but detectable activity in the mouse line (74.9% mRNA, 45.4% protein remaining). The results are summarized in Table 3.

[0259] Table 3. Knockdown of mouse Gpr75-3xFlag in N11 stable cells by mouse and crossspecies human siRNAs.Condition Species match mRNA remaining Protein remaining (%) (%) Control siRNA — 100.0 100.0 mGpr75_686-708 Matched 62.0 66.0mGpr75_811-833 Matched 43.2 12.9 mGpr75_854-876 Matched 62.8 11.1mGpr75_1106-1128 Matched 56.4 14.5 mGpr75_1440-1462 Matched 25.7 1.7304076022 - 87 -Atty. Docket No.: UTSDP4583WO-1001393863hGpr75_1104-1126 Cross-species 74.9 45.4Example 12: Ciliary and mechanistic data

[0260] Representative immunofluorescence / confocal images were obtained from both the human and mouse stable N11 cell lines after transfection with matched-species siRNAs, cross-species siRNAs, or Tulp3 siRNA. Cells were stained for Flag (GPR75 protein), acetylated a-tubulin (cilia marker), and Hoechst (nuclei). As shown in FIGS. 16 and 17, representative images are consistent with the qPCR and Western blot results and show reduced ciliary Flag signal after matched-species siRNA transfection in both the human and mouse stable lines. Stronger reduction in ciliary Flag signal was observed for the best matched-species siRNAs than for the cross-species siRNAs. Tulp3 siRNA was included as a mechanistic control and reduced ciliary localization of both human and mouse GPR75 in N11 cells. Based on representative images, Tulp3 siRNA did not obviously change cilia length and appeared to primarily affect ciliary localization rather than global cellular Flag-GPR75 signal.

[0261] Overall, these data demonstrate that sequence-defined siRNAs targeting the GPR75 CDS effectively reduce Gpr75 mRNA, protein, and ciliary localization, and that matched-species siRNAs outperform closely related cross-species siRNAs, while some orthologous windows retain partial cross-species activity. Furthermore, indirect reduction of ciliary GPR75 localization can be achieved through inhibition of TLILP3.304076022 - 88 -Atty. Docket No.: UTSDP4583WO-1001393863LIST OF SEQUENCES SEQ Name Type SEQUENCEID NO1 Human GPR75 AA MNSTGHLQDAPNATSLHVPHSQEGNSTSLQEGLQ DLIHTATLVTCTFLLAVIFCLGSYGNFIVFLSFFDPAF RKFRTNFDFMILNLSFCDLFICGVTAPMFTFVLFFSS ASSIPDAFCFTFHLTSSGFIIMSLKTVAVIALHRLRMV LGKQPNRTASFPCTVLLTLLLWATSFTLATLATLKTS KSHLCLPMSSLIAGKGKAILSLYWDFTFCVAVVSVS YIMIAQTLRKNAQVRKCPPVITVDASRPQPFMGVPV QGGGDPIQCAMPALYRNQNYNKLQHVQTRGYTKS PNQLVTPAASRLQLVSAINLSTAKDSKAWTCVIIVL SVLVCCLPLGISLVQVVLSSNGSFILYQFELFGFTLIF FKSGLNPFIYSRNSAGLRRKVLWCLQYIGLGFFCCK QKTRLRAMGKGNLEVNRNKSSHHETNSAYMLSPK PQKKFVDQACGPSHSKESMVSPKISAGHQHCGQS SSTPINTRIEPYYSIYNSSPSQEESSPCNLQPVNSF GFANSYIAMHYHTTNDLVQEYDSTSAKQIPVPSV2 Mouse GPR75 AA MNTSAPLQNVPNATLLNMPPLHGGNSTSLQEGLRD FIHTATLVTCTFLLAIIFCLGSYGNFIVFLSFFDPSFRK FRTNFDFMILNLSFCDLFICGVTAPMFTFVLFFSSAS SIPDSFCFTFHLTSSGFVIMSLKMVAVIALHRLRMVM GKQPNCTASFSCILLLTLLLWATSFTLATLATLRTNK SHLCLPMSSLMDGEGKAILSLYVVDFTFCVAWSVS YIMIAQTLRKNAQVKKCPPVITVDASRPQPFMGASV KGNGDPIQCTMPALYRNQNYNKLQHSQTHGYTKNI NQMPIPSASRLQLVSAINFSTAKDSKAVVTCVVIVLS VLVCCLPLGISLVQMVLSDNGSFILYQFELFGFTLIFF KSGLNPFIYSRNSAGLRRKVLWCLRYTGLGFLCCK QKTRLRAMGKGNLEINRNKSSHHETNSAYMLSPKP QRKFVDQACGPSHSKESAASPKVSAGHQPCGQSS STPINTRIEPYYSIYNSSPSQQESGPANLPPVNSFG FASSYIAMHYYTTNDLMQEYDSTSAKQIPIPSV304076022 - 89 -Atty. Docket No.: UTSDP4583WO-10013938633 Human GPR75 DNA ATGAACTCAACAGGCCACCTTCAGGATGCCCCCA (complete ATGCCACCTCGCTCCATGTGCCTCACTCACAGGA CDS) AGGAAACAGCACCTCTCTCCAGGAGGGTCTTCA GGATCTCATCCACACAGCCACCTTGGTGACCTGT AC I I I I CTACTGGCGGTCATCTTCTGCCTGGGTT CCTATGGCAACTTCATTGTCTTCTTGTCCTTCTTC GATCCAGCCTTCAGGAAATTCAGAACCAACTTTG ATTTCATGATCCTGAACCTGTCCTTCTGTGACCTC TTCATTTGTGGAGTGACAGCCCCCATGTTCACCT TTGTGTTATTCTTCAGCTCAGCCAGTAGTATCCC GGATGCTTTCTGCTTCACTTTCCATCTCACCAGTT CAGGCTTCATCATCATGTCTCTGAAGACAGTGGC AGTGATCGCCCTGCACCGGCTCCGGATGGTGTT GGGGAAACAGCCTAATCGCACGGCCTCCTTTCC CTGCACCGTACTCCTCACCCTGCTTCTCTGGGCC ACCAGTTTCACCCTTGCCACCTTGGCTACCTTGA AAACCAGCAAGTCCCACCTCTGTCTTCCCATGTC CAGTCTGATTGCTGGAAAAGGGAAAGCCA I I I I G TCTCTCTATGTGGTCGACTTCACCTTCTGTGTTGC TGTGGTCTCTGTCTCTTACATCATGATTGCTCAGA CCCTGCGGAAGAACGCTCAAGTCAGAAAGTGCC CCCCTGTAATCACAGTCGATGCTTCCAGACCACA GCCTTTCATGGGGGTCCCTGTGCAGGGAGGTGG AGATCCCATCCAGTGTGCCATGCCGGCTCTGTAT AGGAACCAGAATTACAACAAACTGCAGCACGTTC AGACCCGTGGATATACCAAGAGTCCCAACCAACT GGTCACCCCTGCAGCAAGCCGACTCCAGCTCGT ATCAGCCATCAACCTCTCCACTGCCAAGGATTCC AAAGCCGTGGTCACCTGTGTGATCATTGTGCTGT CAGTCCTGGTGTGCTGTCTTCCACTGGGGATTTC CTTGGTACAGGTGGTTCTCTCCAGCAATGGGAGC TTCATTCTTTACCAGTTTGAATTGTTTGGATTTACT CTTATA I I I I I CAAGTCAGGATTAAACCCTTTTATA TATTCTCGGAACAGTGCAGGGCTGAGAAGGAAA GTGCTCTGGTGCCTCCAATACATAGGCCTGGGTTI l l i CTGCTGCAAACAAAAGACTCGACTTCGAGC CATGGGAAAAGGGAACCTCGAAGTCAACAGAAA CAAATCCTCCCATCATGAAACAAACTCTGCCTAC ATGTTATCTCCAAAGCCACAGAAGAAATTTGTGG ACCAGGCTTGTGGCCCAAGTCATTCAAAAGAAAG TATGGTGAGTCCCAAGATCTCTGCTGGACATCAA CACTGTGGTCAGAGCAGCTCGACCCCCATCAAC ACTCGGATTGAACCTTACTACAGCATCTATAACA GCAGCCCTTCCCAGGAGGAGAGCAGCCCATGTA ACTTACAGCCAGTAAACTC I l l i GGATTTGCCAAT TCATATATTGCCATGCATTATCACACCACTAATGA CTTAGTGCAGGAATATGACAGCACTTCAGCCAAGCAGATTCCAGTCCCCTCCGTTTAA304076022 - 90 -Atty. Docket No.: UTSDP4583WO-10013938634 Mouse GPR75 DNA ATGAACACAAGTGCCCCGCTTCAGAATGTCCCCA (complete ATGCCACCTTGCTAAACATGCCTCCCCTGCACGG CDS) GGGAAATAGCACTTCTCTCCAGGAAGGTCTTCGA GA I I I I ATCCACACAGCCACCTTGGTGACCTGCA C I I I I CTGCTTGCCATCATCTTCTGTCTAGGCTCT TATGGAAA I l l i ATTGTCTTCTTGTCTTTCTTTGAC CCATCCTTCAGGAAGTTCAGAACCAACTTTGATTT CATGATCTTGAACCTGTCTTTCTGTGATCTGTTCA TCTGTGGGGTCACAGCCCCCATGTTCACCTTCGT GCTGTTCTTCAGCTCAGCCAGTAGCATCCCAGAT AGCTTCTGCTTCACCTTCCACCTTACCAGCTCAG GCTTCGTCATCATGTCCCTCAAGATGGTGGCTGT GATTGCTCTGCACCGGCTCCGGATGGTGATGGG GAAGCAGCCTAATTGTACAGCCTCC I l l i CCTGC ATCTTGCTCCTTACCCTTCTTCTCTGGGCGACCA GCTTTACACTTGCCACCTTGGCTACACTGAGAAC CAATAAGTCCCACCTGTGTCTCCCCATGTCCAGT CTTATGGATGGGGAAGGGAAAGCCATTCTGTCTC TGTATGTTGTTGACTTTACCTTCTGTGTTGCTGTG GTGTCTGTCTCTTATATTATGATTGCTCAAACCCT TCGGAAAAATGCTCAAGTAAAAAAGTGCCCCCCG GTGATCACAGTTGATGCTTCCAGACCACAGCCAT TCATGGGGGCCTCTGTGAAGGGAAATGGAGATC CCATCCAGTGCACCATGCCAGCTCTGTATAGGAA CCAGAATTATAACAAACTGCAGCACAGTCAAACT CATGGATACACTAAGAATATCAACCAGATGCCAA TCCCCTCAGCCAGTCGACTCCAGCTGGTATCAGC CATCAACTTCTCTACTGCCAAGGATTCCAAAGCC GTGGTCACCTGTGTGGTCATCGTGTTGTCAGTCC TGGTGTGCTGTCTTCCTCTTGGGATTTCCCTGGT GCAAATGGTTCTGTCTGACAATGGCAG I l l i ATC CTTTACCAGTTTGAACTGTTTGGATTTACTCTGAT A I I I I I CAAG I CAGGA I I AAA I CC I I I I ATATATTC TCGGAACAGTGCTGGGCTGAGAAGGAAAGTACT CTGGTGCCTGAGATACACTGGCCTGGGCTTTCTC TGCTGCAAACAGAAAACTCGACTTCGGGCCATGG GAAAAGGGAACCTTGAAATCAATAGAAACAAATC TTCTCATCATGAGACAAACTCTGCCTACATGCTGT CTCCAAAACCACAGAGAAAATTTGTGGACCAGGC TTGTGGCCCAAGTCACTCAAAGGAAAGTGCAGC GAGTCCCAAAGTTTCTGCTGGACATCAACCCTGT GGTCAAAGCAGTTCCACACCCATCAACACTAGGA TTGAACCTTACTATAGCATCTATAACAGCAGCCCT TCCCAGCAGGAGAGCGGTCCGGCAAACTTGCCT CCAGTGAACTC I l l i GGGTTTGCCAGTTCCTACA TCGCCATGCACTATTACACCACCAATGATTTGAT GCAGGAATATGACAGCACGTCAGCAAAACAAATT CCTATCCCCTCTGTTTAA5 Mouse sgRNA RNA ATTGGGGACATTCTGAAGCG6 mGpr75_686- DNA TTCGGAAAAATGCTCAAGTAAAA708 (target)7 mGpr75_811- DNA CTGTATAGGAACCAGAATTATAA833 (target)304076022 - 91 -Atty. Docket No.: UTSDP4583WO-10013938638 mGpr75_854- DNA CTCATGGATACACTAAGAATATC 876 (target)9 mGpr75_1106- DNA CAGGATTAAATCC I I I I A I A I AT 1128 (target)10 mGpr75_1440- DNA ACCTTACTATAGCATCTATAACA 1462 (target)11 mGpr75_686- RNA UUACUUGAGCAUUUUUCCGAA 708 (guidestrand)12 mGpr75_811- RNA AUAAUUCUGGUUCCUAUACAG 833 (guidestrand)13 mGpr75_854- RNA UAUUCUUAGUGUAUCCAUGAG 876 (guidestrand)14 mGpr75_1106- RNA AUAUAAAAGGAUUUAAUCCUG 1128 (guidestrand)15 mGpr75_1440- RNA UUAUAGAUGCUAUAGUAAGGU 1462 (guidestrand)16 mGpr75_686- RNA CGGAAAAAUGCUCAAGUAAAA 708(passengerstrand)17 mGpr75_811- RNA GUAUAGGAACCAGAAUUAUAA 833(passengerstrand)18 mGpr75_854- RNA CAUGGAUACACUAAGAAUAUC 876(passengerstrand)19 mGpr75_1106- RNA GGAUUAAAUCCUUUUAUAUAU 1128(passengerstrand)20 mGpr75_1440- RNA CUUACUAUAGCAUCUAUAACA 1462(passengerstrand)21 hGpr75_294- DNA CCCCATGTTCACCTTTGTGTTAT 316 (target)22 hGpr75_1104- DNA GTCAGGATTAAACCC I I I I A I AT 1126 (target)23 hGpr75_1267- DNA TCCCATCATGAAACAAACTCTGC 1289 (target)24 hGpr75_1439- DNA AACCTTACTACAGCATCTATAAC 1461 (target)25 hGpr75_1503- DNA GCCAGTAAACTC I l l i GGATTTG 1525 (target)26 hGpr75_294- RNA AACACAAAGGUGAACAUGGGG 316 (guidestrand)304076022 - 92 -Atty. Docket No.: UTSDP4583WO-100139386327 hGpr75_1104- RNA AUAAAAGGGUUUAAUCCUGAC1126 (guidestrand)28 hGpr75_1267- RNA AGAGUUUGUUUCAUGAUGGGA1289 (guidestrand)29 hGpr75_1439- RNA UAUAGAUGCUGUAGUAAGGUU1461 (guidestrand)30 hGpr75_1503- RNA AAUCCAAAAGAGUUUACUGGC1525 (guidestrand)31 hGpr75_294- RNA CCAUGUUCACCUUUGUGUUAU316(passengerstrand)32 hGpr75_1104- RNA CAGGAUUAAACCCUUUUAUAU1126(passengerstrand)33 hGpr75_1267- RNA CCAUCAUGAAACAAACUCUGC1289(passengerstrand)34 hGpr75_1439- RNA CCUUACUACAGCAUCUAUAAC1461(passengerstrand)35 hGpr75_1503- RNA CAGUAAACUCUUUUGGAUUUG1525(passengerstrand)36 mm.Ri.Tulp3.1 DNA TGCAGG I l l i ACATGAATTCTATTTAT3.1 (Target)37 mm.Ri.Tulp3.1 DNA CGGGAGGAGAACCGCAAGATATTTCTT3.2 (Target)38 mm.Ri.Tulp3.1 RNA AUAAAUAGAAUUCAUGUAAAACCUGCA3.1 (guidestrand)39 mm.Ri.Tulp3.1 RNA AAGAAAUAUCUUGCGGUUCUCCUCCCG3.2 (guidestrand)40 mm.Ri.Tulp3.1 RNA CAGG U U U U ACAUGAAU UC U AU U U AT3.1 (passengerstrand)41 mm.Ri.Tulp3.1 RNA GGAGGAGAACCGCAAGAUAUUUCTT3.2 (Passengerstrand)42 oligo template DNA TGAGCTGAGATCCTGACTC I l l i CCTGCTGAATTT with 3xFlag tag A I I I I I I I GAGAACACAAGAAAGAGACACCTCTCT and flanking CTGAAGATGGACTACAAAGACCATGACGGTGATT sequence ATAAAGATCATGATATCGATTACAAGGATGACGATGACAAGATGAACACAAGTGCCCCGCTTCAGAATGTCCCCAATGCCACCTTGCTAAACATGC304076022 - 93 -Atty. Docket No.: UTSDP4583WO-100139386343 GPR75 (fwd) DNA GGCGATGATGACTCTAGCCC 44 GPR75 (rev) DNA GTGCCAAAGAAGATAAGCCAGC 45 Polr2a (fwd) DNA CAAGATGCAAGAGGAGGAAGAG 46 Polr2a (rev) DNA TGTTGTCTGTCTGAGGTAAGTG 47 GPR75#1 DNA GATGAACACAAGTGCCCCGC (fwd)48 GPR75 #2 DNA GGCAAGCAGAAAAGTGCAGG (rev)49 GPR75#1 DNA CTTCTTTGGCACATGCTCGTC (fwd)50 GPR75 #2 DNA GTGGCATTGGGGACATTCTGAAG_(rev) _304076022 - 94 -

Claims

1. Atty. Docket No.: UTSDP4583WO-1001393863CLAIMSWhat is claimed is:

1. A composition comprising a small interfering RNA (siRNA) comprising a guide strand and a passenger strand, wherein the guide strand is at least 80% complementary to a 15-23 nucleotide sequence within SEQ ID NO: 3 or SEQ ID NO: 4.

2. The composition of claim 1, wherein the guide strand is at least 80% complementary to a 15-23 nucleotide sequence within any one of SEQ ID NOS: 21-25.

3. The composition of claim 1, wherein the guide strand is at least 80% complementary to a 15-23 nucleotide sequence within any one of SEQ ID NOS: 6-10.

4. The composition of claim 1 or claim 2, wherein the guide strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 26-30 and the passenger strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 31-35.

5. The composition of claim 1 or claim 3, wherein the guide strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 11-15, and the passenger strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 16-20.

6. The composition of claim 4, wherein the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 26 and the passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 31.

7. The composition of claim 4, wherein the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 29 and the passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 34.

8. The composition of claim 7, wherein the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 15 and the passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 20.

9. The composition of any one of claims 1-8, wherein the siRNA reduces ciliary localization of GPR75 protein in neuronal cells.

10. A composition comprising an siRNA targeting TULP3, wherein the siRNA comprises a guide strand comprising a sequence at least 90% identical to SEQ ID NO: 38 or SEQ ID304076022 - 95 -Atty. Docket No.: UTSDP4583WO-1001393863NO: 39, and a passenger strand comprising a sequence at least 90% identical to SEQ ID NO: 40 or SEQ ID NO: 41.

11. The composition of any one of claims 1-10, further comprising one or more nucleic acid modifications.

12. The composition of claim 11 , wherein the modifications comprise one or more of backbone modifications, sugar modifications, base modifications, end modifications, conjugates, or any combination thereof.

13. A pharmaceutical composition comprising the composition of any one of claims 1-12 and a pharmaceutically acceptable excipient.

14. A method of treating obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension, or cardiovascular disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 13.

15. A composition comprising an inhibitor of G protein-coupled receptor 75 (GPR75).

16. The composition of claim 15, wherein the inhibitor directly or indirectly reduces the levels of GPR75 protein on a cell surface.

17. The composition of claim 15 or claim 16, wherein the inhibitor directly or indirectly decreases the levels of GPR75 protein in the primary cilia.

18. The composition of claim 17, wherein the GPR75 protein comprises an amino acid sequence at least 60% identical to any one of SEQ ID NOS: 1 or 2.

19. The composition of any one of claims 15-18, wherein the inhibitor comprises a small molecule inhibitor, a drug, a peptide, a protein, an aptamer, a nucleic acid, an antibody molecule, or any combination thereof.

20. The composition of claim 19, wherein the peptide specifically binds to 2-50 consecutive amino acid residues on any one of SEQ ID NOS: 1 or 2.

21. The composition of claim 19, wherein the antibody molecule comprises a human antibody, a humanized antibody, a recombinant antibody, a chimeric antibody, an antibody derivative, a veneered antibody, a nanobody, a scFv, a minibody, a diabody, a monoclonal antibody, or a polyclonal antibody.304076022 - 96 -Atty. Docket No.: UTSDP4583WO-100139386322. The composition of claim 21 , wherein the antibody molecule directly or indirectly reduces ciliary localization of GPR75.

23. The composition of claim 21 , wherein the antibody molecule reduces or eliminates interaction of GPR75 with GNAQ, TLILP3, or both GNAQ and TLILP3.

24. The composition of claim 19, wherein the nucleic acid is a small interfering RNA (siRNA), an antisense oligonucleotide (ASO), a short hairpin RNA (shRNA), a microRNA (miRNA), or a CRISPR guide RNA.

25. The composition of claim 24, wherein the nucleic acid specifically binds a 10-50 nucleotide sequence region within SEQ ID NO: 3 or SEQ ID NO: 4.

26. The composition of any one of claims 24-25, wherein the nucleic acid is a small interfering RNA (siRNA) comprising a guide strand and a passenger strand, wherein the guide strand is at least 60% complementary to a 15-23 nucleotide sequence within SEQ ID NO: 3 or SEQ ID NO: 4.

27. The composition of claim 26, wherein the guide strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 26-30 and the passenger strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 31-35.

28. The composition of claim 26, wherein the guide strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 11-15, and the passenger strand comprises a sequence at least 90% identical to any one of SEQ ID NOS: 16-20.

29. The composition of claim 27, wherein the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 26 and the passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 31.

30. The composition of claim 27, wherein the guide strand comprises a sequence at least 90% identical to SEQ ID NO: 29 and the corresponding passenger strand comprises a sequence at least 90% identical to SEQ ID NO: 34.

31. The composition of any one of claims 26-30, wherein the siRNA exhibits crossspecies activity, reducing GPR75 mRNA and / or GPR75 protein levels in both human and mouse cells.

32. The composition of any one of claims 26-31 , wherein the siRNA reduces ciliary localization of GPR75 protein in neuronal cells.304076022 - 97 -Atty. Docket No.: UTSDP4583WO-100139386333. The composition of claim 24, wherein the inhibitor is an siRNA targeting TLILP3, wherein the siRNA comprises a guide strand comprising a sequence at least 90% identical to SEQ ID NO: 38 or SEQ ID NO: 39, and a passenger strand comprising a sequence at least 90% identical to SEQ ID NO: 40 or SEQ ID NO: 41, and wherein the siRNA reduces ciliary localization of GPR75.

34. The composition of claim 24, wherein the composition comprises a CRISPR / Cas system on a delivery vector.

35. The composition of claim 34, wherein the composition further comprises a nucleic acid sequence encoding a Cas protein.

36. The composition of any one of claims 15-34, wherein the composition directly or indirectly reduces the levels of proteolipid protein (myelin) 1 (Plp1 ).

37. The composition of any one of claims 15-34, wherein the inhibitor directly or indirectly reduces the association between GPR75 and a ciliary trafficking protein.

38. The composition of claim 37, wherein the ciliary trafficking protein comprises TLILP3.

39. The composition of any one of claims 15-34, wherein the inhibitor directly or indirectly reduces GPR75 interactions with Gq.

40. The composition of any one of claims 15-34, wherein the inhibitor reduces the translocation of Gq into primary cilia, thereby decreasing IP3 and DAG levels in cilia of neurons.

41. The composition of any one of claims 15-34, wherein the inhibitor reduces the activity of other GPCRs in cilia of neurons.

42. The composition of any one of claims 15-41 , wherein the administration of the composition to a subject reduces body weight or reduces the risks of one or more metabolic diseases.

43. The composition of claim 42, wherein the metabolic disease is type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension, cardiovascular disease, or obesity, or any combination thereof.

44. A pharmaceutical composition comprising the composition of any one of claims 15-43 and a pharmaceutically acceptable excipient.304076022 - 98 -Atty. Docket No.: UTSDP4583WO-100139386345. A method of treating obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, hypertension, or cardiovascular disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 44.

46. A method of treating obesity in a subject, comprising administering a therapeutically effective amount of a GPR75 inhibitor to the subject.

47. The method of claim 46, wherein administering the inhibitor decreases IP3 and DAG levels, and / or reduces the levels of PLP1, and / or reduces other GPCRs signaling in cilia of neurons.

48. The method of claim 46, wherein administering of the GPR75 inhibitor reduces the translocation of Gq into primary cilia, thereby decreasing IP3 and DAG levels in cilia of neurons.

49. The method of claim 46, wherein administering the GPR75 inhibitor reduces the activity of other GPCRs in cilia of neurons.

50. A method of reducing food intake or treating hyperphagia in a subject, comprising administering a GPR75 inhibitor to the subject, wherein administering the inhibitor decreases IP3 and DAG levels and / or reduces other GPCRs signaling in cilia of neurons.

51. A method of modulating energy homeostasis, reducing weight gain, or decreasing other GPCRs signaling in primary cilia in a subject, comprising administering a GPR75 inhibitor to the subject, wherein administering the inhibitor decreases IP3 and DAG levels and / or reduces other GPCRs signaling in cilia of neurons.

52. A kit comprising: (i) a unit dose of the pharmaceutical composition of claim 44 in a sterile container; and (ii) instructions for use.

53. A kit comprising: (i) a unit dose of the pharmaceutical composition of claim 13 in a sterile container; and (ii) instructions for use.304076022 - 99 -